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Pyrichalasin H 65 belongs to the cytochalasan family of fungal natural products, and is 
the major phytotoxic metabolite produced by the fungal plant pathogen Magnaporthe 
grisea NI980. In a combined chemical and genetic approach, the biosynthesis and 
chemical modification of 65 were investigated in this work. 
Using a bipartite gene knockout strategy targeting the pyi biosynthetic gene cluster, two 
fundamental genes pyiS and pyiC were disrupted, resulting in the complete abolition of 
65. Five tailoring genes (two P450 encoding genes, one O-AcT, one O-MeT and one 
OXR encoding gene) were also inactivated individually; thirteen novel cytochalasans 
were isolated and identified by HRMS and NMR. For the first time, we discovered that 
O-methyltyrosine 175 was the initial precursor of 65 from the results of pyiA KO. 
Six cryptic P450 genes were investigated in two pyrichalasin H P450 disruption strains 
by heterologous expression. HffD and CYP1 were confirmed to catalyse a C-18 
hydroxylation reaction, HffG catalyses a C-7 hydroxylation reaction and CYP3 
catalyses an epoxidation reaction between C-6 and C-7. Three novel epoxide 
cytochalasans were obtained. 
Four 4’- halogenated phenylalanines, together with 4’-allyl, 4’-propargyl and 4’-azido 
phenylalanine were fed to a ∆pyiA KO strain. This resulted in production of seven new 
4’-functionalised pyrichalasins with titres around 30 - 60 mg/L. 
 
Based on seven 4’-substituted pyrichalasins generated by mutasynthesis, many 
functionalised pyrichalasins were created by various chemical modifications. Triazole 
pyrichalasins were generated by click chemistry, using azide- 258 and alkyne 
pyrichalasin 252 as starting materials. Bromo- pyrichalasin 256 is the substrate for the 
synthesis of dimeric pyrichalasin 318 via Suzuki cross coupling, while Iodo- 
pyrichalasin 257 is a substrate for Sonogashira coupling reactions. Moreover, dye linked 
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pyrichalasins 308 - 316 were generated for actin visualization in cell biology. In total, 



























Schlagwörter: naturstoffe, biosynthese, pyrichalasin 
Pyrichalasin H 65 gehört der Familie der Cytochalasine an und ist das Hauptoxin 
welches von dem Pflanzenpathogen Magnaporthe grisea NI980 produziert wird. Mittels 
Kombination von chemischen und genetischen Methoden wurden in dieser Arbeit die 
Biosynthese und chemischen Modifikationen von 65 erforscht. 
Unter Zuhilfenahme einer zweiteiligen Genknockout-Strategy wurden die beiden 
essentiellen Gene pyiS und pyiC des pyi Genclusters inaktiviert, wodurch die 
Produktion von 65 komplett unterbunden wurde. Fünf weitere Gene (zwei P450 
codierende Gene, ein O-AcT, ein O-MeT and ein OXR codierendes Gen) wurden 
ebenfalls individuell inaktiviert, was zur Bildung dreizehn neuer Cytochalasane führte. 
Diese wurden isoliert und mittels HRMS und NMR charakterisiert. Durch Knockout 
von pyiA haben wir erstmalig nachgewiesen, dass O-Methyltyrosin 175 der initiale 
Vorläufer von 65 ist. 
Die Funktion sechs kryptischer P450-Gene wurde durch heterologe Expression in dem 
Pyrichalasin H P450-Deletionsstamm untersucht. HffD und CYP1 katalysieren eine 
Hydroxylierung an C-18, HffG katalysiert eine Hydroxylierung an C-7 und CYP3 
katalysiert eine Epoxidierung zwischen C-6 und C-7. Drei neue epoxidierte 
Cytochalasane wurden erhalten. 
Vier 4’-halogenierte Phenylalaninvarianten wurden zusammen mit 4’-allyl-, 4’-
propargyl- und 4’-azido-Phenylalanin an den ∆pyiA Knockoutstamm verfüttert. Dies 
resultierte in der Bildung von sieben neuartigen 4’-funktionalisierten Pyrichalasanen mit 






Ausgehend von den 4’-substituierten Pyrichalasanen wurden viele weitere 
funktionalisierte Pyrichalasane durch nachfolgende chemische Modifikationen erhalten. 
Triazol-Pyrichalasane wurden aus Azid 258 und dem Alkin-Pyrichalasin 252 als 
Startmaterial durch Click-Chemie hergestellt. Bromo-Pyrichalasin 256 ist das Substrat 
für die Herstellung des dimeren Pyrichalasins 318 via Suzuki Kreuz-Kopplung, 
während Iodo-Pyrichalasin 257 das Substrat für Sonogashira-Reaktionen darstellt. Des 
Weiteren wurden fünf Farbstoff-gekoppelte Pyrichalasane 308 - 316 für die 
Visualisierung von Aktin in der Zellbiologie hergestellt. In der Summe wurden 
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Abbreviations and Units 
A adenylation domain Kb kilobase 
aa amino acid KR β-ketoreductase 
ACE1 avirulence conferring enzyme 1 KS β-ketosynthase 
ACP acyl carrier protein KO knockout 
AMT agrobacterium mediated 
transformation 
L liter 
ATP adenosine triphosphate LB lysogeny broth 
AT acyl transferase LCMS liquid chromatography- mass 
spectrometry 
aq. aqueous LDKS lovastatin diketide synthase 
bar basta resistance gene LNKS lovastatin nonketide synthase 
BGC biosynthesis gene cluster M mol/l 
BLAST basic local alignment search tool mg milligram 
bp base pair mRNA messenger RNA 
℃ Celsius m/z mass tocharge ratio 
CDNA complementary DNA mFAS mamalian 
C-MeT c-methyl transferase min minute 
CoA co-enzyme A mL millilitre 
COSY correlation spectroscopy MS mass spectrometry 
CuI copper iodide MT methyltransferase 
CuSO4 copper(II) sulfate NADPH nicotinamide adenine dinucleotide 
(phosphate) 
DA Diels Alder(ase) NHEJ non-homologous end-joining 
DAD diode array detector NMR nuclear magnetic resonance 
ddH2O double distilled H2O ORF open reading frame 
DMAP dimethylaminopyridine PAM protospacer adjacent motif 
DMF dimethylformamide PEG polyethylene glycol 
DMSO dimethylsulfoxide PKS polyketide synthase 
DNA deoxynucleic acid PT product template 
 
DH dehydratase PMT protoplast mediated transformation 
DIPEA N,N-diisopropylethylamine PCR polymerase chain reaction 
DKC Dieckmann cyclisation PCP peptide carrier protein 
dNTP deoxynucleotide triphosphate Q-TOF quadrupole time- of-flight 
EDTA ethylenediaminetetraacetic acid R reductive release domain 
EtOH ethanol RT room temperature 
EDC N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide  
RT-PCR reverse transcriptase 
EtOAc ethyl acetate RNA ribonucleic acid 
ER enoyl reductase rpm revolutions per minute 
eGFP enhanced green fluorescent protein SAM S-adenosyl methionine 
eq equivalent SAT starter unit acyl carrier protein 
ESI electron-spray ionisation SDR short chain dehydrogenase/reductase 
ELSD evaporative light scattering detector SDS-PAGE sodium dodecyl sulfate polyacrylamide 
gel electrophoresis 
FAD flavin adenine dinucleotide S. 
cerevisiae 
Saccharomyces cerevisiae 
FAS fatty acid synthase sp. species 
g gram T thiolation 
gDNA genomic DNA TAE tris-acetate-EDTA 
GOI gene of interest TCEP tris(2-carboxyethyl)phosphine 
HMBC heteronuclear multiple bond 
correction 
THF tetrahydrofuran 
HPLC high performance liquid 
chromatography 
TE thiolesterase 
hyg hygromycin B resistance cassette TFA trifluoroacetic acid 
HR homologous recombination U uracil 
HRMS high resolution mass spectrometry UV ultra violet 
HSQC heteronuclear single quantum 
correlation 
v/v volume per volume 
Hz hertz w/v weight per volume 
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1.1 Natural Products in Fungi 
Fungi are important eukaryotic microorganisms.1 Many fungi can produce a wide range 
of organic compounds, including primary metabolites and secondary metabolites.2,3 
Primary metabolism can be divided into sugars, organic acids, amino acids, proteins and 
lipids.4 They are essential for growth, development and reproduction of cells. The 
primary metabolites participate in the primary response by the regulation of 
carbohydrates, protein and lipids.5 
Fungi are important producers of secondary metabolites. Many fungal secondary 
metabolites exhibit potent biological activities. For example: penicillin V 1 is a useful 
antibacterial agent; aflatoxins 2 are potent toxic and carcinogenic compounds which 
threaten human, animal, and plant health; cephalosporin C 3 can cure Gram-positive and 
some Gram-negative bacterial infections; compactin 4 reduces the risk of cardiovascular 
disease by preventing conversion of mevalonate into cholesterol; and kojic acid 5 is 
currently used to lighten skin color and treat abnormal hyperpigmentation.6 In China, 
Japan and Korea, mizoribine 6 is used for renal transplants (Figure 1.1).7 
 
 




In general, natural products can be divided into four major classes. They are alkaloids, 
terpenes, polyketides and peptides.5-7 
 
1.1.1 Alkaloids 
Alkaloids are a group of basic nitrogen-containing, low molecular-weight compounds, 
mostly derived from amino acids. Different from other kinds of secondary metabolites, 
most of alkaloids have unique biosynthetic origins. Clavicipitaceae and Trichocomaceae 
are the main fungal producers of ergot alkaloids 7 - 9 which have both harmful and 
beneficial effects to humans and have possibly been known for thousands of years.8 Due 
to their potent biological activity, many of them have been exploited as pharmaceuticals, 
narcotics and poisons, such as compounds 10 - 12 (Figure 1.2).6,8 
 
 
Figure 1.2 Examples of fungal alkaloids.6,8 
 
1.1.2 Terpenes 
Terpenes are mainly produced by odoriferous plants, for example, camphor and 
turpentine. However, fungi also biosynthesize many important terpenes, including 
aristolochenes 13, gibberellins 14, oleane 15,9 myrcene 16 and carotenoids 17. All 
terpenes are built from isoprene units and can be linear or cyclic, unsaturated or 
13 
 
saturated. Furthermore, they can be modified in many ways. Common terpenes can be 
divided into four classes: monoterpenes (C10), which are generated from geranyl 
pyrophosphate; sesquiterpenes (C15) come from farnesyl pyrophosphate; diterpenes (C20) 
and carotenoids originate from geranylgeranyl pyrophosphate. Triterpenes (C30) are 
classified among an extensive and structurally diverse group of natural substances, 
referred to as triterpenoids.10 Their structure includes 30 carbon atoms. Derivatives of 
squalene, are usually tetracyclic and pentacyclic, containing respectively four and five 
rings (Figure 1.3).9,10 
 
 
Figure 1.3 Examples of fungal terpenes.9,10 
 
1.1.3 Polyketides 
Polyketides have been regarded as one of the most important classes of secondary 
metabolites.11 They are produced by plants, bacteria and marine organisms as well as 
fungi.12 The best-characterized fungal polyketides include: the yellow spore-pigment 
intermediate naphthopyrone (WA) 18,11 produced by Aspergillus nidulans; the 
carcinogen aflatoxin B1 19; the commercially useful cholesterol-lowering compound 





Figure 1.4 Examples of fungal polyketides.6,12 
 
Polyketides are biosynthesized by large multifunctional enzymes called polyketide 
synthases (PKS).6 PKS proteins are characterised into three types: Types I, II and III. 
Type I PKS are found in bacteria and fungi. Type II PKS consist of individual 
monofunctional proteins and are restricted to bacteria. Type III PKS (chalcone and 
stilbene synthases) are very simple systems found in plants, bacteria and fungi (Figure 
1.5).10 
Fatty acids serve as central components of membrane lipids and act as energy storage 
compounds in the form of triacylglycerols. They play important role in life. In the 1970s, 
it was reported that eukaryotic fatty acid biosynthesis is executed by large, 
multifunctional proteins known as type I fatty acid synthases (FAS). Type I FAS can be 
divided into yeast FAS (yFAS) and metazoan FAS (mFAS) based on the complete 
different domain organisation.13 
Both type I FAS and PKS catalyse multiple rounds of precursor elongation by the same 
set of enzymatic domains in one multienzyme. Polyketides are synthesised from small 
coenzyme-A (CoA) esters, such as, acetyl-CoA 22, malonyl-CoA 23, propionyl-CoA 24 
and butyryl-CoA 25 by continuous decarboxylation condensation catalysed by 
polyketide synthase enzymes. The vast diversity of polyketides originates from the use 
of small units like acetyl CoA, after elongation and modification. Fungal polyketide 
biosynthesis is closely related to fatty acid biosynthesis, which is often used as a guide 




Figure 1.5 Chemical structures of Acetyl-CoA, NADPH, ATP and SAM.14,15 
 
Both fatty acid and polyketide biosynthesis begin by using an acyltransferase (AT) to 
load an acetyl-CoA starter unit 22 onto the ketosynthase (KS) domain. A malonyl-CoA 
extender unit 23 is then loaded onto an acyl carrier protein (ACP), which has a 
phosphopantetheine (PP) moiety 34 from CoA (Scheme 1.1, steps I-III).16 Then, 
triggered by decarboxylation, the KS domain catalyses a Claisen condensation between 
the starter unit 22 and extender unit 23, resulting in carbon chain extension intermediate 
compound 24 attached to the PP arm of the ACP domain (Scheme 1.1, steps IV-V). 
Both polyketide and fatty acid biosynthesis requires the KS domain, while the ACP 
domain used by all FAS is not needed in Type III polyketide biosynthesis.17 Similarly, 




After the condensation, fatty acid biosynthesis continues with processing of the β-keto 
group, attached to the phosphopantetheine (PP) arm of the ACP domain. The β-keto 
group is first reduced to an alcohol 25 by the ketoreductase (KR) domain. The alcohol is 
dehydrated by the dehydratase (DH) domain to form olefin 26, which is then reduced 
again by the enoyl reductase (ER) domain to yield a fully reduced thiolester 27 (Scheme 
1.1, steps VI-VIII). The KR and ER domains use the cofactor NADPH 35 (Figure 1.5) 
to reduce the β-keto group in 25 and 27 respectively (Scheme 1.1). The AT domain then 
transfers this newly formed saturated thiolester from the PP arm of the ACP domain 
back to the KS domain. The cycle repeats with the condensation of malonyl units until 
the chain reaches a critical length 28 (usually 16-18 carbons, step IX). Finally, the 
thiolesterase (TE) releases the fatty acid 33 (Scheme 1.1, steps X-XII).19 
 
 
Scheme 1.1 Biosynthesis of polyketides and fatty acids.19 
 
Polyketide biosynthesis proceeds through all the same catalytic steps, however the 
growing chain does not always need to be fully reduced and transferred back to the KS 
domain from the PP arm of the ACP domain at either the KR 25, DH 26, or ER 27 
stages. In addition, the growing chain can be methylated by a C-methyltransferase (C-
17 
 
MeT) domain, the methyl group come from S-adenosyl methionine (SAM) 36 (Figure 
1.5).18 This occurs at the β-keto 24 stage, then either KR, DH, or ER are involved and 
yield the non-reduced 31 or reduced/partly-reduced polyketide 32 (Scheme 1.1, step 
XIII). Fungal PKS are also known to use alternative starter units including benzoate, e.g. 
strobilorin.20,21 Finally, once the polyketides have been assembled, a series of ‘tailoring’ 
enzymes can further modify the core structure by post-assembly modifications 
(reduction, oxidation, cyclisation, etc.).22,23,24 
The major catalytic domains of fungal PKS are closely related to those of mFAS. They 
include KS, DH, ER, KR and C-MeT domains. There is very little structural data for 
fungal PKS, but there are good crystal structures of mFAS.13 mFAS consists of a 
dimeric polypeptide with domains in the order (N to C) KS, AT, DH, ψC-MeT, ψKR, 
ER, KR, ACP and TE. The ψC-MeT domain is a non-functional methyl transferase. The 
ψKR domain is a structural (non-catalytic) domain of the KR. The mFAS protein forms 
an X-shaped dimer (Figure 1.6). The dimeric structure is divided into two subunits and 
connected by a narrow polypeptide linker in the center. The N-terminal KS domain is 
linked to the AT domain through an α/β fold linker domain. The KS, and AT domains 
were defined as the “condensing region”. The second subregion consists of KR, DH and 
ER domains, which are required for β-carbon modification and referred to as the 
“modifying region” (Figure 1.6). The modifying and condensing regions are connected 
by a covalent peptide linker. The crystal structure of dimeric mFAS suggests that the 






Figure 1.6 Schematic architecture of mFAS domain connectivity.13 Abbreviations: KS, 
ketosynthase; AT, acetyl transferase; DH, dehydratase; C-MeT, C-methyltransferase; ER, 
enoylreductase; KR, ketoreductase; ACP, acyl-carrier protein; TE, thiolesterase. 
 
Type I PKS consist of very large multifunctional proteins with individual functional 
domains, they can be either modular or iterative. All fungal PKS belong to the iterative 
type I class (iPKS). Modular type I PKS systems are found in bacteria.10,25 In iterative 
type I PKS systems, the chain is reloaded to the single KS after each extension and β-
modification cycle. Each β-processing cycle can be different. The variation in β-
processing is referred to as programming. 
Based on the degree of programming and extent of β- processing, fungal iterative PKS 
can be further grouped into three major subtypes: non-reducing (NR-PKS); partially 
reducing (PR-PKS); and highly reducing (HR-PKS).26,27,28 
To date, all HR-PKS consist of an N-terminal KS domain, followed by AT and DH 
domains. The DH is often followed by a functional C-methyltransferase (C-MeT) 
domain in many cases.10,29,30 Some HR-PKS have a functional ER, but in many HR-
PKS, there is a broken ER domain, and these systems often have a trans-acting ER 
encoded by a separate gene. After the ER domain is the KR domain and the PKS is 
terminated by an ACP domain. Fungal HR-PKS thus have the same catalytic domains 
19 
 
arranged in the same order as mFAS, but with the difference that C-MeT is usually 
functional. T-toxin 38 and squalestatin 39 are examples of polyketides produced by HR-
PKS (Figure 1.7 A).10 
 
 
    
Figure 1.7 A, Domain structure of HR-PKS and related metabolites; B, Domain structure of PR-
PKS and related metabolites; C, Domain structure of NR-PKS and related metabolites.10 
 
The enzymology of PR-PKS is much less understood. The domain structure is similar to 
mFAS. They consist of an N-terminal KS domain, followed by AT, TE, KR and ACP 
domain. In some cases, there is a DH domain, but an ER domain has never been found. 
6-MSA 40 is an example of a polyketide produced by a PR-PKS (Figure 1.7 B).10 
The final class of fungal PKS are the NR-PKS. They usually begin with a starter unit 
ACP transacylase (SAT) domain, which is responsible for starter unit loading. KS and 
AT domains follow, and as usual are involved in the chain extension.10 A product 
template (PT) domain is unique in NR-PKS, and has a cyclisation function. The PT 
20 
 
domain is followed by a C-terminal ACP domain.31,32 Many additional domains have 
been reported at the C-terminus, such as the Claisen-cyclase-thiolesterase (CLC-TE), 
and C-methyltransferase (C-MeT) doamins. A reductive release (R) domain can be 
found in some NR-PKS domains, playing a role to release the polyketide as an aldehyde 
or primary alcohol.10,31 An example of a polyketide produced by NR-PKS is citrinin 41 
(Figure 1.7 C).10 
 
1.1.4 Peptides 
Peptides are another extremely diverse group of natural products produced by fungi.4 
Both proteinogenic and non-proteinogenic amino acids can be the building blocks of 
peptides.33 Their structural diversity is vast, with variations in the length of peptide, 
cyclisation pattern, and very many possible tailoring modifications. Peptides have 
already shown great potential.33,34 For example, the bioactive cyclosporin A 42, the 
antifungal compounds threoninepeptide 43 and valinepeptide 44, and the glucan 
synthase inhibitor phalloidin 45 (Figure 1.8).7,18,32,35,36 
 
 




Peptides are made by two different systems. These are ribosomal and the non-ribosomal 
peptides. Nonribosomal peptides synthetases (NRPS) are responsible for the 
biosynthesis of nonribosomal peptides. NRPS consist of a large multidomain modular 
enzymes. These contain three core domains: adenylation (A); condensation (C); and 
peptidyl carrier protein (PCP) domains. These three domains, working together, 
constitute the repeating module responsible for activation and incorporation of amino 
acid into the growing peptide chain.37 
The modules of NRPS are made up of catalytic domains that catalyse single steps 
(Scheme 1.2). Each amino acid is precisely selected, activated and loaded by the 
adenylation (A) domain with the participation of ATP, then transferred to the terminal 
thiol of a phosphopanteteine prosthetic group of a peptidyl carrier protein (PCP), which 
is the transport unit through the loading step (Scheme 1.2, step I). 
PCP are functionally and structurally closely related to ACP in FAS and PKS systems. 
In the initiation and elongation steps, the condensation (C) domain catalyses the 
formation of an amide bond between amino acids held by adjacent PCP domains 
(Scheme 1.2, step II-IV). Once the completed peptide is formed, it can be released either 
by a thiolesterase (TE) domain or by a modified C domain in the termination step to 





Scheme 1.2 A schematic overview of a general NRPS biosynthethic pathway.37,40 
 
Gramicidin S 48 is one of the most effective antibacterial peptides with regard to its 
ability to inhibit the growth and kill bacterial cells.41 48 is biosynthesized by two NRPS 
proteins, GrsA and GrsB, that catalyse thiotemplated peptide bond formation and 
release by cyclodimerization to form the cyclic decapeptide (Scheme 1.3).42 
Phenylalanine, proline, valine, leucine and asparagine are precisely selected by the A-
domain of each module and then transferred to the cognate PCP domains. The 
condensation domain then catalyses the formation of a linear peptide 47 before final 





Scheme 1.3 Gramicidin S 48 biosynthesis.41 
 
The genome sequencing efforts lead to the finding of ribosomal peptides, they are 
ribosomally–synthesized and post-translationally-modified peptides (RiPPs).7 
Phallotoxins are produced by several species of mushrooms in the genera Amanita, 
Galerina and Conocybe.43 Phallotoxins such as phalloidin can bind to actin and have 
been used as an imaging tool to stain the cell skeleton. The precursor peptides contain a 
10-residue leader peptide, a 7- residue core peptide and a C-terminal recognition 
sequence (Scheme 1.4). The leader and recognition sequences are highly conserved, but 





Scheme 1.4 The chemical structure of Phalloidin 45.43 
 
1.1.5 Polyketide Synthase – Nonribosomal Peptide Synthetase 
(PKS - NRPS) Hybrids 
PKS–NRPS hybrids have been known in fungi for more than ten years.44,45 These 
hybrid enzymes are made up of a fungal iterative type I PKS fused to a single NRPS 
module that is sometimes truncated. Fungal type I PKS–NRPS use a set of catalytically 
active domains to build up a polyketide-amino acid (PK–AA) hybrid molecule, in an 
iterative way.46 The biosynthetic pathway for PKS-NRPS hybrids cytochalasin E and K 
can be proposed, based on the deduced gene functions of the ccs gene cluster. The 
domain organization of the PKS-NRPS encoded by ccsA, which is similar to other 
reported PKS-NRPS genes, for example, including CheA in Penicillium expansum (35% 
identity to ccsA), TenS in Beauveria bassiana (33% identity to ccsA) and FusA in 
Fusarium venenatum (36% identity to ccsA).47,48 
Two different release mechanisms have been demonstrated from PKS-NRPS hybrids. 
These are, Dieckmann condensation and reductive release. Tenellin 55 is produced by 
the insect pathogen fungus Beauveria bassiana CBS 110,16 which belongs to fungal 2-
pyridones, are also interesting from biosynthesis perspective. The tenellin biosynthetic 
gene cluster was found by the Cox group by systematic screening of a genome library 
with degenerate primers based on conserved regions in the C-MeT domain of highly 
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reducing PKS and fungal PKS-NRPS hybrids.49 The positive clone revealed a gene 
cluster comprised of 4 putative genes: two cytochrome P450 oxygenases (TenA and 
TenB); a trans acting ER (TenC); and the iterative PKS-NRPS hybrid (TenS). 
Heterologous expression of TenS in A. oryzae M-2-3 showed the PKS-NRPS to produce 
pretenellin A 53 when expressed together with TenC. However, prototenellin A-C, 
tetramic acids with incorrect polyketide side chain were produced when express TenS 
alone.50 Formation of tetramic acids without involvement of any oxygenase suggests 
that the release domain functions as a Dieckmann cyclase in this case rather than as 
reductase. The biosynthetic pathway then requires ring expansion from tetramic acid 
precursor 52 to the 2-pyridone pretenellin B 54 is catalysed by TenA. The other 
cytochrome P450 oxygenase, TenB, then catalyses the N-hydroxylation as shown in a 
combination of heterologous expression, RNA silencing and cell free extract 
experiments, lead to the production of tenellin 55 (Scheme 1.5).51 
 
 




Fusarins have been isolated from various species of Fusaria.53 These compounds are a 
group of mycotoxin acyl-pyrrolidones.54 The gene cluster involved in the biosynthesis 
of fusarin C 62 in Fusarium venenatum was confirmed by Simpson and co-workers. 
The fusA gene is responsible for the early stages biosynthesis of compound 62.  
Fusarin synthetase (FUSS), encoded by fusA, consists of a type I iterative PKS fused to 
an NRPS. A tetramethylated polyunsaturated heptaketide 58 is generated by the FUSS 
PKS and held by the ACP domain.45 Homoserine 56 is adenylated and transferred to the 
PCP domain. The condensation domain then catalyses nucleophilic attack by the 
homoserine nitrogen atom on the ACP-bound polyketide, forming an intermediate 
amide 59 held by the NRPS of FUSS. The final biosynthetic step is the reduction of the 
PCP-bound thiolester catalysed by the reductive domain of NRPS. In the biosynthesis of 
fusarin, the product of the reduction is thought to be a free aldehyde 60, which then 
undergoes a cyclisation reaction to form the pre-fusarin 61 in which the polyketide has 
been fully elaborated and fused to homoserine aldehyde to give the unmodified 1,5-
dihydropyrrol-2-one ring 61. Pre-fusarin then undergoes with several steps of 
modification reactions to produce the final product fusarin C 62 (Scheme 1.6). 
 




Over 300 cytochalasans have been described in the literature.56 Cytochalasans are a 
large class of structurally diverse fungal hybrid polyketide-non ribosomal peptide 
secondary metabolites, which possess a wide range of biological activities. 
The major biological activity of cytochalasan is targeting the actin cytoskeleton. This 
affects cellular processes such as cell adhesion, motility, signalling and cytokinesis.57 
New bioactivities of cytochalasans have been reported, including nematicidal,58 
antifouling,59 and anti-inflammatory properties.60 Also including induction of apoptosis 
in leukemia cells,61 inhibition of angiogenesis,62and activity against multi-drug resistant 
bacteria.48 
Typical cytochalasans contain a tricyclic core, formed from a macrocycle fused to an 
octahydro isoindole moiety, derived from a highly reduced polyketide backbone and an 
amino acid. Common cytochalasans are biosynthesized from the amino acids 
tryptophan63 (e.g. chaetoglobosin A 63) or phenylalanine (e.g. cytochalasin E 64).64 
Moreover, cytochalasans can also incorporate other amino acids such as tyrosine (e.g. 
pyrichalasin H 65, phenochalasin 68),65 leucine (e.g. periconiasin A 66),66 valine (e.g. 
trichalasin A 67, Figure 1.9).64,67 
 
 




1.2.1 Isotopic Labelling Experiment of Cytochalasin E 
Tang and co-workers revealed the origin of carbon atoms in cytochalasin E 64 by using 
isotopic labelling experiments.69 Doubly labelled [13C and 18O2] acetate was fed to 
Aspergillus clavatus grown in potato-extrose (PD) liquid stationary culture at 30 ℃ for 
4 days. Labelled compound was isolated, purified by column chromatography and 
characterized by 1H and 13C NMR. The result showed that the origin of carbon atoms of 
both C-1 and C-21 derived from acetate. Also, C-7, C-13, C-15, C-17 and C-19 were 
shown to originate from acetate through NMR spectra. Both C-1 and C-21 of 64 
recovered from culture supplemented with double labelled acetate, indicating that these 
carbonyl oxygen atoms are derived from acetate during polyketide assembly (Scheme 
1.7 A). To confirm the origin of oxygen at C-17, cytochalasin E 64 was isolated from A. 
clavatus grown in a closed system in which the oxygen consumed was replaced by 18O2 
for 4 days. Labelled 64 was isolated and characterized by 1H and 13C NMR. The result 








1.2.2 Biosynthesis of Cytochalasin E and Cytochalasin K 
The biosynthetic pathway for cytochalasins E 64 and K 82 can be proposed, based on 
the deduced gene functions of the ccs gene cluster (Table 1.1).70 

















ccsD 78670 Cytochrome P450 P450 monooxygenase 
ccsE 78680 αβ-hydrolase Esterase 
ccsF 78690 n/a Unknown 
ccsC 78700 
Enoyl reductase of the 
MDR family 
Enoyl_reductase 




The ER domain of the PKS – NRPS hybrid encoded by ccsA is probably inactive, 
because it lacks the key NADPH 35 binding motif (LXHXG(A)XGGVG, Scheme 1.5). 
An octaketide backbone 69 is synthesized by the HR-PKS module of ccsA. Then, 
phenylalanine 70 is selectively activated by the A domain of the NRPS module and 
transferred to the phosphopantetheinyl arm of the PCP domain. This is followed by a 
condensation catalysed by the C domain, between the nucleophilic amino group of 
phenylalanine and the electrophilic carbonyl of the ACP-bond polyketide. This gives 
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the PCP tethered amide intermediate 71. The R domain from the NRPS module is then 
proposed to catalyse reductive release to give an aminoaldehyde intermediate 72, which 
then undergoes an intramolecular Knoevenagel condensation to give the 3,5-
disubstituted 3-pyrrolin-2-one 73.68,71 Subsequently, this is cyclized by intramolecular 
[4+2] Diels-Alder reaction between the terminal polyketide diene and the 3-pyrrolin-2-
one dienophile to give the 11-membered carbocycle-fused perhydroisoindolone 
backbone 74 (Scheme 1.8). The Knoevenagel and Diels-Alder reactions have been long-
proposed, but currently there is little evidence to show which proteins catalyse these 
steps. 
After the formation of the 11-membered carbocycle-fused perhydroisoindolone 
intermediate 74, several steps of oxidation occur to afford the final cytochalasins E 64 
and K 82.68,71 Two Baeyer–Villiger oxidations are catalysed by ccsB to afford 
intermediates 76 and 77. Afterwards, two hydroxylations at C-17 and C-18, catalysed 
by CcsD and CcsG, produce compounds 78 and 64. Cytochalasin E then catalyzed by 
CcsE to give cytochalasin K 82. Epoxidation at C-6/C-7 to yield 80, is also catalysed by 






Scheme 1.8 Proposed biosynthetic pathway of cytochalasin E 64 and K 82.70,74 
1.3 Tailoring Modifications in Natural Product 
Biosynthesis 
 
1.3.1 Cytochrome P450 Monooxygenase 
Biological oxygenation is often provided by iron-based monooxygenases, in both heme 
and non-heme varieties. The mechanisms by which electrons are passed from iron to 
liganded O2 and for the reaction with bound substrates, by both subclasses have been 
studied deeply.75 
Cytochrome P450 monooxygenase enzymes are the most common enzymes to 
oxygenate natural products. They are heme-proteins in which iron is bound to four 
nitrogen atoms of a porphyrin e.g. heme B 83 (Scheme 1.9) and to a protein cysteine 
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residue. The cytochrome P450 enzymes form a family of heme proteins that participate 
in the biosynthesis of secondary metabolites. These monooxygenases catalyse many 
reactions such as hydroxylations, epoxidations and Baeyer-Villiger oxidations. P450 
enzymes use NADPH as a source of electrons via a redox partner that is required to 
transfer these electrons between NADPH and the iron centre.  
The catalytic cycle is initiated by the substrate (RH) binding to the ferric P450 to yield 
85. The first electron is then transfered from NADPH to P450 to give compound 86 
(Scheme 1.9, step I-II). The reduced iron then rapidly binds with oxygen to produce an 
Fe(II)-O2 complex 87 (Scheme 1.9, step III). A second electron transfer results in the 
formation of an iron-peroxide species 88 which is protonated, followed by loss of water 
to form a high valent oxo-iron cation radical intermediate 90 (Scheme 1.9, step IV-VI). 
This intermediate is proposed to abstract a hydrogen atom from the substrate to form an 
FeIII-hydroxide complex. Radical recombination then occurs to produce the oxygenated 
product (Scheme 1.9, step VII). This step is usually referred to as the rebound step. In 
the whole process, P450 take two electrons from NADPH and deliver one oxygen atom 











Scheme 1.9 Schematic representation of the consensus P450 catalytic cycle and peroxide 
shunt pathway.76 
 
An example is the late stage chaetoglobosin A 63 biosynthesis, after the Diels-Alder 
cyclization to form the intermediate 91. This is oxidised by two P450 enzymes and one 
oxidoreductase in two separate steps to generate the final compound 63. Deletion of 
P450-2 led to the production of 93, revealing that this P450 catalyses iterative 




Scheme 1.10 The late stage biosynthesis of Chaetoglobosin A 63.77,78 
 
1.3.2 Alpha Keto Glutarate Dependent Dioxygenase 
Fe(II)/α-ketoglutarate (α-KG) dependent oxygenases are a large class of enzymes that 
catalyse a wide array of oxygenation reactions. α-KG Oxygenases are typically involved 
in processes, including protein side chain modification, repair of alkylated DNA and 
RNA, biosynthesis of antibiotics, biosynthesis of plant metabolites and other assorted 
functions.79 
Crystal structure and magnetic circular dichroism (MCD) data reveal that the resting 
form of the enzyme consists of a six coordinate octahedral Fe2+ center coordinated to 
three protein facial triad residues and three water molecules 96.80,81 The first step is 
binding of α-KG, forming the (Fe + α-KG) 98 form of enzyme (Scheme 1.11, step I). 
Next, primary substrate binds, inducing water release to give 99 and the opening of a 
coordination site for O2 binding (Scheme 1.11, step II). The next steps in the consensus 
mechanism are not fully understood, but are proposed to involved the same hydrogen 
atom abstraction (HAT) / rebound paradigm of the P450 oxygenases.  
Due to the loss of the water ligand, a binding site for O2 is created, and the substrate 
binding reactivity towards O2 is significantly increased.
82 It is thought that O2 binds to 
form a Fe(III)-peroxyl adduct 100 (Scheme 1.11, step III), which attacks the keto group 
of α-KG to form an intermediate which can be formulated as a bicyclic peroxybridge 
Fe4+ species 101. Decarboxylation and heterolytic cleavage of the O-O bond leads to the 
production of an Fe(IV)-oxo intermediate 102 (Scheme 1.11, step IV-V) which was 
identified as the species responsible for the HAT from the primary substrate.83,84 
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Scheme 1.11 Chemical mechanism for α-KG oxygenases.83,84 
 
Clavaminate synthase-2 (CS2) is an interesting member of the α-KG dependent 
oxygenase class. It plays an important role in the construction of the strained bicyclic 
clavam ring structure during the biosynthesis of clavaminic acid 109, an advanced 
precursor of the potent β-lactamase inhibitor clavulanic acid.85 During the biosynthesis 
of clavulanic acid 109, CS2 catalyzes the hydroxylation of 
deoxyguanidinoproclavaminic acid (DGPC) 105 to guanidinoproclavaminic acid, 
coupled to the oxidative decarboxylation of the cosubstrate α-KG to succinate and CO2. 
In the first step, one atom of O2 is incorporated into the hydroxylated product 106 and 
the other one appears in succinate.86,87 Next, proclavaminate amidino hydrolase (PAH) 
removes the guanyl group to yield proclavaminic acid (PC 107).88,89 Then CS2 catalyses 
the oxidative ring closure of PC 107 to dihydroclavaminic acid 108, which is 
subsequently desaturated to clavaminic acid 109. Both steps are coupled to the oxidative 
decarboxylation of α-KG. In the ring-closure and desaturation reactions, the second 




Scheme 1.12 Biosynthetic pathway of clavulanic acid 109.85 
 
1.3.3 Methyltransferase 
Methylation can be divided into S-, O-, N-, and C-types and are found in various 
organic compounds from small molecular phenols to macromolecular proteins. O-
methyltransferases (O-MeT), a subgroup of methyltransferases, found in diverse 
organisms, including plants,91 animals92 and microbes93,94 can transfer the methyl group 
to a hydroxyl or carbonyl group from S-adenosyl methionine (SAM, 36).95 Many O-
MeT in fungi, such as those involved in aflatoxin biosynthesis have been well 
characterised. 
Aflatoxin B1 19 and B2 114 are secondary metabolites produced by the filamentous 
fungi Aspergillus flavus and Aspergillus parasiticus. These compounds are known to 
present a potential threat to human health. Many researchers have conducted extensive 
biomedical and genetic studies to better understand the biosynthesis and molecular 
regulation of aflatoxin biosynthesis.96,97,98 In the later biosynthestic steps of aflatoxin B1 
and B2, the conversion of sterigmatocystin 110 to O-methyl sterigmatocystin 111 and 
the conversion of dihydro-sterigmatocystin 112 to dihydro-O-sterigmatocysin 113 were 





Scheme 1.13 Late stages of the aflatoxin B1 and B2 biosynthesis pathway.99 
 
1.3.4 Acetyltransferase 
O-acetyltransferases play a significant role in the synthesis of many natural products 
(Scheme 1.14).100 T-2 toxin 117 is a trichothecene with an ester-linked isovaleryl group 
at C-8, produced by Fusarium sporotrichioides. The core trichothecene ring structure is 
formed from trichodiene synthase and subsequent multiple oxygenations, yielding the 
toxic intermediate isotrichodermol 115. TRI 101 is part of trichothecene gene cluster in 
Fusarium sporotrichioides encodes 3-O-acetyltransferase, which converts 
isotrichodemol 115 to isotrichodemin 116 through acetylation at C-3 hydroxyl position 








Scheme 1.14 Biosynthesis of isotrichodermin 117 catalyzed by TRI 101 enzyme.100 
 
1.3.5 Short-Chain Dehydrogenase/Reductase 
Short-chain dehydrogenases/reductases (SDR) are defined by few but distinct sequence 
motifs and form a well-established enzyme family of oxidoreductases. Currently, 
around 3000 structures of the SDR family are annotated in sequence databases, and the 
corresponding genomes represent all forms of life.101 
Citrinin 123 was discovered by Harold Raistrick and coworkers in 1930s and it was first 
isolated from Penicillium citrinum.102 The citrinin biosynthesis gene cluster Penicillium 
was systematically analysed. Several genes involved in the biosynthesis include: citS, 
encoding an nr-PKS; mrl1, encoding a serine hydrolase of no known function; mrl2, 
encoding a non-heme Fe(II) dependent oxygenase; mrl4, encoding an NAD(P)+ 
dependent aldehyde dehydrogenase; mrl6, encoding a short-chain dehydrogenase; and 
there is another NAD(P)+ oxidoreductase encoded by mrl7. 
The ACP-bound thiolester 118 was catalysed by CitA to form 119, then 119 undergoes 
an oxidation reaction to give 120, compound 120 was catalysed by the oxidoreductase 
CitC to form 121, the CitD catalyse the aldehyde 121 into acid product 122, citrinin 123 





Scheme 1.15 Deduced biosynthetic pathway to citrinin 123.102 
 
1.4 Pyrichalasin H 
 
1.4.1 Introduction 
Pyrichalasin H 65 is a member of the cytochalasan family. It is the first cytochalasan 
known to contain the methoxyphenyl group (Figure 1.10, Section 1.4.2). It is made up 
of three major parts: a methylated tyrosine, an isoindolone core and a macrocycle. 65 is 
first isolated as a phytotoxic metabolite from Pyricularia grisea (IFO 7287) in 1987, 
also called Magnaporthe grisea, which is a pathogenic fungus which causes blast 
disease in crabgrass (Digitaria sanguinalis).103,104 Isolations (thirty one from crabgrass, 
one from pangolagrass and six from D. horizontalis) show that pyrichalasin H is 
pathogenic to all Digitaria species (crabgrass, pangolagrass, Digitaria horizontalis, 
Digitaria ciliaris and Digitaria ischemum).105 65 shows various biological properties,106 
and has some biological activity against rice seedlings,107 strong effect on cell 
morphology and actin distribution in C3H-2K cells, and lymphocyte capping. 
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Figure 1.10 Structure of Pyrichalasin H 65 and rice blast disease.107 
 
1.4.2 Bioinformatic Analysis of the Pyirichalasin H Gene Cluster 
Pyrichalasin H 65 producing strain M. grisea NI980 was provided by the Lebrun group. 
Genomic DNA from M. grisea was prepared by Dr Elizabeth J. Skellam and the whole 
genome was sequenced in collaboration with CeBiTec in Bielefeld and the raw data was 
assembled to give a high quality draft genome.108 The whole genome sequence was then 
submitted to the fungiSMASH database for preliminary identification of secondary 
metabolite biosynthetic gene clusters (BGC). 
Genome annotation of M. grisea NI980 was done by Dr Elizabeth Skellam. The 
sequencing of M. grisea NI980 identified 66 BGC including 8 PKS-NRPS clusters. 
Three cytochalasan-like gene clusters were identified: a putative Avirulence Conferring 
Enzyme1 (ACE1) gene cluster; and a putative SYN2 gene cluster (Figure 1.11 A). A 
putative pyrichalasin H gene cluster located on M. grisea Scaffold Mg-Sc00012 was 
also identified. The putative pyrichalasin H gene cluster was further analysed using 
Softberry, FGENESH and NCBI Protein Blast (Table 1.2, GenBank accession number 
MK801691).109 Dr Elizabeth Skellam designated this putative BGC as the pyi gene 
cluster and assigned trivial names to the genes in analogy to the names of genes from 
the cytochalasin E 64 cluster.70 
The pyi BGC encodes a PKS-NRPS (pyiS), a trans-ER (pyiC), a putative Diels-Alderase 
(pyiF), and an αβ-hydrolase (pyiE). These are the four core genes which are present in 
all known cytochalasan BGC. Moreover, a transcriptional regulator (pyiR), an 
oxidoreductase (pyiH), and a transporter (pyiT) were also found in the BGC. The 
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presence of an O-methyltransferase (pyiA) and an O-acetyltransferase (pyiB) is also 
good evidence that the identified cluster is involved in the biosynthesis of pyrichalasin 




Figure 1.11 Cytochalasan BGC identified in Magnaporthe sp. A, M. grisea NI980; B, P. oryzae 
Guy 11. The ACE1 gene cluster from P. oryzae are highlighted in yellow, and the SYN2 cluster 













Table 1.2 Gene annotation of pyi cluster located on Scaffold00012.109 













































M.grisea_g1698.t1 PyiF pDA 




















M.grisea_g1701.t1 PyiB O-acetyltransferase SPI_05896 49% 98% 













1.4.3 Bioinformatic Analysis of the ACE1 Gene Cluster 
Pyricularia oryzae isolates that carry the gene encoding Avirulence Conferring 
Enzyme1 (ACE1) are specifically recognized by rice (Oryza sativa) cultivars carrying 
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the resistance gene Pi33.110 The avirulence gene ACE1 was identified by map-based 
cloning at one end of P. oryzae cosmid clone D31C12.111 The genomic sequence of the 
ACE1 locus was obtained from pyricularia oryzae Guy 11. 
Lebrun and co-workers analysed and characterized the ACE1 BGC from P. oryzae Guy 
11. The ACE1 BGC contains 15 genes and consist of two parts (Figure 1.11 B, Table 
1.3); the ACE1 gene cluster (Figure 1.11 B, highlighted in yellow); and the SYN2 gene 
cluster (Figure 1.11 B, highlighted in pink). OME1 encodes a putative SAM-dependent 
O-methyltransferase, SYN2 encodes a hybrid PKS-NRPS highly similar to ACE1. RAP1 
and RAP2 were identified to encode trans-acting enoyl reductases, ORF3 (pDA) and 
ORFZ (αβ-hydrolase) were identified between them. OXR1 (short-chain alcohol 
dehydrogenase) and OXR2 (FAD-dependent oxidase), were also identified between 
ACE1 and SYN2. The gene MFS1 identified between CYP2 and RAP2 encodes a 
putative transporter. Finally, the gene BC2 located between CYP1 and OXR2 encodes a 


















Table 1.3 predicted function of the ACE1 gene clusters in P. oryzae.112 
Gene  Name Conserved domain 
Putative 
function 




























MGG_08384.5 MFS1 Major facilitator superfamily 
MFS 
transporter 























Artemis comparison between the P. oryzae Guy 11 ACE1 cluster and the M. grisea 
NI980 pyi cluster revealed that 7 genes from the pyrichalasin H 65 cluster are homologs 
of the genes from the ACE1 cluster: OME1, SYN2, CYP4, RAP2, ORF3, MFS1, ORFZ 
and ACE1 (Figure 1.12). The core cluster of ACE1 (homologs of ACE1, RAP1 and 
ORF3) is present in the putative pyrichalasin H 65 gene cluster. The αβ-hydrolase 
ORFZ, is similar for pyrichalasin H and the ACE1 metabolites. The function of ORF3 
and ORFZ are particularly interesting as they could play a key role in the cyclization 
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reactions of cytochalasans. However, previous KO experiments of the ACE1 gene 
cluster failed, probably due to the chromatin structure.111 Heterologous expression of 
ACE1 and RAP1 in A. oryzae lead to theisolation of the shunt product 124 (Scheme 
1.16). This is derived from tyrosine and a C18 polyketide. It is thought that the A. oryzae 
host reduces the tyrosine-derived aldehyde to a primary alcohol. However 124 is clearly 
closely related to proposed cytochalasin intermediates (e.g. see cheme 1.8). In particular 
124 resembles 125 which is a key proposed intermediate during pyrichalasin H 65 
biosynthesis (Scheme 1.16). The structure of the ACE1 metabolites itself is unknown 
because the BGC is expressed only for a brief time in single cells (appressoria) during 
penetration of the rice leaf epidermis.  
 
 
Figure 1.12 Artemis comparison of cytochalasan BGC identified in Magnaporthe sp. M. grisea 




Scheme 1.16 Proposed key precursors from 65 and ACE1 biosynthesis.113 
 
This project focuses on investigating the tailoring enzymes involved in the late stage 
biosynthesis of pyrichalasin H 65. For example, the oxidoreductase encoding gene pyiH, 
the pyiA gene encoding an O-methyltransferase, the pyiB gene encoding an O-
acetyltransferase and two P450 genes, pyiD and pyiG. There are also four cytochrome 
P450 monooxygenase encoding genes, CYP1, CYP2, CYP3 and CYP4 contained in the 
ACE1 gene cluster, all predicted to encode monooxygenases with unknown selectivity. 
Heterologous expression of these cryptic P450 monooxygenase gene will be carried out 
to elucidate their functions.  
 
1.5 Diversifying Natural Products through 
Mutasynthesis and Semisynthesis 
 
1.5.1 Application of Mutasynthesis in Natural Products 
Natural products are an important source of lead compounds for drug development. To 
diversify natural products a number of approaches have been used. Mutasynthesis is 
built upon precursor-directed biosynthesis but utilises mutant micro-organisms deficient 
in a key aspect of the biosynthetic pathway.114 A typical strategy used for this approach 
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would be to supplemented a KO strain with a particular precursor, leading to the p 
roduction of a new natural product.114 
One typical example of mutasynthesis was in the production of new analogues of the 
aminoglycoside-aminocyclitol antibiotic neomycin 132. A mutant of the producing 
strain, Streptomyces fradiae, was selected. When the mutant strain was supplemented 
with the aminocyclitol precursor deoxystreptamine 129, neomycin 132 was produced. 
When this mutant strain was supplemented with the aminocyclitols streptamine 130 and 
epistreptamine 131 these unnatural precursors were also utilised by the biosynthetic 
machinery to produce the novel neomycin analogues, hybrimycin A1 133 and 
hybrimycin B2 134 respectively.115 The successful production of active neomycin 
analogues by mutasynthesis, lead to the application of this method to generate a whole 
range of aminoglycoside-aminocyclitol antibiotics (Scheme 1.17).114 
 
 
Scheme 1.17 Mutasynthesis of neomycin analogues.114 
 
1.5.2 Application of Semisynthesis in Natural Products 
Secondary metabolites generated by microbes have proven to be a valuable source of 
providing lead compounds for drug and agrochemical discovery. Over the past few 
decades, the investigation has revealed a portion of biologically active natural products 
that microorganism can provide. The unique small molecule structures offer an 
unprecedented potential for the creative application of semisynthetic transformations to 




One famous example of generating a semisynthetic library starting with a marine natural 
product utilizes the readily available natural product aureole 135 to create a library of 
semisynthetic products for biological evaluation. The target of this study was the 
rational and high-throughput modification of a marine natural product into a library of 
derivatives by utilizing hydroxyl functionality to generate more desirable molecules. 
Aureol 135 was used to generate a series of new semisynthetics beginning with 
commercially available acid chlorides with derivatives 136 - 143. All the derivatives 
were prepared with a mixture of 1 M eq. of activated zinc dust and an excess of acid-
chloride, stirred for 15 min followed by addition of aureol (Scheme 1.18).117 
 
 
Scheme 1.18 Representative acid chlorides utilized to generate new semisynthetic products.117 
 
1.6 Project Aims 
Genome sequencing of M. grise NI980 showed there are 8 PKS-NRPS cluster. However, 
only the pyi BGC contains gene encoding all four core enzymes necessary for 
cytochalasan biosynthesis a PKS-NRPS; a trans-ER; a putative Diels-Alderase (pDA); 
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and an αβ-hydrolase (section 1.4.2). Therefore, the pyi BGC was assumed to be 
responsible for 65 biosynthesis. Some tailoring genes encoding O-MeT, O-AcT and 
P450s are also presented in this BGC (Figure 1.12). 
First of all, the gene encoding PKS-NRPS from pyi BGC will be disrupted. The 
abolition of 65 will confirm that the pyi BGC is the correct cluster involved in 65 
biosynthesis. The mutant strain will be tested on crabgrass for pathogenicity by 
collaborators. If crabgrass no longer be infected, 65 will have the potential to be a 
genus-specific natural herbicide. 
Our major aims are to elucidate the late stage biosynthetic pathway of pyrichalasin H 65 
by knocking out the tailoring genes involved in its biosynthesis individually. Bipartite 
gene fragments combined with protoplast mediated transformation methods will be used 
to generate the KO mutants.126 The obtained intermediates and shunt metabolites 
isolated from KO strains will be fully analysed by LCMS and NMR. The structure of 
the shunts and intermediates will help us understand the function of each tailoring gene 
and how each catalyst participates in the biosynthesis. Finally, a detailed late stage 65 
biosynthetic pathway will be elucidated either in a linear, parallel or spontaneous way. 
Then, with some KO strains in hand, we will attempt to develop our mutant strains into 
a synthetic bioengineering platform by heterologous expression of unknown function 
genes from other biosynthetic pathways. These are two cryptic P450 genes from 
Hypoxylon fragiforme cytochalasin BGC (Figure 3.7) and four unknown CYP genes 
from the ACE1 gene cluster (Figure 1.12). The hffD and hffG genes will be investigated 
in P450 disruption strains. CYP gene will be expressed in the same host. We are aiming 
to achieve three goals: first, clarification of the promiscuity of cryptic P450 enzymes; 
second, the generation of novel cytochalasans by using combinatorial biosynthesis of 
different P450 genes; and finally, engineering the confirmed biosynthetic pathway to 
develop new branches for the main route. 
The adenylation domain of NRPS often shows tolerance towards different amino acid 
substrates. So the A-domain will be investigated in mutasynthesis experiments by 
feeding various 4’-substituted phenylalanines to pyiA KO strain. A small library of 4’-
functinalised pyrichalasans will be built during this study. 
Based on the library generated by mutasynthesis, a range of different chemical reactions 
can be executed to introduce interesting pharmacophores to pyrichalasin. For example: 
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the 4’-iodo-pyrichalasin could be used as substrates for Sonogashira reactions to add 
alkyne groups, the 4’-bromo-pyrichalasin could be the substrate for Suzuki cross 
coupling to generate un-natural dimeric pyrichalasins; and 4’-azido- and 4’-alkyne-
pyrichalasins could be starting materials for copper catalyzed Huisgen azide alkyne 
cycloaddition click reactions. Many bioconjugations can be generated by these chemical 
modifications.  
Pyrichalasin H 65 can bind with actin and has strong inhibition on actin polymerization. 
We can link dye molecules to it by click chemistry. These hybrid molecules could be 
developed into cell imaging tools to visualize the actin in cells. Finally, all the new 
cytochalasans generated by pathway elucidation, pathway engineering, mutasynthesis 
and semisynthesis will be tested systematically on antitumor activity, cytotoxicity and 
anti-microbial activity by our collaborators. Hopefully, we can find some promising 

















2 Investigation the Biosynthesis of Pyrichalasin H by 
Gene Disruption 
 




Fungal natural products are very important but they are not always produced in high 
yields, or they may need to be modified for pharmaceutical / agrochemical use. Before 
natural products can be engineered, their biosynthesis needs to be understood. One way 
to do this is through gene knockout (KO) studies – genes individually inactivated to 
reveal their function.118 
A good example of the use of this strategy comes from the investigation of the 
biosynthesis of the tropolone stipitatonic acid. Stipitatonic acid 144 is the true precursor 
of stipitatic acid 145. Stipitatonic acid is produced by the enzymes encoded by the 
Talaromyces stipitatus trop gene cluster, which contains 12 putative open reading 
frames clustered around the gene tspks1 (Scheme 2.1).119,120 
Cox and co-workers investigated the biosynthesis of stipitatic acid 145 using the 
bipartite KO strategy in T. stipitatus.121 The tsL2 gene, which encodes a putative 
cytochrome P450 monooxygenase, was targeted for KO.120,121 The mutant strain was no 
longer able to synthesize 144, 145, 150, 153 or 155, but tropolone 146 was formed. 
Next, the tsR7 gene, which encodes a putative NAD-dependent dehydrogenase was 
targeted for KO. Compounds 144, 145, 150, 153 and 155 were abolished from the 
metabolic profile, the major new compound obtained was stipitafuran 148. TsL2 is the 
C-9 hydrolase due to all isolated compounds are oxidized at C-9. The direct-9 oxidation 
products stipitacetal 147 / 149 was not observed.  
Another putative NAD-dependent dehydrogenase encoding gene, tsR4, was targeted for 
KO, and stipitaldehydic acid 153 was produced. The gene tsR1 encoding a putative 
hydrolase was targeted.122 The LCMS analysis of tsR1 KO showed that 154 was 
produced. In vitro experiments assay of TsR1 confirmed that it can rapidly hydrolyse 
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the bright yellow stipitatonic acid 144 to give colorless diacid 145. Compound 145 is 
the final product of the normal pathway. In vitro experiments confirmed that TsL3 can 
convert 154 to 145, the conversion speed was much increased by adding TsR1 into the 





Scheme 2.1 Proposed biosynthetic pathway of stipitatonic acid 144.121 
 
2.1.1 Bipartite Gene Targeting Strategy 
Although gene knock outs are an essential strategy for investigating gene function, it is 
difficult to achieve the desired genetic modification in fungi. Frequent ectopic 
integration of the introduced DNA fragments is caused by non-homologous end joining 
(NHEJ) mechanisms.123 DNA repair mechanisms make it difficult to generate efficient 
gene targeting frequencies. There have been reports that KO of genes involved in NHEJ 
in fungi can result in strains which have higher frequencies of desired recombination 
into target genes. However, the creation of NHEJ deficient strains requires KO 
experiments which are themselves low efficiency.124  
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Several strategies have been reported to achieve increased desired homologous 
recombination (HR) frequencies rather than the application of a NHEJ pathway 
deficient strain.125 One of the most useful methods is the use of a bipartite gene 
targeting strategy. This strategy involves the creation of two fragments of a KO 
construct, neither of which can on its own confer antibiotic resistance. When these 
fragments are introduced into fungi, the two fragments are recombined by HR and only 
then will the fungal selection marker become functional, leading to the targeted 
introduction of the full fragment into the genome by the activated HR mechanism 
(Scheme 2.2). The HR efficiency is much higher, then compared to using a single gene 
targeting fragment because the frequency of ectopic integration is greatly reduced.126 
 
 
Scheme 2.2 PMT with bipartite gene targeting substrates. TG, target gene; HR, homologous 
recombination; HygR, hygromycin resistant cassette; LF, left fragment; RF, right fragment; WT, wild 
type.126 
 
2.1.2 Protoplast-Mediated Transformation 
Protoplast mediated transformation (PMT) is the most widely used fungal 
transformation method, which relies on the creation of a large number of competent 
fungal protoplasts. The principle is to use some commercially available enzymes (such 
as Trichoderma harzianum lysing enzyme and Driselase enzyme) to digest fungal cell 
wall components, thereby generating protoplasts. Next, some chemical reagents (such as 






Scheme 2.3 Basic steps of the protoplast-mediated transformation. 
 
2.2 Aims 
The pyrichalasin H 65 producing strain M. grisea NI980 was provided by our 
collaborator Prof. Marc-Henri Lebrum. Genome sequence results showed that there are 
only three putative cytochalasin BGC (Chapter 1.4.2). Our first goal is to elucidate the 
chemical structures of all interesting metabolites produced by the WT strain. Then the 
pyiS gene will be the target for KO to confirm if the pyi BGC is responsible for 65 
biosynthesis.  
Once the pyi BGC has been confirmed, all the tailoring genes will be targeted for KO to 
confirm their possible functions. By systematic KO of these genes, we might also be 
able to isolate some novel cytochalasans or shunt products from the KO strain. In the 







2.3.1 Chemical Investigation of Magnaporthe grisea WT 
 
2.3.1.1 Major Compound 
Magnaporthe. grisea NI980 was used as the wild type (WT) strain in this study. For 
pyrichalasin H 65 the WT production strain was cultivated in DPY liquid medium for 7 
days at 25 ℃, 110 rpm. The liquid culture was extracted. The organic extract was 
drived and evaporated and the residue was dissolved into 1 mL HPLC MeOH and 
analysed by LCMS (Figure 2.1). 
In the DAD chromatogram several peaks were detected. Six interesting peaks were 
targeted for purification by Preparative LCMS (Figure 2.1).109 Approximately 61.6 mg 
65 (tR = 6.3 min) was obtained as white powder from 1 L DPY culture extracts. The UV 
spectra (MeCN / H2O) showed the maximum absorption at 276 nm (Figure 2.2), which 
indicated the presence of several isolated double bonds and a substituted aromatic ring. 
HRMS of 65 confirmed a molecular formula of C31H41NO6 ([M+Na]
+ calculated 
546.2832, found 546.2834). 
 
 









    
Figure 2.2 UV and mass spectra of compound 65. 
 
Full NMR was acquired, and analysis of 1H and 13C NMR data of 65 identified 31 
carbons and 41 protons (Table 2.1). The assignment of the 1H NMR spectrum is based 
on the results of 2D homonuclear correlation spectroscopy (COSY). Cross peaks were 
observed between the following pairs of signals: (δH - δH) 7.08-6.87, 5.85-5.57, 5.75-
5.41, 5.36-5.12, 5.36-3.86, 5.75-2.93,5.43-2.05, 3.83-2.98, 3.21-2.80, 2.80-2.65, 2.78-
0.99, 2.05-1.81, 1.81-1.06. This indicated the presence of a tertiary methyl group, two 
secondary methyl groups, a para-substituted benzene ring, two disubstituted double 

















Table 2.1 NMR data of 65 recorded at 400 MHz in CDCl3. Values are in agreement with published data.109 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.4 - - - 
2 5.57 s - - - - - 
3 3.23 ddd 4.6, 9.5, 
4.5 
54.0 CH 1‘, 1, 4, 9 4, 10 
4 2.12 dd 4.5, 4.9 50.4 CH 5, 6, 10, 11, 21 3, 5 
5 2.79 m - 33.0 CH 1’, 7, 11 4, 12 
6 - - - 148.1 - - - 
7 3.84 dd 10.8, 1.3 69.9 CH 5, 6, 8, 9, 13 8, 12 
8 2.95 dd 10.8, 9.8 47.3 CH 1, 3, 6, 7, 13, 14 7, 13 
9 - - - 51.9 - - - 
10a 2.61 dd 13.6, 9.5 44.8 CH2 1’, 3, 4 3, 11 
10b 2.80 dd 13.6, 4.6 - - - - 
11 0.99 d 6.7 14.2 CH3 4, 5, 6 10 
12a 5.12 brs - 114.2 CH2 5, 6, 7 5, 7, 15 
12b 5.36 brs - - - - - 
13 5.75 ddd 9.8, 
15.5, 1.3 
127.3 CH 7, 8, 15, 16 8, 14 
14 5.41 ddd 15.5, 
5.2, 10.4 
138.8 CH 8, 15, 16 13, 15 
15a 1.83 m - 42.9 CH2 13, 14, 16, 17, 22 12, 14, 22 
15b 2.05 m - - - - - 
16 1.83 m - 28.4 CH 17 17 
17a 1.56 dd 14.3, 2.7 53.8 CH2 16 16 
17b 1.88 m - - - - - 
18 - - - 74.5 - - - 
19 5.55 dd 17.1, 2.3 138.2 CH 8, 9, 20, 21, 23 20 
20 5.89 dd 17.1, 2.1 126.1 CH 8, 18, 19, 21 19, 21 
21 5.56 dd 2.1, 2.3 77.6 CH 8, 19, 20, 23, 24 20 
22 1.06 d 6.3 26.6 CH3 15, 16, 17 15 
23 1.37 s - 31.3 CH3 16, 17, 18, 19 - 
1‘ - - - 129.5 - - - 
2’ 6’ 7.07 d 8.6 130.2 2 x CH 3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 6.86 d 8.6 114.4 2 x CH 2’, 6’, 4’ 2’, 6’ 
4’ - - - 158.8 - - - 
24 - - - 170.3 - - - 
25 2.26 s - 21.0 CH3 21, 24 - 





The 1H-1H correlation spectroscopy (COSY) indicated 1H-1H correlations between H-
2’,6’/H-3’,5’, and the HMBC correlation between H-26 and C-4’, suggested the 
methoxyl group was located at C-4’. The 1H-1H correlations between H-2’,6’/H-3’,5’, 
H-10/H-3 and H-11, the long range COSY cross peaks appeared between the following 
pairs: H-2’,6’/H-10 (7.08-2.61, 7.08-2.79) and the heteronuclear multiple bond 
correlation (HMBC) between H-10 and C-1’, C-3, C-4, suggested the para-substituted 
benzene ring was linked to C-10. The long range 1H-1H correlation between H-19/H-23 
(5.57-1.36), and the HMBC correlation between H-19 and C-23, indicated the tertiary 
methyl group to C-18 was adjacent to C-19. Moreover, there is no proton signal found 
at C-18, suggesting the hydroxyl group was also linked to C-18. The 1H-1H correlations 
between H-11/H-10, and the HMBC correlation between H-11 to C-4, C-5, C-6, 
suggested one secondary methyl group was linked to C-5. The 1H-1H correlations 
between H-22/H-15, and the HMBC correlation between H-22 to C-15, C-16, C-17, 
suggested the other secondary methyl group was linked to C-16.128 
The two hydrogens linked to C-12 showed typical broad singlets in the 1H NMR and 
typical olefinic signals from heteronuclear single quantum correlation (HSQC, δH – δC, 
5.12/5.36-113.9). Three methylene groups: 10 (δH – δc, 2.61/2.88-44.8), 15 (1.83/2.05-
42.8), and 17 (1.56/1.88-53.7), also showed clear olefinic signals from HSQC. The 
HMBC correlation from H-25 to C-24 and C-21 revealed the link of the acetyl group to 
C-21.129 
The chemical shifts of the carbons from C-1 to C-23 of 64 were almost identical values 
to the respective carbon chemical shifts of cytochalasin H 174. The comparison of the 
proton-proton coupling constants for cytochalasin H 174 and 65 indicates that the 
relative stereochemistry of both compounds are the same. Moreover, the full NMR data 
of pyrichalasin H was elucidated and published in 1987.104 The data of 65 is almost 
identical to that previously reported for pyrichalasin H. Taking all this evidence together, 







2.3.1.2 Minor Compounds 
We also obtained pure compounds 65a (tR = 6.5 min, 4.8 mg/L) and 65b (tR = 7.3 min, 
2.6 mg/L) as white powders. The UV and mass spectra for both compounds looks 
identical to each other and very similar to that for pyrichalasin H (Figure 2.3 A-C). 
HRMS of 65a showed a molecular formula of C31H41NO6 ([M+Na]
+ calculated 
546.2832, found 546.2836), while 65b also showed an identical molecular formula of 
C31H41NO6 ([M+Na]
+ calculated 546.2832, found 546.2829). These results could 
suggest that 65a and 65b might be isomers of 65. Next, the full NMR data of 65a and 
65b (Appendix, Table 6.8 & 6.9) were obtained. The proton, carbon, H-H COSY, 
HMBC and HSQC data of 65a and 65b were fully elucidated. The two sets of data 
between 65a and 65b are almost identical. Then we individually compared the data of 
65a and 65b to pyrichalasin H. Again, these three sets of NMR data are identical to 
each other. Moreover, we mixed the three compounds and dissolved in MeOH and re-
injected the sample into LCMS, and only a single peak was observed (Figure 2.3 D). 
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Figure 2.3 UV and mass spectrum of compound 65a and 65b. 
 
Compound 156 (tR = 5.2 min, 2.1 mg/L) was purified as a white powder. The UV 
spectra showed the maximum absorption at 276 and 224 nm (Figure 2.4), which is 
similar to pyrichalasin H. HRMS of 156 confirmed a molecular formula of C29H39NO5 
([M+Na]+ calculated 504.2726, found 504.2725).  
 
Full NMR was acquired and analysed. 1H and 13C NMR data of 156 identified 29 
carbons and 39 protons.109 The signal of H-25 was not observed in proton NMR and 
HSQC spectra, also the chemical shift of H-21 moved downfield due to the effect of the 
new hydroxyl group, the remaining signals of both carbon and hydrogen chemical shifts 
were similar to pyrichalasin H. On the basis of the above evidence the structure was 
















     
Figure 2.4 UV and mass spectrum of compound 156. 
 
 
Figure 2.5 Chemical structure of minor compounds isolated from M. grisea NI980 wild type (WT) strain. 
 
Compound 157 (tR = 3.1 min, 10.4 mg/L) was purified as yellow powder. The UV 
spectra showed the maximum absorption at 333 and 260 nm (Figure 2.6), which is 
different from pyrichalasin H. HRMS of 157 confirmed a molecular formula of 
C10H10O4 ([M-H]
- calculated 193.0501, found 193.0497). 
 
Full NMR was acquired and analysis of 1H and 13C NMR data of 157 identified 10 
carbons and 10 protons (Appendix, Table 6.6). Combined with 2D NMR, 1H-1H COSY, 
HMBC and HSQC, compound 157 was confirmed as known compound 3,4,8-






         
Figure 2.6 UV and mass spectrum of compound 157. 
 
Compound 158 (tR = 3.5 min, 13.7 mg/L) was purified as a yellow powder. The UV 
spectra showed a maximum absorption at 280 nm (Figure 2.7), which is different from 
pyrichalasin H. HRMS of 158 confirmed a molecular formula of C14H18O4 ([M+Na]
+ 
calculated 273.1103, found 273.1105).  
 
Full NMR was acquired and analysis of 1H and 13C NMR data of 158 identified 14 
carbons and 18 protons (Appendix, Table 6.7). Combined with 2D NMR, 1H-1H COSY, 
HMBC and HSQC, compound 158 was confirmed as dihydropyriculol (Figure 2.5).131 
 
    







2.3.2 pyiS Gene Knockout 
 
2.3.2.1 Preparation of Deletion Strain 
Bioinformatic analysis of the genome of M. grisea NI980 carried out by Dr. Elizabeth 
Skellam (Chapter 1.4.2) showed that eight PKS-NRPS BGC are present. Detailed 
analysis suggested that the pyi cluster could be responsible for pyrichalasin biosynthesis. 
In order to prove this hypothesis we set out to delete pyiS encoding the central PKS-
NRPS. For targeted gene disruption, a KO vector consisting of a selection marker 
Hygromycin B resistance cassette flanked by arms homologous to the target gene (TG) 
has to be assembled. DNA fragments can be recombined in S. cerevisiae by 
homologous recombination with an overlap sequence of 30 bp. This method has been 
used extensively to build up vector constructs through PEG mediated co-transformation 
of individual DNA fragments (Scheme 2.4).132 
In this study pE-YA was used as the vector for the assembly of all KO constructs. This 
vector contains the 2µ origin of replication (ori) and ura3 gene (encoding an orotidine 
5’-phosphate decarboxylase) to select uracil auxotroph S. cerevisiae in uracil and 
uridine free medium. All DNA fragments for yeast recombination were amplified by 
PCR using gDNA of M. grisea as the template. Oligonucleotides P722-P725 (Chapter 
6.1.5, Cox group ID) were used together with Q5 High-Fidelity DNA Polymerase (New 
England, Biolabs) to precisely amplify the pyiS gene (Scheme 2.4). The pTH-GS-egfp 
vector was used as a PCR template for the amplification of a fungal selection marker, in 
this case hygromycin B under the control if the gdpA promoter (PgdpA) from Aspergillus. 
sp. The primer pair P55- P56 were used to clone the hygromycin resistant cassette 
(HRC) (Scheme 2.4, Chapter 6.1.5). The necessary 30 bp sequence overlap for 
homologous recombination of the individual DNA fragments was introduced by PCR 
through tails on the designed oligonucleotides. The 5’ and 3’ bipartite substrates for 
pyiS were amplified using oligonucleotides P722+ P1327 and P725+ P1328 from the 
corresponding template vector plasmid (Scheme 2.4, Chapter 6.1.5).  
The vector pE-YA was then linearized by restriction hydrolysis with AscI and NotI 
enzymes prior to PEG mediated co-transformation with the PCR amplified DNA 
fragments. The constructed plasmid DNA was isolated from S. cerevisiae and directly 
used to transform competent E. coli. For propagation in E. coli, there is an additional ori 
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(pUC) and the nptII gene, encoding the neomycin phosphotransferase II, which also 
confers resistance to kanamycin (kanR).133 Obtained colonies were screened by PCR 
and confirmed by sequencing (Eurofins, Ebersberg).  
The obtained plamid was then used as a template for two final PCR to produce the two 
bipartite transformation fragments (Scheme 2.4). These two PCR products were purified 
and directly used for PEG/CaCl2 mediated protoplast transformation of M. grisea. 
Transformation mixtures were selected on hygromycin plates, and picked colonies sub-
cloned on 2-3 further selection plates.134 
 
 
Scheme 2.4 General method for assembly of KO cassettes targeting pyiS KS domain in pE-YA 




2.3.2.2 Chemical and Genetic Analysis of pyiS KO  
In total, over 30 colonies were obtained from the initial transformation recovery plates 
(hygromycin B concentration 240 µg/mL, Figure 2.8 A); 20 colonies were obtained 
from the second round selection (hygromycin B concentration 120 µg/mL, 2nd selection 
plates, Figure 2.8 B); 15 transformants were obtained from the third selection (Figure 
2.8 C). 15 transformants were inoculated into DPY liquid medium at 25 ℃, 110 rpm for 
7 days before supernatant was filtered to be free from cell material and extracted twice 
with ethyl acetate (Figure 2.8 D). 
 
 
Figure 2.8 Transformants obtained from three rounds of selection. 
 
The organic extracts from 15 transformants were analysed by LCMS. The results 
showed 4 out of 15 mutants no longer produced pyrichalasin H 65, no other interesting 
peaks were detected, peak (tR = 5.40) is not relevant (Figure 2.9).  
 
Figure 2.9 LCMS chromatogram (DAD trace) of liquid extracts from M. grisea pyiS KO experiments. A, 




For genetic testing of the 4 putative positive transformants obtained from pyiS KO 
transformation, genomic DNA (gDNA) was extracted and used as the PCR template. 
Primers were designed to bind to the region outside the target gene, and inside the 
resistant cassette for both targeting fragments. The disruption of pyiS was analysed with 
oligonucleotides P827-P830 which could differential both a disrupted pyiS and an intact 
pyiS (Figure 2.10, Chapter 6.1.5). As shown clearly in the gel picture (Figure 2.10 B) of 






Figure 2.10 A, Genetic analysis of transformants obtained with bipartite marker strategy by PCR; B, PCR 
analysis for confirmation of target gene replacement events at the pyiS locus. Expected fragment sizes: 





2.3.3 Targeted Inactivation of Tailoring Genes in Pyrichalasin 
BGC 
 
2.3.3.1 Preparation of pyiC, pyiB, pyiH, pyiD, pyiG, pyiA 
Deletion Strains 
Next, we targeted all the putative tailoring genes (pyiA, pyiB, pyiD, pyiG, and pyiH) as 
well as the pyiC gene which is assumed to encode a trans-ER protein. Using the same 




Figure 2.11 Overview of constructed KO vectors in this work. 
 
2.3.3.2 Chemical and Genetic Analysis of pyiC KO 
The transformation process was performed following the same protocol described in 
section 2.3.1. The number of transformants generated per experiment and the number of 






Table 2.2 Transformation efficiency using the bipartite method in M. grisea NI980.109 
Gene Disrupted 
Number of transformants 
screened 
Number of disrupted genes 
(confirmed by PCR) 
Success 
rate (%) 
PyiS 15 4 26.7 
PyiC 20 4 20 
PyiB 92 1 1.1 
PyiH 24 1 4.1 
PyiG 53 7 13.2 
PyiD 18 3 16.7 
PyiA 57 5 8.8 
 
 
2.3.3.2 Chemical Analysis of pyiC KO 
The LCMS data of pyiC KO (encoding the trans-ER) showed that the abolition of 
pyrichalasin H 65, and no other interesting peaks were detected (Figure 2.12). 
 
 
Figure 2.12 LCMS chromatograms (DAD trace) of organic extracts from pyiC KO experiments 





The same strategy described in section 2.2.2 was adopted for the genetic testing of pyiC 
KO transformants. The agarose gel electrophoresis shown the precise binding of 






Figure 2.13 PCR analysis for confirmation of target gene replacement events at the pyiC locus. Expected 
fragment sizes, left fragment = 867 bp, and right fragment = 943 bp. M, DNA ladder marker. 
 
2.3.3.3 Chemical and Genetic Analysis of pyiB KO 
The LCMS chromatogram of pyiB KO showed the complete loss of pyrichalasin H 65, 
and a peak corresponding to pyrichalasin J 156, was detected (tR = 5.3 min, Figure 2.14), 






Figure 2.14 LCMS chromatograms (DAD trace) of organic extracts from pyiB KO experiments 
in M. grisea. A, wild type control; B, KO-19. Compound 159 and 160 are unrelated metabolites. 
 
The genetic testing of pyiB KO transformation was performed using the same method as 
above (Figure 2.15 A). However, for some unknown reasons, we could not generate the 
expected PCR fragments when using one primer outside of the target gene and another 
primer binding within the hygromycin resistance cassette (HRC) region. In contrast, the 
predicted size of undisrupted pyiB appeared from wild type control by using the same 
pair of primers (Figure 2.15 B, Table 6.4). This result clearly indicated that the 
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Figure 2.15 A, PCR analysis for confirming targeted gene replacement events at the pyiB locus; B, 
Expected fragment sizes: 4927 bp. M, DNA ladder marker kb; C, chemical structure of 156. 
 
Compound 156 (tR = 5.3 min, 2.1 mg / L) was purified as white powder. The UV 
spectra (methanol) showed the maximum absorption at 276 and 228 nm, which is 
different from pyrichalasin H. HRMS of 156 confirmed a molecular formula of 
C29H39NO5 ([M+Na]
+ calculated 504.2726, found 504.2725). HRMS and full NMR data 
confirmed this compound is the same as pyrichalasin J 156 (Appendix, Figure 2.15 
C).109 
 
2.3.3.4 Chemical and Genetic Analysis of pyiH KO 
Chemical analysis of transformants obtained after introducing the pyiH KO (encoding 
an oxidoreductase) fragments revealed that pyrichalasin H 65 was completely abolished 
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from the LCMS profile of the pyiH KO extract. However, three new interesting peaks 
were detected 161 (tR = 5.7 min), 162 (tR = 7.0 min) and 163 (tR = 8.2 min, Figure 2.16). 
 
 
Figure 2.16 LCMS chromatograms (DAD trace) of organic extracts from pyiH KO experiments 
in M. grisea. A, wild type control; B, KO-5. 
 
The same strategy described in section 2.2.2 was used for the genetic testing of pyiH 
KO transformants (Figure 2.16 A). The agarose gel electrophoresis shows the precise 
integraty of both left and right bipartite fragments to the target gene in the only 
transformant obtained from transformation. In contrast, there is no bands amplified from 
the WT gDNA, which also confirms of bipartite the target gene (Figure 2.16 B). 
Compound 161, 162 and 163 were purified as white powders, the compound physical 

















Figure 2.17 A, Genetic analysis of transformants obtained with bipartite marker strategy by PCR; B, PCR 
analysis for confirmation of target gene replacement events at the pyiH locus. Expected fragment sizes: 
left fragment = 868 bp, and right fragment = 745 bp, M, DNA ladder marker; C, chemical structure of 161, 










































C29H37NO4 1.0 white 
 
Full NMR data was acquired, and analysis of 1H and 13C NMR spectra of 161 identified 
29 carbons and 39 protons. The signal of H-25 of pyirichalasin H 65 was not found 
from proton NMR and HSQC, also the chemical shift of H-21 moves to the lower field 
due to the attachment of hydroxyl group. The signal of olefin H-6 and H-12 were not 
found from proton NMR and HSQC, the 1H-1H correlations between H-12 / H-4 and H-
7 (3.93-2.41, 3.93-5.49), and the HMBC correlation between H-12 to C-5, C-6, C-7, 
suggesting that a C-12 methyl group added to C-6. In the meantime, the double bond 
migrated from C-6 and C-12 to C-6 and C-7, proved by the drastic increase of carbon 
chemical shift of C-6 (143.8) and C-7 (124.9). New olefinic signal appeared from 
HSQC (δH – δC, 3.93, 61.7), which indicated a methylene group connected with a 
hydroxyl group linked to the C-6. Moreover, the olefin signal between C-19 and C-20 
disappeared. The rest signals of both carbon and hydrogen chemical shifts were similar 
to pyrichalasin H 65. Based on the above evidence, the structure of compound 161 was 
confirmed (Figure 2.17 C).109 
Full NMR data of 162 was also achieved and analysis of the data revealed, 29 carbons 
and 39 protons. The signal of H-25 of pyrichalasin H 65 was again not found from 
proton NMR and HSQC, also the chemical shift of H-21 move to the lower field due to 
the presence of a hydroxyl group, the signal of double bond H-6 and H-12 were not 
found from proton NMR and HSQC, the 1H-1H correlations between H-12/H-4 and H-
7(3.93-2.41, 3.93-5.49), and the HMBC correlation between H-12 to C-5, C-6, C-7, 
suggesting that C-6 and C-12 olefin was replaced by a C-12 methyl group linked to C-6. 
The rest signals of both carbon and hydrogen chemical shifts were similar to 161. Based 
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on the above evidence, the structure of compound 162 was confirmed (Figure 2.17 
C).109 
Full NMR data was also acquired for 163. Analysis of its 1H and 13C NMR identified 29 
carbons and 37 protons. The signal of H-25 of pyrichalasin H 65 not found from proton 
NMR and HSQC, also the chemical shift of H-21 move to the lower field due to the 
presence of the hydroxyl group, the 1H-1H correlations between H-12/H-4 and H-
7(3.93-2.41, 3.93-5.49), and the HMBC correlation between H-12 to C-5, C-6, C-7, 
suggesting that the C-6 and C-12 double bond was replaced by a C-12 methyl group 
linked to C-6. The rest of the signals of both carbon and hydrogen chemical shifts were 
similar to 162. Based on the above evidence, the structure of compound 163 was 
confirmed (Figure 2.17 C).109 
2.3.3.5 Chemical and Genetic Analysis of pyiD KO 
The liquid extraction of three pyiD KO (encoding a P450 vytochromo monooxygenase) 
mutants were analysed chemically. The result showed the complete abolition of 
pyrichalasin H 65 from the LCMS chromatogram, and four new peaks were detected 
164 (tR = 5.3 min), 165 (tR = 5.7 min), 166 (tR = 6.5 min) and 167 (tR = 7.6 min, Figure 
2.18).  
 
Figure 2.18 LCMS chromatograms (DAD trace) of organic extracts from pyiD KO experiments in M. grisea. 







Genetic analysis of the genomic DNA extracted from the pyiD transformants was 
repeated as (Figure 2.19 A, Chapter 6.1.5). The gel picture clearly showed that both the 







Figure 2.19 A, Genetic analysis of transformants obtained with bipartite marker strategy by PCR; B, PCR 
analysis for confirmation of target gene replacement events at the pyiD locus. Expected fragment sizes: 




Compounds 164, 165, 166 and 167 were purified, the compound physical data were 
measured (Table 2.4). 
 













Titre (mg / 
L) 
Appearence 




C30H39NO6 2.5 white 




C28H37NO4 1.8 white 




C31H41NO6 3.8 white 




C30H40NO5 3.1 white 
 
 
Full NMR data was acquired and analysis of 1H and 13C NMR spectra of 164 identified 
30 carbons and 39 protons. The signal of H-22 and H-26 of pyrichalasin H 65 were not 
found from proton NMR and HSQC, there are clear olefinic signal showed in HSQC (δH 
– δC, 3.26/3.38-67.1), indicating that a methylene attached. The
 1H-1H correlations 
between H-22/H-15, and the HMBC correlation between H-22 to C-15, C-16, C-17, 
suggested that the C-22 methyl group was replaced by methylene connected with a 
hydroxyl group, but still linked to C-16. The rest fo the signals of both carbon and 
hydrogen chemical shifts were similar to pyrichalasin H. Therefore, the structure of 
compound 164 was confirmed (Figure 2.19 C).109 
Full NMR data was acquired and analysis of 1H and 13C NMR spectra of 165 identified 
28 carbons and 37 protons. Compared to compound 164, the signal of H-25 was not 
found from proton and HSQC spectra of 165, also the chemical shift of H-21 moved to 
lower field due to the link of the hydroxyl group. This demonstrated the lack of the 
acetyl group. The typical methyl signal from HSQC and the HMBC correlation from H-
12 to C-5, C-6, C-7, suggested a methyl group was linked to C-6. The rest signals of 
both carbon and hydrogen chemical shifts were similar to 164. Putting all above 




Similarly, the full NMR data of 166 were acquired and summarized, then compared to 
pyrichalasin H 65). The 1H-1H correlation spectroscopy (COSY) indicated 1H-1H 
correlations between H-2’,6’/H-3’,5’, and the HMBC correlation between H-26 and C-
4’, suggesting the methoxyl group was located at C-4’. The rest signals of both carbon 
and hydrogen chemical shifts were similar to 65. Therefore, the structure of compound 
166 was confirmed (Figure 2.19 C).109 
 
The full NMR data was acquired and analysis of 1H and 13C NMR spectra of 167 
identified 30 carbons and 40 protons. Compared to pyrichalasin H 65, the HMBC 
spectrum of 167 did not show the correlation between H-26 and C-4’, suggesting the 
cleavage of methoxyl group. Moreover, there is H-18 to C-17 and C-19 from HMBC 
correlation, suggesting the cleavage of hydroxyl group at C-18. Hence, the structure of 
compound 167 was confirmed (Figure 2.19 C).109 
 
2.3.3.6 Chemical and Genetic Analysis of pyiG KO 
The LCMS results showed 5 mutants from pyiG KO (encoding a second P450 
monooxygenase) did not produce pyrichalasin H 65, but five new interesting peaks were 
detected 168 (tR = 6.3 min), 169 (tR = 7.0 min), 170 (tR = 7.5 min), 171 (tR = 7.9 min) 















Figure 2.20 LCMS chromatograms (DAD trace) of organic extracts from pyiG KO experiments 
in M. grisea. A, wild type control; B, KO strain. 
 
Genetic analysis of the genomic DNA extracted from pyiG KO transformants was done 
(Figure 2.21 A, Chapter 6.1.5). The agorose gel electrophoresis results showed that both 
the LF and RF of bipartite substrates were integrated correctly into the genome of pyiG 























Figure 2.21 A, Genetic analysis of transformants obtained with bipartite marker strategy by PCR; B, PCR 
analysis for confirmation of target gene replacement events at the pyiG locus. Expected fragment sizes: 
left fragment = 1018 bp, and right fragment = 1007 bp, M, DNA ladder marker; C, chemical structures of 






Compounds 168 -172 were purified, the compound physical data were measured and 
summerized in Table 2.5. 
 












Titre (mg / 
L) 
Appearence 




C31H41NO7 2.5 white 




C31H41NO6 3.7 white 




C30H39NO5 3.7 white 




C31H41NO5 3.9 white 




C31H41NO6 11.2 white 




C30H39NO5 23.2 white 
 
Full NMR data of 168 was obtained and after analysis of 1H and 13C NMR spectra 31 
carbons and 41 protons were identified. Compared to pyrichalasin H 65, the signals of 
alkene carbons H-6 and H-12 were not found from proton and HSQC spectrum, a broad 
singlet appeared in proton NMR (δH 1.65) and HSQC (δH – δC, 1.65-19.6), the
 1H-1H 
correlations between H-12/H-8 (3.19-1.65), and the HMBC correlation between H-12 to 
C-5, C-6, C-7, suggested that a C-12 methyl group is linked to C-6. In the meantime, the 
double bond migrated from C-6 and C-12 to C-6 and C-7, proved by the increase of 
carbon chemical shift of C-6 (137.7) and C-7 (127.4). However, the signal of H-10 
methylene group was not observed from proton NMR, instead by the observation of the 
correlation of (δH – δC, 4.48-77.0) from HSQC, combined with the 
1H-1H correlations 
between H-10/H-3 (4.48-3.16), and the HMBC correlation between H-10 to C-1’, C-3, 
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suggesting that a hydroxyl group linked to C-10. The 1H-1H correlations between H-
22/H-17, and the HMBC correlation between H-22 to C-16, C-17, suggesting that a 
hydroxyl group was linked to C-22. The rest signals of both carbon and hydrogen 
chemical shifts were similar to pyrichalasin H. Based on the above evidence, the 
structure of compound 168 was confirmed (Figure 2.21 C).109 
 
NMR analysis of 169 revealed that it is actually a mixture of two co-eluting compounds, 
designated as compounds 169i and 169ii. Full NMR data of 169i was acquired. 
Compared to 168, the only difference came from the HMBC correlation from H-10 to 
C-1’ and C-3, which indicated the methylene group at C-10. Therefore, the structure of 
compound 169i was confirmed (Figure 2.21 C). 
Furthermore, full NMR data of 169ii was also obtained. The only difference between 
169i and 169ii is the HMBC correlation from H-4’ to C-3’, C-4’ and C-5’, indicating 
that the cleavage of methoxyl group from C-4’. The structure of 169ii was elucidated 
(Figure 2.21 C). 
 
The full NMR of 170 was also fully assigned. Compared to compound 169i, the signal 
of C-26 methyl was not found from proton NMR and HSQC, while without the 
observation of the correlation of H-4’ to C-3’, C-4’ and C-5’from proton and HMBC 
spectra, suggested the cleavage of C-26 methyl and the hydroxyl group attached to C-4’. 
The COSY correlations between H-22/H-15, and the HMBC correlation between H-22 
to C-15, C-16 and C-17, suggested the methyl group is linked to C-16. Therefore, the 
structure of compound 170 was confirmed (Figure 2.21 C). 
 
Full NMR spectra of compound 171 was obtained, 1H and 13C NMR spectra were 
closely elucidated and identified 31 carbons and 41 protons. Compound 168 was used 
as template to elucidate the structure of 171. The 1H-1H correlation spectroscopy 
(COSY) indicated 1H-1H correlations between H-2’,6’/H-3’,5’, and the HMBC 
correlation between H-26 and C-4’, suggested the methoxyl group was located at C-4’. 
Meanwhile, the signal of H-10 methylene group not observed from proton NMR, 
instead by the observation of the correlation of (δH – δC, 4.48-77.0) from HSQC, yet the 
1H-1H correlations between H-10/H-3(4.48-3.16), and the HMBC correlation between 
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H-10 to C-1’, C-3, suggested that a hydroxyl group was linked to C-10. The remaining 
signals of both carbon and hydrogen chemical shifts were similar to 168. Based on the 
above evidence, the structure of compound 171 was elucidated. (Figure 2.21 C). 
 
Full NMR data of 172 were acquired and analysis of 1H and 13C NMR spectra, 
identified 31 carbons and 41 protons. Compared to 171, the 1H-1H correlation 
spectroscopy (COSY) showed the 1H-1H correlations between H-2’,6’/H-3’,5’, and the 
HMBC correlation between H-26 and C-4’, suggested the methoxyl group was linked at 
C-4’. The rest signals of both compound 171 and 172 were similar to each other. Taken 
all together, the evidence confirmed structure of compound 172 (Figure 2.21 C).109 
 
2.3.3.7 Chemical and Genetic Analysis of pyiA KO 
The liquid extracts from pyiA KO (encoding the O-methyltransferase) transformants 
showed 5 mutants no longer produced pyrichalasin H 65, instead two interesting peaks 
were detected 173 (tR = 5.2 min) and 174 (tR = 6.3 min, Figure 2.22). 
 
 
Figure 2.22 LCMS chromatograms (DAD trace) of organic extracts from pyiA KO experiments 




Genetic analyse of the genomic DNA extracted from the ∆pyiA transformants was done 
(Figure 2.23 A, Chapter 6.1.5). The agarose gel electrophoresis results showed that both 
the LF and RF of bipartite substrates were integrated correctly into the genome of pyiG 







Figure 2.23 A, PCR analysis for confirmation of target gene replacement events at the pyiA 
locus. B, expected fragment sizes: left fragment = 1020 bp, and right fragment = 823 bp M: 




Compound 173 - 174 were purified, the compound physical data were measured and 
summerized in Table 2.6. 
 






















C30H39NO6 2.8 white 




C30H39NO5 1.0 white 
 
 
Compound 173 was purified and full NMR data was recorded. This revealed 30 carbons 
and 39 protons. The signal of the C-26 methyl group not found from proton NMR and 
HSQC. In the meantime, the lack of the correlation of H-4’ to C-3’, C-4’ and C-5’ from 
proton and HMBC spectra, suggested the loss of the C-26 methyl and the hydroxyl 
group attached to C-4’. That is the major difference between 173 and 65. Based on these 
evidences, we confirmed that 173 is magnachalasin  (Figure 2.23 C). 
Full NMR data of compound 174 was also acquired. The HMBC correlation from H-4’ 
to C-3’, C-4’ and C-5’, indicated that the cleavage of methoxyl group from C-4’. In the 
meantime, with the observation of the correlation of H-4’ to C-3’, C-4’ and C-5’ from 
proton and HMBC spectra, suggested the cleavage of hydroxyl group from C-4’. The 
rest signals of both carbon and hydrogen chemical shifts were similar to pyrichalasin H. 
Based on these evidence, we confirmed the structure of 174 is cytochalasin H (Figure 
2.23 C). 
Compound 173 and 174 were fully elucidated by both HRMS and NMR. 173 is the 
expected de-methyl product. However, the discovery of cytochalasin H 174 is surprising, 
since it is a known compound derived from phenylalanine and has not previously been 
detected in M. grisea WT culture. Pyrichalasin H is not postulated to derive from 
phenylalanine, and none of the KO experiments described above indicate that 
phenylalanine is incorporated, hydroxylated at the para-position and then methylated, 
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although, several minor isolated compounds do contain a phenyl moiety. An alternative 
explanation may be the true precursor for PyiS is O-methyltyrosine. When PyiA is not 
functional, O-methyltyrosine cannot be synthesized and in its absence, the A-domain of 
PyiS can select tyrosine and/or phenylalanine. This hypothesis fits with the lower titres 
of both compounds and a number of intermediates characterized in the KO experiments, 
e.g. 164, 167, 169ii, 170, 173 and 174 also in low titres.  
In order to confirm our hypothesis, O-methyltyrosine 175 was fed to a pyiA KO strain. 
O-Methyltyrosine (200 mg) was dissolved into double distilled water (10 mg / mL) and 
filter sterilized. 100 μl of this solution was fed to the ∆pyiA knock-out strain inoculated 
into 500 mL Erlenmeyer flasks containing 100 mL DPY. The feeding was repeated at 
24 hour intervals four times. On the 7th day the cultures were extracted. 
The feeding result showed the pyrichalasin H production was restored (Figure 2.22 C). 
This is a convincing experiment to confirm that O-methyltyrosine 175 is the real 
precursor involved in the biosynthesis of pyrichalasin H. 
 
2.4 Discussion & Conclusion 
In order to confirm that the pyi BGC is responsible for pyrichalasin H biosynthesis, we 
first targeted the pyiS gene by using the bipartite gene knockout (KO) strategy. 
Functional disruption of the PKS-NRPS resulted in the total disappearance of 65 and 
156. Next, pyiC was targeted. This gene encodes a trans-ER protein. Production of 
compounds 65 and 156 was completely abolished, and no new metabolites were 
detected. These experiments confirmed that pyrichalasin H was synthesized by the 
enzymes encoded by the pyi BGC. 
Moreover, all genetically tested transformants possessed a disrupted target gene, while 
the wild type control showed a non-disrupted result. This indicated that the bipartite 
substrate cassette combined with protoplast-mediated transformation is a reliable and 
effective method to disrupt genes in the M. grisea strain. 
With the purpose of understanding the full biosynthetic pathway to pyrichalasin H and 
generating novel cytochalasans, we targeted all the tailoring genes individually. These 
genes were believed to encode enzymes involved in modifying the backbone of 
pyrichalasin H. Inactivation of pyiB, encoding a putative acetyltransferase, led to the 
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abolition of 65. The de-acetyl product 156 still exist, but its titre was not greatly 
increased (Scheme 2.5). Therefore, pyiB involved in the biosynthesis of 156 by 
encoding the O-acetyltransferase. 
Then, the pyiA gene encoding an O-methyltransferase, was disrupted. The result showed 
the total abolition of 65, and two new metabolites 173 and 174 were obtained in low 
yield. Both compounds were fully identified by HRMS and NMR. Compound 173 is a 
tyrosine derived and compound 174 is a phenylalanine derived analogues of 65. 
Metabolite 173 is the expected de-methyl product, which confirmed the function of 
PyiA. However, the appearance of phenylalanine derived cytochalasin H 174 is 
unexpected. This result also shows that the downstream enzymes are not sensitive to the 
change in structure of the aromatic ring. 
Literature investigation around the engineering of NRPS was done to provide evidences 
to our novel findings. In the biosynthesis of cyclosporine, various natural amino acids 
(e.g., tryptophan, tyrosine, phenylalanine) can be incorporated by the NRPS domain to 
produce novel cyclosporine analogues in Tolypocladium inflatum.135,136 Moreover, the 
NRPS adenylation (A) domain is flexible enough to allow incorporation of the modified 
precursors into the final peptide. 
With the support of this evidence, one possible explanation to the pyiA KO results is 
that the A domain of PKS-NRPS prefers to incorporate O-methyltyrosine 175. It can 
also weakly accept tyrosine and phenylalanine in the absence of 175. Therefore, O-
methyltyrosine 175 is the true precursor for the pyrichalasin H biosynthesis. PyiA is 
involved in the very first step of biosynthetic pathway, rather than the previous 
assumption that it will methylate the pyrichalasin scaffold in the late stage biosynthesis. 
To test whether 175 is the true substrate for PyiS, 175 was fed to the pyiA KO strain. 
Pyrichalasin H 65 was restored in a similar titre compared to the WT strain, while 
compound 173 and 174 were not detected any more. This shows that 175 is the true 
precursor for the NRPS A domain. Therefore, PyiA methylates tyrosine 176 into O-
methyltyrosine 175, then 175 serves as a precursor in the 65 biosynthesis. 
 
Next, pyiH encoding an oxireductase was disrupted, resulting in the loss of 65 and 
production of three novel compounds 161 – 163 All three compounds were fully 
elucidated by NMR and HRMS (Figure 2.17 C). The olefin between C-19 and C-20 was 
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reduced in both 161 and 162. There is an unusual hydroxyl group at C-12 in 161, 
indicating other cryptic enzymes involved, therefore 161 is produced as a shunt 
metabolite. 163 was obtained in a very low yield, result in some signal missing from 
NMR spectra, but the key functional groups can be identified. All three compounds 
contain the C-21 carbonyl group, which confirmed that the function of PyiH is to reduce 
the carbonyl group into a hydroxyl group, followed by the PyiB transfer of an acetyl 
group to it. 
Disruption of the P450 monooxygenase encoded by pyiD, led to the complete abolition 
of 65 and production of four new compounds 164 - 167. Structure elucidation was done 
and described in section 2.3.2 (Figure 2.19 C). All compounds lack a hydroxyl group at 
C-18, indicating PyiD introduces a hydroxyl group at C-18, therefore, it is a C-18 
hydroxylase. Compound 164, 165 and 166 all contain a C-22 hydroxyl group, this result 
can be explained by the modification of unknown enzymes, these three compounds can 
be regarded as shunt products. 
The second P450 monooxygenase encoded by pyiG, was disrupted, causing the loss of 
65, and production of five new compounds 168 – 172. Structure elucidation (described 
in section 2.3.2, Figure 2.21), showed that all compounds lacked a hydroxyl group at C-
7, indicating PyiG is a C-7 hydroxylase. Compound 169 turned to be 169i and 169ii 
based on the NMR analysis. Compound 168, 171, 169i and 169ii are shunt products as 
they all contain a C-22 hydroxyl group, which was assumed to be modified by cryptic 










Taken together, these results reveal the overall biosynthetic pathway of pyrichalasin H 
(Scheme 2.5). In the early step, PyiA transfers a methyl group from SAM 36 to tyrosine 
to generate O-methyltyrosine 175, which is then the preferred substrate of the PyiS A-
domain. Compound 178 is then probably released as an intermediate before a 
Knoevenagel condensation, possibly catalysed by PyiE, then followed by a putative 
Diels-Alder cyclization, possible catalysed by PyiF to form the pyrichalasin backbone 
179 as a putative middle stage product. All compounds isolated featured the tricycle 
core typical of the cytochalasans showing that this is formed before the late-stage 
enzymes investigated here, and after the activity of PyiS / PyiC. 
Then the biosynthetic route branches into two directions. On the first branch, PyiD is 
one of the first tailoring enzyme to act due to the observation of 161 and 162 in the 
PyiH KO. The PyiH KO intermediate 163 went off the pathway to give the shunt 
products 161 and 162. Both PyiB and PyiG can modify the intermediate 180 and 181 
which has already been decorated by PyiH, to give 156, 170 and 171 in parallel. These 
compounds will be further substrates of PyiB and PyiG to give the final products 65 and 
174 (shown in green rectangle, Scheme 2.5). Compound 170 and 172 will further leave 
the pathway by the formation of shunt compounds 168 - 171.  
On the second branch, PyiH first acts on the Diels-Alder product 179, to give 182 and 
183. Then PyiG catalyses a hydroxylation reaction on 182 and 183 to produce 184 and 
185. The compound 184 and 185 were modified by PyiB and PyiD at the same time to 
give 156 and 167. Again, catalysis happened on both 156 and 167 to generate 
compounds 65 and 73 (shown in green rectangle, Scheme 2.5). Compound 164 and 166 
were released as shunt products.  
The tailoring enzymes which are all able to act on more than one substrate lead to the 
complexity of this pathway. In addition, when PyiA is absent, the PyiS A-domain is 
able to select phenylalanine and/or tyrosine, this can be explained by the observation of 
164, 165, 167, 169ii, 170, 173 and 174. PyiB, PyiD and PyiG can modify many 
different substrates. This can be observed by the discovery of 156, 163, 167 and 172. 
The three tailoring enzymes also participated in the production of the final compounds 
65, 173 and 174.  
There are several reported cases regarding the pathway investigation of cytochalasans. 
Watanabe and co-workers elucidated the function of redox enzymes during the 
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biosynthesis of Chaetoglobosin A 63 (Chapter 1.3.1).137 Tang and co-workers 
investigated the regulator gene ccsR in the A. clavatus BGC.138 They also determined 
the function of Baeyer–Villiger monooxygenase (BVMO) during the biosynthesis of 
cytochalasins E 64 and K 82 (Chapter 1.2.2).69 However, no one fully elucidated the 
complete pathway for cytochalasin biosynthesis. To the best of our knowledge, this is 


















3 Combinatorial Biosynthesis of Late Stage 
Cytochalasan Tailoring Cytochrome P450 
Monooxygenases 
 




Combinatorial biosynthesis can be defined as the application of genetic engineering to 
modify biosynthetic pathways encoding natural products in order to generate novel and 
decorated architectures using nature’s biosynthetic machinery. Heterologous expression 
techniques play an important role in this strategy.140 
 
3.1.1 Heterologous Expression 
Heterologous expression has been used as a major tool in the study of fungal synthetic 
biology, it can not only allow us to study fungal enzymes/pathways in different hosts, 
but also shows the capability of fungi to be the heterologous host. Heterologous 
expression of fungal natural product (NP) gene or gene cluster that use a host from the 
same species lead to positive results in most cases. Moreover, the chances of success 
will also be improved by using a host that already exhibits the ability of producing NP. 
Heterologous expression can also be used as an effective method in the discovery of 





Scheme 3.1 Structures of synthetic biology strategy for natural product production in 
filamentous fungi.141 
 
Moreover, successful NP production needs not only a good host, but also the 
involvement of different enzymes. Understanding their biosynthesis requires expression 
of several genes simultaneously. Plasmids which contain one or more expression genes 
have been designed to provide high-level expression in filamentous fungi.141 
Lazarus and co-workers developed the multigene expression vector pTYGS-bar, which 
has the herbicide glufosinate ammonium (bar) as a selection marker, contains four 
fungal promotors/terminators (P/TamyB, P/Tadh, P/TgpdA, P/Teno). The shuttle vector 
contains the 2 µ origin of replication and the URA3 gene for plasmid maintenance and 
the selection in ura3 mutant strains of yeast.142 For selection and propagation in E. coli 
the vector contains an appropriate ori (colE1) and confers resistance to chloramphenicol 
(camR) as well as ampicillin (ampR). The plasmid was designed with attR1 and attR2 
recombination sites adjacent to PamyB and TamyB, respectively. A Gateway destination 
cassette, comprising a kanamycin (kanR) resistance gene and the toxic ccdB gene 
flanked by attR1 and attR2 sites was inserted into the expression vector (Figure 3.1).134 
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Three of these cloning sites include an AscI restriction sequence (P/Tadh, P/TgpdA, P/Teno) 
and are designed for in vivo homologous recombination in S. cerevisiae. The general 
process of assembling the multigene expression vector starts from the digestion of the 
plasmid with AscI. Then the tailoring enzyme coding regions are amplified from 
genomic DNA, and the amplified fragments and restriction digest are examined by 
agarose gel electrophoresis. Finally, the target vector is assembled by co-transformation 
of DNA fragments and the digested plasmid in yeast.143  
 
 
Figure 3.1 Structures of multigene expression vector pTYGS-bar.134 
 
3.1.2 Benzenediol Lactone Engineering 
Fungal benzenediol lactone (BDL) polyketides exhibit many of bioactivities, including 
immune system modulatory effects and heat shock response, serving as an important 
pharmacophore. BDL backbones are biosynthesized by pairs of collaborating, 
sequentially acting iterative polyketide synthases (iPKSs), forming quasi-modular BDL 
synthases (BDLSs).140 
O-methylation has been engineered in natural product biosynthetic pathways by 
disrupting the genes encoding native O-methyltransferase (O-MeT) enzymes or 
augmenting the pathways with genes for heterologous O-MeT. Molnar and co-workers 
have described a combinatorial biosynthesis strategy to modulate the BDL scaffolds. 
They identified two orthologous O-MeT, LtOMT and HsOMT involved in the 
biosynthesis of two fungal benzenediol lactones.144,145 LtOMT obtained from 
Lasiodiplodia theobromae methylates the C-3 phenolic hydroxyl of the 
demethylasiodiplodin (DLD) 186 to produce lasiodiplodin 187 (Scheme 3.2 A). 
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HsOMT from Hypomyces subiculosus methylates the C-5 phenolic hydroxyl of 
dehydrozearalenol (DHZ) 188 to afford 5-O-methyl-DHZ 189 (Scheme 3.2 B), an 
intermediate of hypothemycin. To investigate whether these regiospecific enzymes can 
modify different substrates, Molnar and co-workers used S. cerevisiae as a host to co-
express LtOMT and HsOMT with the DLD-producing iPKS pair and DHZ-synthesizing 
pair, seperately. Luckily, both O-MeTs recognise the BDL substrates offered by the 




Scheme 3.2 Combinatorial biosynthesis of O-methylated BDLs using LtOMT and HsOMT.144 
 
This example confirmes that combinatorial biosynthesis can be a good strategy for 





Previous knockout (KO) experiment targeting pyrichalasin H 65 produced by 
Magnaporthe grisea showed that the tailoring enzymes are promiscuous and can modify 
a range of cytochalasan intermediates. However, the tailoring modifications are highly 
regio-selective, they can only recognize part of the cytochalasan molecule. For example, 
PyiD can only catalyses a hydroxylation reaction at C-18 and PyiG can only catalyses a 
similar reaction at C-7. The differences between different cytochalasan skeletons away 
from the reaction region are not important enough to disrupt the enzyme functions. 
 
Figure 3.2 Structures of metabolites isolated from M. grisea NI980 P450 mutant strain. 
 
To investigate the range of the promiscuity of the tailoring genes during cytochalasan 
biosynthesis, we decided to use the P450 disruption strain (∆pyiD and ∆pyiG) as a 
bioengineering platform and use the combinatorial biosynthesis approach to 
heterologously express modification genes (such as P450s, BVMO and O-MeT) from 
other putative cytochalasin biosynthetic gene clusters (BGC). The result would achieve 
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two goals: firstly, to elucidate the biological role of cryptic enzymes, and secondly, to 




3.3.1 Combinatorial Biosynthesis with ccsB into Magnaporthe 
grisea NI980 pyiH Disruption Strain 
 
3.3.1.1 Introduction 
The ccsB gene (ACLA_078650) comes the cytochalasin E BGC of Aspergillus clavatus 
NRRL1. The size of ccsB is 1967 bp with only one intron. Tang and co-workers have 
already elucidated the function of ccsB. It it is the first reported carbonate-forming 
Baeyer-Villiger monooxygenase in fungi.69 
CcsB has been confirmed to catalyse the formation of an in-line carbonate in the 
macrocyclic portion of cytochalasin E.69 The beginning step is a classic BVMO 
mechanism of oxygen insertion, FI-4a-OO- 194a on C-21 of 194 forms the intermediate 
195 (Scheme 3.3). Expected migration of tertiary C-9 to the distal oxygen on FI-4a-OO- 
leads to release of FI-4a-OH and formation of ester 196. Release of ester 196 into an 
aqueous environment can generate the observed shunt product 204. In another way, 196 
can remain in the active site of CcsB or be recaptured by CcsB and undergo further 
oxidation to yield 202.146,147 After reduction and regeneration of FI-4a-OO-, it was 
supposed the nucleophilic FI-4a-OO- complex performs a 1,4-conjugate Michael 
addition at C-19 to yield adduct 197, which leads to the formation of epoxide 198. 
Epoxidation of the αβ-unsaturated ester is observed in the cytochalasan family, such as 
in the epoxycytochalasin compounds. 
Subsequently, base-catalysed abstraction of the acidic α-proton leads to formation of the 
vinylogous C-17 ketone and the alcoholate anion species 199. Attack at the 
neighbouring carbonyl group affords an epoxy alkoxide 200, which can readily 
rearrange with aid of the distal vinylogous ketone to yield the enolate 201. Moreover, 
ketonization of C-17 followed by proton abstracting from the protonated general base 
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affords the carbonate 202. Unlike 204, 202 does not undergo double bond migration, 
possibly due to resonance stabilization through the carbonate oxygen. Examples of the 
rearrangement of the α-hydroxyl, β-diketones into esters have been reported in 
literature,148 and can proceed under thermal or basic conditions via the proposed epoxy-
tetrahedral intermediate such as shown in 200. Furthermore, an example of Lewis-acid-
promoted conversion of an α-hydroxyl, β-dicarbonyl compound to a carbonate 
rearrangement has been reported (Scheme 3.3).149 
 
 
Scheme 3.3 Proposed reaction mechanism of ccsB in converting 194 to 202 and 204.69 
 
3.3.1.2 Aim 
The ccsB gene from A. clavatus has been confirmed to encode the BMVO and catalyse 
the insertion of two oxygen atoms between carbonyl in the macrocycle of cytochalasin 
E. Previous knockout (KO) experiment targeting pyiH, resulted in the isolation of three 
novel compounds 161 - 163 (details are described in chapter 2.3.1, Figure 3.3). All three 
compounds contain the carbonyl group in the macrocycle. They are similar to 194, but 
lack the keto function at C-17, and hydroxylation at C-16 would prevent the second 
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oxidation, but the first oxidation could work. The purpose of heterologous express ccsB 
into ΔpyiH strain is try to determine if CcsB can catalyse the oxygen insertion into the 
KO substrates 161-163. Moreover, we want to generate some novel carbonate 
pyrichalasans by combinatorial biosynthesis of ccsB. 
 
 
Figure 3.3 Structures of metabolites isolated from M. grisea NI980 pyiH mutant strain. 
 
3.3.1.3 Vector Construction and Gene Transformation 
The detailed information of pTYGS-bar plasmid has been described in section 3.1.1.142 
There is a NotI restriction sequence between the P/TamyB positions. The pTYGS-bar 
plasmid was first digested by NotI. The ccsB fragments were amplified from plasmid 
PUC57-kan vector (ccsB gene was codon optimized before synthesis, purchased from 
BASECLEAR). S. cerevisiae was then used to assemble the vector and gene by 
homologous recombination (LR) in the desired order as the DNA fragments include 30 
bp unique homologous overlap sequence. These were introduced by PCR through tails 
at the designed oligonucleotides. The desired pTYGSbar-ccsB vector was purified from 
S. cerevisiae and propagated in E. coli TOP10. The verified vector was transformed into. 
pyiH disruption protoplaste by PMT. Hygromycin B was used as the selection marker 
for KO experiment, previously. M. grisea is also sensitive to glufosinate ammonium 
(basta). So it can be used as the second selection marker for heterologous expression 





Scheme 3.4 General procedure for assembly of heterologous expression vector for ccsB gene in 
pTYGSbar by yeast homologous recombination (HR) and protoplast-mediated transformation (PMT).142 
 
3.3.1.4 PCR Analysis of pTYGSbar – ccsB 
The pTYGSbar-ccsB plasmids were analysed by PCR (Chapter 6.1.5). Twenty 
transformants were obtained from three rounds of selection with basta as a second 





     
Figure 3.4 Agarose gel electrophoresis analysis for confirmation of ccsB genes fused into the genome of 
M. grisea ΔpyiH; M, DNA ladder marker (kb), different colonies are represented by numbers. 
 
3.3.1.5 Chemical Analysis 
Liquid extraction from the ccsB heterologous expression strain led to no observed 
change in the metabolite profiles compared to the pyiH KO metabolites (Figure 3.5). 
 
 
Figure 3.5 LCMS chromatogram (DAD trace) of ccsB heterologous expression into M. grisea ΔpyiH 
extracted on the 7th day from DPY medium. A, M. grisea WT; B, M. grisea ΔpyiH; C, ccsB heterologous 
expression into M. grisea ΔpyiH. 
 
 
161 162 163 
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According to the catalytic mechanism of BVMO mentioned above, the catalytic 
substrates for CcsB are ketones in the macrocyclic portion of cytochalasans.142 In the 
ΔpyiH strain, compound 161, 162 and 163 all contains a ketone group, make them good 
substrates participate in the oxidation reaction. However, there were no any carbonate 
products found in the ccsB expression experiment. One possible reason would be the 
extremely low yield of the ketone metabolites, CcsB cannot functionalise in low 
concentration. Secondly, although the ccsB gene from A. clavatus have already been 
codon optimised in order to fit in M. grisea, for some un-known reasons, it is still 
difficult for ccsB to express properly in another different fungal species. Also we know 
PamyB is relatively weak promoter in M. grisea. 
 
3.3.2 Heterologous Expression of Cryptic Cytochalasan P450s 
into Magnaporthe grisea NI980 P450 Disruption Strain 
 
3.3.2.1 Bioinformatic Analysis of P450s from Hypoxylon 
fragiforme Gene Cluster 
Hypoxylon fragiforme MUCL 51264 was proved to be responsible for the biosynthesis 
of cytochalasin H 174, deacetylcytochalasin H 205, epoxycytochalasin H 206, 
fragiformin E 207, L-694,474 208, and L-687,318 209 (Figure 3.6).128 Cytochalasin H 
174 has an almost identical structure to 65, the only difference is the 4’-O-methyl of 
pyrichalasin H. Methyltyrosine is a precursor of 65, while 174 incorporates 
phenylalanine.129 Compounds 205 and 208 are precursors of 174, while compounds 206, 





Figure 3.6 Structures of metabolites isolated from Hypoxylon fragiforme MUCL 51264.14,129 
 
Genome sequencing of H. fragiforme MUCL 51264 was achieved and analysed by Dr 
Eric Kuhnert. Only two BGC contained PKS-NRPS genes, and only one of them 
contained genes encoding an α,β-hydrolase and a putative Diels-Alderase (pDA) which 
are indicative of cytochalasan BGC.150 This putative cytochalasan BGC was assigned as 
the hff nomenclature (Table 3.1, GenBank accession no. MN477016). Gene annotation 
were executed by using fungiSMASH,108 GenDBE, and FGENESH.151 In total ten 
genes were identified in the hff gene cluster: a PKS-NRPS (hffS); a trans-ER (hffC); a 
putative Diels-Alderase (hffF); an oxidoreductase (hffH); an acetyltransferase (hffB); a 
transporter (hffT); an αβ-hydrolase (hffE); two P450s (hffD and hffG); and a 






















H.fragiforme_g4342.t1 hffH Oxidoreductase PyiH 80.2 





H.fragiforme_g4346.t1 hffE αβ-Hydrolase PyiE 77.4 
H.fragiforme_g4347.t1 hffT MFS transporter PyiT 74.1 



















Figure 3.7 Artemis comparison of cytochalasan BGC identified in Magnaporthe sp. M. grisea 




Artemis comparison between M. grisea NI980 and H. fragiforme were executed. This 
showed two differences between the clusters. First, compared to M. grisea NI980, the 
BGC identified in H. fragiforme MUCL 51264 does not encode an O-methyltransferase, 
which is expected since 207 does not require O-methyltyrosine for its biosynthesis. 
Second, the gene order and the orientation of the homologues are not conserved (Figure 
3.7). Similar comparison between M. grisea NI980 and P. oryzae Guy11 were done and 
described in chapter 1.4.3. Sequence alignment showed hffD, a gene encoding a P450 
has 80% sequence similarity with pyiD. Next, hffG has 75% sequence similarity to pyiG, 
while only 20% identity with pyiD (Table 3.2).  
There are four P450 genes CYP1-4 in the P. oryzae ACE1 BGC (Chapter 1.4.3). 
Alignment showed that pyiD shares more sequence similarity to CYP4 (49% identity) 
and pyiG shares more similarity to CYP3 (40% identity). CYP1 has 38% similarity with 
pyiD and CYP2 shares 34% identity with pyiG (Table 3.2). However, these similarities 
were not recognised by the Artemis comparison tool. One possible reason might be that 
the bioinformatics predictions create a confusion between pyiD and pyiG.150 
 






Cytochrome P450 (CYP) monooxygenases are one of the most versatile biological 
catalysts which have the ability to oxidase a wide range of substrates. The CYP 
enzymes play important roles in various fungal metabolisms. To investigate the range of 
the promiscuity of the cytochrome P450 monooxygenases during cytochalasan 
biosynthesis, the P450 disruption strain (∆pyiD and ∆pyiG) obtained from previous KO 
experiments were designed as a bioengineering platform and use the combinatorial 
biosynthesis approach to heterologous express P450 encoding genes from other putative 
cytochalasan biosynthetic gene cluster (BGC). We aim to elucidate the biocatalytic 
properties of different fungal CYPs. In the meantime, we hope to generate novel 
cytochalasans modified by different functional CYPs. 
 
3.3.2.3 Vector Construction and Gene Transformation 
The detailed information of pTYGS-bar plasmid has been described in section 3.1.1. 
There is a NotI restriction sequence between the P/TamyB cloning sites. The pTYGSbar-
P450 plasmids used for heterologous expression in pyiD/pyiH disruption strain was 
constructed in the same way described in section 3.3.1.3 (Scheme 3.4). P450 
heterologous expression experiment were follow the same protocol as we used in the 
transformation in pyiH KO strain. 
 
Six P450 genes (hffD and hffG from H. fragiforme, and CYP1-4 from P. oryzae) were 
cloned and the corresponding pTYGSbar – P450 plasmid were constructed using above 





   
     
   
Figure 3.8 Overview of constructed heterologous expression plasmids in this work.139 
 
3.3.2.4 PCR analysis of pTYGSbar – P450s 
Around 5 µg of purified pTYGSbar-P450 plasmids were used in the fungal 
transformation. Transformants were obtained from three rounds of selection with basta 
and screened for genetic testing before being inoculated into liquid culture. Genomic 
DNA was extracted and used as the PCR template. Target genes were analysed with 
oligonucleotides specific for the targeted P450 gene region and as well as M. grisea 
ΔPyiD gDNA (Figure 3.9, Chapter 6.1.5). Forward primer binding with the region of 
PamyB, while the reverse primer binding in the 3’ end of each P450 gene. All the the PCR 




            
                           
                     
                                   
                                          
                                   
Figure 3.9 Oligonucleotide strategy of PCR analysis for confirmation of P450 genes fused into the genome 





3.3.2.5 Chemical Analysis 
The heterologous expression process was done following the same protocol described in 
section 3.3.1.4. The number of positive transformants confirmed by PCR, and the 
transformation efficiency of P450 genes into M. grisea ΔpyiD strain were summarized 
(Table 3.3).139 
 













hffD 30 8/10 80 
hffG 30 10/10 100 
CYP1 41 7/20 35 
CYP2 50 5/20 25 
CYP3 51 5/10 50 
CYP4 18 6/10 60 
 
 
Selected positive transformants were inoculated into DPY liquid medium at 25 ℃, 110 
rpm for 7 days before the filtration were extracted with ethyl acetate. Liquid extraction 
was dissolved in methanol and analysed by LCMS.  
 
 
3.3.2.6 Heterologous Expression of hffD into ∆pyiD Strain 
 
The hffD heterologous expression transformants were extracted and analysed by LCMS. 





Figure 3.10 LCMS chromatogram (DAD trace) of mycelia extracts derived from M. grisea ΔpyiD 
strains transformed with crytic P450 genes. Chromatograms were monitored using a diode array 
detector scanning at 276 nm. A, M.grisea WT; B, M. grisea ΔpyiD; ; C – H indicated 
heterologous complementation experiments.139 
 
The new compound (tR = 6.2 min, 21.7 mg/L) was purified as white powder. The UV 
spectra (methanol) showed the maximum absorption at 275 and 223 nm (Figure 3.10), 
which is similar to pyrichalasin H 65. HRMS of the new compound confirmed a 
molecular formula of C31H41NO6 ([M-H]
- calculated 522.2856, found 522.2852), 
identical to 65. 
 
 



















          
Figure 3.11 UV spectrum (left) and mass spectra (right) of 210 isolated from hffD heterologous 
expression into M. grisea ΔPyiD. 
 
Full NMR was acquired and analysis of 1H and 13C NMR data of the new compound 
identified 31 carbons and 41 protons.139 Both carbon and proton spectra were almost 
identical to pyrichalasin H 65. Furthermore, 2D NMR, such as, H-H COSY, HMBC and 
HSQC were also investigated. The 2D signals of the new compound were also identical 
to the data from 65. Based on those evidence, we elucidated that the new compound is 
pyrichalasin H 65. As compounds 164 - 167 all lack a hydroxyl group at C-18, the 
production of 65 was restored when hffD was transformed into M. grisea ΔpyiD strain. 
This indicates that hffD encodes the C-18 hydroxylase and is functionally equivalent to 
pyiD. 
 
3.3.2.7 Heterologous Expression of CYP1 into ∆pyiD Strain 
The CYP1 heterologous expression transformants were extracted and analysed by 
LCMS. The result showed a new peak appeared (Figure 3.10 E), laso at a RT 
corresponding to 65. 
The new compound (tR = 6.2 min, 15.3 mg/L) was purified as a white powder. The UV 
spectra showed the maximum absorption at 276 nm (Figure 3.12), which is similar to 65. 
HRMS of the new compound confirmed a molecular formula of C31H41NO6 ([M+Na]
+ 






    
Figure 3.12 UV spectrum (left) and mass spectra (right) of 211 isolated after heterologous 
expression of CYP1 into M. grisea ΔPyiD. 
 
Full NMR was acquired and analysed of 1H and 13C NMR data of the new compound 
identified 31 carbons and 41 protons. Both carbon and proton spectrum were almost 
identical to pyrichalasin H. Furthermore, 2D NMR, such as, H-H COSY, HMBC and 
HSQC were also investigated. The 2D signals of the new compound also identical to the 
data from 65. Based on those evidence, we elucidated that the new compound is 
pyrichalasin H 65. As compounds 164-167 all lack a hydroxyl group at C-18, the 
production of 211 was restored when CYP1 was transformed into M. grisea ΔpyiD 
strain. This indicates that CYP1 also encodes a C-18 hydroxylase. 
 
3.3.2.8 Heterologous Expression of CYP3 into ∆pyiD Strain 
The CYP3 heterologous expression transformants were extracted and analysed by 
LCMS. Two new peaks 212 and 213 appeared from the LCMS profile (Figure 3.10 G). 
These had RT which did not correspond to 65. 
Compound 212 and 213 were purified as white powders, the compound physical data 
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Full NMR was acquired and analysis of 1H and 13C NMR data of 212 identified 28 
carbons and 37 protons compound to 65. The signal of H-22 and H-26 of 65 were not 
found from proton NMR and HSQC. There are two obvious correlations observed by 
HSQC (δH – δc, 3.26/3.38-67.1), indicating that there is a new methylene formed. The 
1H-1H correlations between H-22/H-15, and the HMBC correlation between H-22 to C-
15, C-16, C-17, suggest that a hydroxyl group is linked at C-22. The signal of methyl 
group at C-24 is not found in the proton NMR, confirming the lack of the acetyl group. 
The chemical shift of C-5, C-6 and C-7 changed dramatically compared to pyrichalasin 
H, which is in accordance with an epoxide between C-6 and C-7, in the new compound. 
The remaining signals of both carbon and hydrogen chemical shifts were similar to 
pyrichalasin H. Therefore, the structure of compound 212 was confirmed (Figure 3.13). 
 
 






Full NMR data of 213 were acquired, and analysis of 1H and 13C NMR data identified 
30 carbons and 39 protons. Compared to 212, the signal of H-25 was found from proton 
and HSQC spectra, indicating the acetyl group attached to the C-21 hydroxyl group. 
The remaining  signals of 213 are similar to 212, therefore the structure of compound 
213 was confirmed (Figure 3.13). 
 
3.3.2.9 Heterologous Expression of hffG, CYP2 and CYP4 into 
∆pyiD Strain 
 
The same transformation method was used to generate transformants for the 
heterologous expression of hffG, CYP2 and CYP4 into M. grisea pyiD KO strain. 
However, liquid extraction from hffG, CYP2 and CYP4 containing strains led to no 
observed change in the metabolite profiles compared to the KO metabolites (Figure 3.10 
D, F and H). The plasmids used for heterologous expression in pyiG disruption strain 
are the same as we used in the pyiD disruption strain (Figure 3.8). All P450 genes 
heterologous expression experiments follow the same protocol as we used in the 
transformation in pyiD KO strain. The heterologous expression process was done 
following the same steps described in section 3.3.1.4, the number of positive 
transformants were confirmed by PCR, the transformation efficiency of P450 genes into 






















hffG 30 9/10 90 
CYP1 32 5/10 50 
CYP2 37 5/18 27.8 
CYP3 10 2/10 20 
CYP4 36 6/12 50 
 
All pTYGSbar-P450 plasmids were analysed with the same oligonucleotides and the 
same methods described in section 3.3.1.4. All the agarose gel electrophoresis analyse 
results are summarized (Figure 3.14). 
A  
B    C  
 D                        E  
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Figure 3.14 Agarose gel electrophoresis analysis for confirmation of P450 genes fused into the genome of 
M. grisea ΔpyiG; M, DNA ladder marker (Kb), different colonies are represented by numbers. A-E: Colony 
PCR results of hffG, CYP1, CYP2, CYP3, CYP4 heterologous expression transformants. 
3.3.2.10 Heterologous Expression of hffG into ∆pyiG Strain 
All positive hffG containing transformants were extracted and analysed by LCMS. The 
result showed a new peak appeared which corresponded with 65(Figure 3.15 C). 
 
 
Figure 3.15 LCMS chromatogram (DAD trace) of mycelia extracts derived from M. grisea ΔpyiG 
strains transformed with crytic P450 genes. Chromatograms were monitored using a diode array 
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Compound 214 was purified as white powder the compounds physical data were 
measured (Table 3.15). 
 































Full NMR was acquired and analysis of 1H and 13C NMR data of 214 identified 31 
carbons and 41 protons. Both carbon and proton spectra were almost identical to 
pyrichalasin H. Furthermore, 2D NMR, such as, H-H COSY, HMBC and HSQC were 
also investigated. The 2D signals of 214 were also identical to the data from 65. Based 
on these evidence, we elucidated that compound 214 is pyrichalasin H 65. As 
compounds 168 - 172 all lack a hydroxyl group at C-7, the production of 65 was 
restored when hffG was transformed into M. grisea ΔpyiG. This indicates that hffG 










3.3.2.11 Heterologous Expression of CYP3 into ∆pyiG Strain 
The CYP3 heterologous expression transformants were extracted analysed by LCMS. 
The result showed one new peak 215 appeared (Figure 3.15 F). The physical data of 215 
is listed in Table 3.6. 
 
Full NMR data was acquired and analysis of 1H and 13C NMR spectra of 215 identified 
31 carbons and 41 protons. The chemical shift of C-5, C-6 and C-7 changed 
dramatically compared to pyrichalasin H, which is in accordance with the presence of 
an epoxide between C-6 and C-7 in the new compound. The remaining signals of both 
carbon and hydrogen chemical shifts were similar to pyrichalasin H 65. Therefore, the 
structure of compound 215 was confirmed (Figure 3.16). 
 
 
Figure 3.16 Chemical structure of 215. 
 
3.3.2.12 Heterologous Expression of CYP1, CYP2 and CYP4 into 
∆pyiG Strain 
Liquid extraction from the CYP1 heterologous expression strain led to no observed 
change in the metabolite profiles compared to the pyiG KO metabolites (Figure 3.15 D). 
This result is not beyond our expectation, since we have elucidated that CYP1 catalyses 
a C-18 hydroxylation in pyiD KO strain. 
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Liquid extraction from either CYP2 or CYP4 containing strains also led to no observed 
change in the metabolite profiles compared to the pyiG KO metabolites (Figure 3.15 E, 
Figure 3.15 G). 
 
3.4 Discussion & Outlook 
Heterologous expression experiments indicated that HffD and HffG site-selectively add 
a hydroxyl group to C-18 and C-7 of metabolites from the P450 disruption strain 
separately. Both HffD and HffG perform a single hydroxylation at the desired position. 
These results connect the production of compounds 205 - 209 in H. fragiforme with the 
hff gene cluster. Moreover, cryptic P450s from other synthetic pathway were proved to 
be functional in our P450 disruption strain. This synthetic biology platform can be used 
to systematically investigate the function and scope of different cryptic tailoring 
enzymes.  
Subsequently, we systematically investigated four putative p450s (CYP1-4) from 
Pyricularia  oryzae Guy 11 ACE1/SYN2 BGC in this platform. First, we expressed 
CYP1-4 into the M.grisea ΔpyiD strain and investigated the resulting extracts by LCMS. 
Expressing CYP1 restored the production of 65 with a low titer of 15.3 mg/L, the 
structure of compound 65 was confirmed by HRMS and NMR. Therefore, the function 
of the putative CYP1 is uncovered as a site-selective C-18 hydroxylase (Table 3.7). The 
decreased yield is likely caused by the use of a non-native gene under the control of a 
non-native promoter. We already know that PamyB is not a strong promoter in M. 
grisea. 
Table 3.7 Summary of heterologous expression experiment.139 
Gene added 
Compounds produced (mg / L) 
Deduced function of 




hffD 65 (21.7) - C-18 hydroxylase 
hffG - 65 (13.8) C-7 hydroxylase 
CYP1 65 (15.3) - C-18 hydroxylase 
CYP2 - - - 
CYP3 
212 (2.0) 
215 (28.6) C-6/C-7 epoxidase 
213 (1.5) 







The introduction of CYP3 resulted in two new compounds 212 and 213 in small 
amounts. The NMR of 212 and 213 shown to have typical epoxide resonances at C-6, 
C-7 and H-7. The production of 212 and 213 can be explained as derivatives from the 
epoxidation of compound 165 by CYP3 (Scheme 3.5 B). Compound 165 comes from 
the off-pathway shunt in the biosynthesis of 65. Compound 213 is the acetylated 
product of compound 212 catalysed by acetyltransferase PyiB. Compounds 164, 166, 
and 167 already have a hydroxyl group at C-7 introduced by the native P450 PyiG, and 
therefore cannot act as substrates for CYP3. Only when compound 165 is present can 
CYP3 perform its function as a site-selective epoxidase of the C-6/C-7 olefin. However, 
introduction of either CYP2 or CYP4, led to no observable changes in the metabolite 
profiles. 
Then, we expressed CYP1-4 P450s into M. grisea ΔpyiG host and the liquid extractions 
of transformants were analysed by LCMS. Expression of either CYP1, CYP2, or CYP4 
did not result in any observed metabolites. It is not surprising that CYP1 did nothing in 
M. grisea ΔpyiG host, as we have previously confirmed that CYP1 is a site-selective C-
18 hydroxylase in M. grisea ΔpyiD strain and compounds 168 - 172 from M. grisea 
ΔpyiG host already possess a hydroxyl group at C-18 (Scheme 3.5 A, Table 3.7).  
The introduction of CYP3 lead to the production of the new compound 215 (28.6 mg/L). 
Compound 215 was purified and fully elucidated by HRMS and NMR. The production 
of 215 can be explained from the epoxidation of on-pathway intermediate 172 catalysed 
by CYP3 (Scheme 3.5 A). Combined with new epoxide metabolites 212 and 213 
isolated from CYP3 heterologous expression into M. grisea ΔpyiD strain. The function 





Scheme 3.5 Network of tailoring modifications observed during the biosynthesis of 65 and summary of the 
functionality introduced by the heterologous expression of P450s, HffD, HffG, CYP1, and CYP3 into M. 




There are different functional P450 enzymes known in cytochalasan biosynthesis, for 
example, P450s catalyse hydroxylation reaction in cytochalasin K 82 at C-7 and 
epoxycytochalasin H 206 at C-18, epoxidation P450s at C-6 and C-7 in 
epoxycytochalasin H and chaetoglobosin A 63 and also iterative hydroxylation P450s in 
cytochalasin K 82 at C-17 and C-18, epoxycytochalasin H at C-19 and C-20 (Figure 
3.17).129,138, 76 In our case, neither CYP1 nor CYP3 operate iteratively, even though 
neither of them react with their native substrates. 
 
 
Figure 3.17 Structures of cytochalasan derived from the action of P450s.129,138, 76 
 
The proposed polyketide backbone 217 synthesised by the ACE1 PKS-NRPS is two 
carbons longer than the pyrichalasin H 65 skeleton. (Scheme 3.6). The CYP1 gene 
originates from ACE1 gene cluster, encoding CYP1 that catalyzes a regioselective 
hydroxylation at C-18 of pyrichalasin H intermediate.113 However, there is a methyl 
group at the corresponding position of putative ACE1 intermediate 217, it is impossible 
for CYP1 to catalyse a hydroxylation reaction at C-18 of 217. Therefore, it is likely that 
the hydroxylation happens at C-20 to produce 218, since both of these two carbons are 
next to olefin.  
Larsen and co-workers obtained compound 219 from expression of SYN2 and RAP2.152 
Epoxidation usually happen at C-6 / C-7 olefin generating compound 221, no matter if 




Scheme 3.6 Putative structures for the cryptic cytochalasans encoded by the P. oryzae Guy11 
ACE1/SYN2 BGC and catalysed by P450 enzymes.139 
Systematic investigation of cryptic P450 genes CYP1-2 from ACE1 cluster, and CYP3-
4 from the SYN2 cluster, resulted in changes to the observed metabolites from three out 
of eight experiments. But, heterologous expression CYP2 and CYP4 into ΔpyiD / ΔpyiG 
strains, no metabolite profile change, making it difficult to predict the function of CYP2 
and CYP4. Böhnert and co-workers reported that CYP2 gene is split in ACE1 gene 
cluster,150 maybe that is the reason we did not find any chemical changes from CYP2 
expression. However, it is surprising that we did not observe any metabolite change in 
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CYP4 expression experiment. Especially as bioinfomatic analyse indicates that CYP4 
shares higher sequence similarity with PyiD as (49%), while CYP1 which shares less 
than 38% similarity with PyiG, but still catalyses a hydroxylation reaction at C-18 
(Table 3.2). CYP4 may not recognise the cytochalasin P450 metabolites and this could 
be one of the possible reasons. 
To sum up, for the first time, we demonstrated the possibility of using a combinatorial 
biosynthesis strategy between different cytochalasan BGC. The functions of four cryptic 
P450 enzymes were elucidated. It is an effective strategy to decorate the cytochalasan 
backbone by introducing functional P450 genes. In the meantime, these experiments 
uncover the selectivity and versatility of cytochalasan P450 enzymes. Moreover, this 
bioengineering platform can be developed into a cell factory to design and generate 




We have developed the P450 disruption strain as a synthetic platform. In future, 
multifunction cryptic P450s from different pathways could be introduced into this 
platform to generate more structural complicated cytochalasans. Moreover, P450s from 
different fungal species or from different microorganisms can also be heterologous 
expressed into the platform to further elucidate the actual function of those mysterious 
P450s. Except for P450s, other functional tailoring enzymes, for example, halogenase, 
methyltransferase etc, could be tested in this cell factory, these enzymes will 









4. Generating New Pyrichalasins by Mutasynthesis 
 
4.1 Introduction to Mutasynthesis and Other Methods of 
Pathway Engineering 
Natural products play an essential role in many industries, in particular pharmaceuticals. 
However, the implementation of many promising biologically active compounds as 
pharmaceuticals is limited by natural product isolation. Many of these compounds are 
produced in very limited amounts by their natural source, and isolation of these 
compounds from their host organisms consumes natural supply. Historically, chemists 
have attempted to solve this problem through organic synthesis. However, while organic 
synthesis has allowed affordable access to some natural products, total synthesis of 
many natural products is still not economically feasible for mass production.1,153 
Recent trends in the synthesis and production of bioactive molecules have shown 
increased interest in green synthetic processes. Particularly, there has been a movement 
toward implementation of fermentation to solve problems commonly encountered in 
organic synthesis. This technology can be expanded to produce advanced intermediates 
in the synthetic process. Microorganisms such as yeast, bacteria, and filamentous fungi 
can convert simple starting materials into stereochemically complex natural products. 
Fermentation reduces the use of organic solvents and organic reagents. Natural products 
obtained by fermentation can be efficiently converted into new structures that would be 
difficult to obtain synthetically.154 
Using the respective wild-type (WT) strain to generate novel structural diversity of 
microbially produced secondary metabolites is one of the oldest strategies (Scheme 4.1 
a). Precursor-directed biosynthesis (PDB) is performed by supplementing biosynthetic 
precursor-analogues to the fermentation of WT strains (Scheme 4.1 b). Based on the 
fact that WT producers are used, PDB is a straightforward way for exploiting the 
biosynthetic machinery of secondary metabolites, compared to the time-consuming 
genetic manipulations using methods of modern molecular biology. However, there is 
usually an internal competition of natural and unnatural precursors, and yields of the 
desired analogues can be low, and this problem is consequently accompanied by 
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Scheme 4.1 Biosynthetic conceptions for natural product synthesis and derivatives (I-IV = 
enzymes; A = starter building block; B-D = biosynthetic intermediates; E = natural product or 
derivative).153 
 
Chaetoglobosins are structurally intriguing fungal cytochalasans with an isoindole 
moiety fused to a macrocycle.155,156 They are well known for their specific binding to 
actin filaments, making them important chemical tools in cell and molecular 
biology.157,158 Halogenated derivatives as biosynthetic precursors are particularly useful 
in the producing of modified chaetoglobosins, since they are structurally very similar to 
the natural substrates. The introduction of halogen atoms such as fluorine can often 
127 
 
improve the bioavailability, bioactivity and stability of the starting compounds in 
numerous ways. 
A comprehensive example of PDB was applied by Tan and co-workers who generated 
new analogues of chaetoglobosins by feeding halogenated precursors to Chaetomium 
globosum. Chaetoglobosins A 63, B 229 and J 222 (Scheme 4.2),159 were isolated with 
high yields from Chaetomium globosum (strain no. 1C51). Halogenated precursors 223 
- 225 were fed to the organism, and novel halogenated chaetoglobosins 226 - 228 and 
230 - 232 were isolated (Scheme 4.2). All isolated compounds were tested and found to 
be immunosuppressive in a mouse model.160 
 
 
Scheme 4.2 Precursor-directed biosynthesis of chaetoglobosin.160 
 
Another interesting strategy which combines chemical and biosynthesis, is the use of 
genetically engineered microorganisms. This strategy has been termed as mutational 
biosynthesis (MBS), or in short mutasynthesis.161,162 According to Rinehart,163 
mutasynthesis involves the generation of biosynthetic blocked mutants, feeding of 
mutasynthons to these mutants and their integration into novel metabolites, followed by 
isolation of the unnatural products for evaluation of their biological activities (Scheme 
4.1 c). More recently, mutasynthesis has experienced a rapid development because the 
number of fully sequenced biosynthetic gene clusters coding for pharmaceutically 
important natural products has substantially increased, accelerating the stage for easier 
creation of specific blocked mutants and therefore efficient access to modified drug 
candidates. 
An impressive application of MBS for lead optimisation was reported by Wilkinson and 
co-workers. They dealt with the polyketide derived angiogenesis inhibitor borrelidin 
234 (Scheme 4.3).164 Using a non-producing strain disrupted in the biosynthesis of the 
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starter unit dicarboxylic acid 233, supplementation with various analogues resulted in a 
set of novel borrelidins 235 – 238 differing in the C-17 side chain. Biological evaluation 
of their anti-proliferative activity indicated a significantly improved selectivity of the C-
17 cyclobutyl analogue 235 for in vitro angiogenesis inhibition over cytotoxicity. These 
results demonstrate that MBS can be successfully applied for lead optimisation, while 
total- or semisynthetic approaches towards such compounds would be difficult.165 
 
Scheme 4.3 Mutational biosynthesis of borrelidins 234 - 238.165 
 
4.2 Aims 
Targeted disruption of the pyiA O-MeT (Chapter 2.3.1) led to the discovery of the 
unexpected phenylalanine-derived cytochalasin H 174. Previous O-MeT KO result 
suggested that the true precursor for the A-domain might be O-methyltyrosine 175.109 
This hypothesis will be investigated by observing whether pyrichalasin H 65 is restored 
after feeding 175 to pyiA KO strain. 
Next, we will investigate whether halogenated pyrichalasans can be made: 4’-
halogenated phenylalanines will be fed to the ∆pyiA strain to confirm this idea. As 
copper catalysed azide alkyne cycloaddtion (click) reactions are widely used in 
generating new compounds, we will also feed 4’-azido and 4’-alkyne phenylalanines to 
determine whether a clickable system can be built. Furthermore, we will feed the ∆pyiA 
strain more complex alkyne and azide substrates, to see if we can build an even more 
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complex system. Eventually, a library of un-natural 4’-substitute pyrichalasans will be 




4.3.1 Synthesis of Substrates 
O-Propargyl phenylalanine was synthesized in three steps from L-tyrosine 176.166,167 
Treatment of 176 with di-tert-butyl pyrocarbonate in a mixture of dioxane and water 
gave the amine protected 239. Allyl bromide was added into the solution of 239 with 
potassium carbonate under reflux conditions overnight. The obtained crude product 240 
was directly dissolved in a solution of TFA and DCM to cleave the BOC protecting 
group to give the desired feeding precursor 243 (Scheme 4.4). O-Propargyl- tyrosine 
244 and O-but-3-ynyl tyrosine 245 were synthesized by the same method. All other 




Scheme 4.4 Chemical synthesis of 243 - 245. Reagents and conditions: a, (Boc)2O, dioxane, 
H2O, Et3N, RT, 1 h; b, 1-bromobut-3-yne, K2CO3, THF, reflux, 12 h; c, TFA, CH2Cl2, RT, 2 h. 
 
M. grisea WT strain produces 65 at 60 mg/L (Figure 4.1 A), but the KO strain produces 
much less of 173 (2.8 mg/L) and 174 (19.5 mg/ L, Figure 4.1 B). After addition of O-
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methyltyrosine 175 (10 mg/mL) to the pyiA KO strain over 7 days, the crude extract 
was dissolved in MeOH and analysed by LCMS ((Figure 4.1 C, Chapter 2.3.3).109  
 
 
Figure 4.1. LCMS chromatograms (DAD trace) of organic extracts from pyiA KO experiments in 
M. grisea: A, wild type control; B, pyiA KO strain; C, feeding O-methyltyrosine 175 to pyiA KO 
strain.109 
 
The result showed the restoration of 65 with a yield of 61.6 mg/L (Table 4.1), almost 
equal titers compared to the WT strain. Compound 173 and 174 could no longer be 
detected under these conditions clarifying that 175 is the preferred substrate of the PyiS 
NRPS A-domain. 
 
In order to explore the tolerance of the PyiS NRPS A-domain, 4’-fluoro- / chloro- 
/bromo- /iodo-/azido-phenylalanine, 4’-O-allyl-tyrosine and 4’-O-propargyl-tyrosine 
243 - 250 were fed using the same method as feeding 4’-O-methyltyrosine. Surprisingly, 
all 7 substrates were incorporated to give the corresponding 4’-functionalised 
pyrichalasins 251 -258 in purified yields from 26 to 60 mg/L (Scheme 4.5, Table 4.1, ). 
However, we did not obtain the 4’-O-butynyl pyrichalasin 253. All new pyrichalasans 








252 and 257 were synthesized by Maurice, compound 253 and 258 were synthesized by 
Adrian). 
 
Scheme 4.5 Precursor-directed biosynthesis of 4-substituted pyrichalasins. 
    
    
Figure 4.2. LCMS and mass chromatograms (DAD trace) of 254 and 255 feeding studies. A, C, E, F: 
compound 254 LCMS chromatogram, UV absorbtion, mass spectra of 254; B, D, G, H: compound 255 












 (10 mg/mL)  (powder) 




2 4’-O-allyl-tyrosine 243 
 
C33H43NO6 light yellow 32.2 




4 4’-fluoro phenylalanine 246 
 
C30H38FNO5 
light yellow 26.8 




6 4’-bromo phenylalanine 248 
 
C30H38BrNO5 white 41.3 




8 4’-azido phenylalanine 250 
 
C30H38N4O5 light yellow 38.9 
 
 
4.4 Discussion & Conclusion 
 
In order to investigate the tolerance of the A-domain of PyiS, we then fed 4 different 4’- 
halogenated phenylalanines (246 - 249) to ∆pyiA KO strain. To our surprise, all 4 
substrates were incorporated by PyiS to give the corresponding new 4’-halogenated 
pyrichalasans (254 - 257). 
Compound 252 and 258 were obtained, after feeding 4’-azido phenylalanine and O-
propargyl tyrosine to the pyiA deficient strain. Subsequently, a more complex system 
was tested by feeding 4’-O-allyl-tyrosine 243 and O-butynyl phenylalanine 245 to the 
KO strain in parallel, we obtained the desired 4’-O-allyl pyrichalasin 251, while no 4’-
O-butynyl pyrichalasin 253 was detected.  
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From the above feeding experiments, we can draw the conclusion that the A-domain of 
PyiS can recognise different 4’-substituted phenylalanines. The A-domain is therefore 
tolerant to different substrates. It can process small (e.g. 4’-F) and medium (e.g. 4’-O-



























Natural products are an important source of lead compounds for drug development, 
these compounds often exhibit great potency when tested against specific targets, 
however, other properties of these compounds, such as solubility, bioavailability, 
exposure, stability, and metabolism, many need to be improved. Several approaches 
have been used to diversify natural products.168 
There is a long history of the use of synthetic chemistry to modify natural products to 
generate compounds with improved pharmacological properties. For example, 
amoxicillin 260, a β-lactam antibiotic produced by semisynthesis has a broader 
spectrum than penicillin G 259, while methicillin 261 has a greater resistance to 
penicillinase.169 Similarly, the semisynthetic simvastatin 262 is more potent than the 
fungal polyketide natural product lovastatin 20 (Scheme 5.1).170 This semisynthetic 
approach has been widely used to diversing the structural complexity of many natural 
product drug candidates. 
 
 




Mutasynthesis experiment by feeding 4’-substituted phenylalanines 243 - 250 to ∆pyiA 
strain, gave the corresponding 4’-functionalised pyrichalasins 251 - 258 in titres around 
30-60 mg / L similar to the pyrichalasin H 65 production in wild type strains (Chapter 
4.3). These compounds themselves may have new properties. Alternatively the 
introduced functional groups could be used in further chemical derivatisation reactions. 
 
5.1.1 Total synthesis of Cytochalasin B  
Total synthesis of several cytochalasans has been reported. For example, the first total 
synthesis of cytochalasin B 268 was done by Stork and co-workers (Scheme 5.2).171,172 
A triene 263 was esterified with N-acetylhydroxypyrrolone 264 to form the precursor 
265 for the key intramolecular [4+2] cycloaddition. The Diels-Alder reaction required 
harsh conditions (180 - 190 ℃, 6 d) and provided the macrocycle 266 in low yield 
(30%). Subsequently, compound 266 undergoes several more steps to form epoxide 267, 
then two more steps were carried out to produce the final product cytochalasin B 268. 
Therefore, the scope and practicality of total synthesis are limited, and the syntheses 
have not been extended to the production of functionalised analogues.173,174 
 
 
Scheme 5.2 Total synthesis of cytochalasin B 268. Reagents and conditions: a, 2-chloropyridine 
methiodide, 20 mol% DMAP, NEt3, RT, CH2Cl2, 69%; b, 180-190 ℃, 6 d, 30%; c, 3 equiv. LDA, -78 ℃, 
THF; d, 3 equiv. PhSeCl, H2O2, pyridine, CH2Cl2 76% trans-selective; e, Ac2O, DMAP, NEt3 88%; f, 1 equiv. 
t-BuOOH, 2.5 mol% Mo(CO)6, 0.7 M in benzene, 75 ℃, 1.5 h, 89%; g, Al(OiPr)3, ∆, xylene, 8 h, 74%; h, 




5.1.2 Chemical Modification of Cytochalasin D  
Considering the vast knowledge on the backbone of natural cytochalasans and their 
biological activities, it is surprising to find that very few investigations have been 
reported on the chemical modification of cytochalasans, or attempts to functionalise 
them for more targeted use in chemical biology. 
Tanenbaum and co-workers examined the synthesis and biological activities of 
cytochalasin D derivatives (Scheme 5.3).173 Cytochalasin D 269 was reacted with 
phenyltrimethylammonium perbromide to give 6,12-dibromocytochalasin D 270 
(stereochemistry not given). 270 was then selectively monodehydrohalogenated with 
lithium chloride. Nucleophilic substitution reactions with sodium iodide, cyanide and 
azide gave three novel cytochalasan derivatives 272 - 274. Cytochalasin C 275 and D 
269 caused almost identical biological responses to tumor cell lines, while derivatives 
with iodo 272 or azido 274 functions significantly reduced the effectiveness (30-50%). 
The dibromo derivative 270 exhibit even lower potencies, which may be rationalized by 
steric hinderance, or the high electronegativity of 273 likely due to the C-12 nitrile.171 
 
 
Scheme 5.3 Derivatization of cytochalasin D 269. Reagents and conditions: a, PhNMe3Br3, THF; 
b, LiCl, DMF; c, NaI, X = I; NaCN, X = CN; NaN3, X = N3.171 
 
In our case the 4’-functionalised pyrichalasans 251 - 258 obtained from feeding 
experiment, should allow us to do some chemical modifications targeting these 





A library of different 4’-substituted pyrichalasans was created by mutasynthesis 
(Chapter 4). These pyrichalasins can be used as substrates to further generate different 
functional molecules by various chemical reactions. More and more novel cytochalasan 
have been reported, while few dimeric cytochalasan have been found. Generating 
dimeric pyrichalsins would be worth trying by chemical modification. For example, 4’-
bromo pyrichalasin 256 could be used to generate dimeric pyrichalasins by Suzuki 
reaction; triazole containing pyrichalasins could be synthesized by click chemistry using 
azide and alkyne substrates; fluorescent dyes could also be linked to pyrichalasin by 
Huisgen cycloaddtion. Furthermore, these synthesized functional pyrichalasins will be 
tested on microorganisms, tumor cell lines and in the cell biology area. Our target is to 
develop some anti-fungal or anti-tumor drug candidates, or to generate new cell imaging 




5.3.1 Generating New Hybrid Molecular Pyrichalasans by 
Copper-Catalyzed Azide-Alkyne Huisgen Cycloaddition (CuAAC) 
The concept of click chemistry (CC), first introduced by K. B. Sharpless, has been 
widely adopted for use in drug discovery. For a decade, CC has provided the ability to 
rapidly and reliably synthesize novel materials. The use of CC is likely to significantly 
advance drug discovery and bioconjugation development.175 The copper-catalyzed 
Huisgen azide-alkyne cycloaddition (CuAAC) is the leading method of the “click 
chemistry” group.176,177 Because of the straightforward procedures, the high functional 
group tolerance, and the usually high yields. CuAAC has affected all fields of chemistry 
from materials to life science.178,179 
An alkyne-azide cycloaddition occurs between an organic azide and a terminal alkyne in 
the presence of Cu(I) to form a 1,4 disubstituted 1,2,3 triazole. The rate of this reaction 
is fast, which means that it proceeds efficiently at room temperature. However, the 
mechanism of the alkyne - azide click reaction mediated by copper (CuAAC) remains 
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difficult to establish owing to the involvement of several reaction intermediates and the 
widespread use of copper-catalyzed cycloaddition reaction.180  
 
5.3.2 Application of Huisgen Cycloaddition 
Targeted protein degradation, using bifunctional small molecules (Protacs) to remove 
specific proteins from cells, has emerged as a powerful new modility of chemical 
biology and drug discovery. Protacs composed of a ligand for a target protein of interest, 
and a ligand for an E3 ubiquitin ligase, combined by a flexible linker.181 This approach 
“hijacks” the function of a ligase to transfer ubiquitin subunits to the target protein, 
thereby tagging it for recognition by the proteasome and coding its destruction.182,183 
There is little literature insight into the ideal linker and suggested experience in protac 
design. A comprehensive study of ligase ligand/linker length activity relationship with a 
bromodomain and extraterminal domain-4 (BRD4) targeting protac been investigated to 
understand of the structure active relationship (SAR) of these bispecific molecules.184 A 
reliable linking strategy to couple ligase ligand-containing motifs and target protein 
ligands, which led to the Huisgen 1,3-dipolar cycloaddition reaction. A new triazole 
ring was formed by using the azides and alkynes as substrates and catalyzed by copper. 
This reaction was referred as “click chemistry” due to its ease of use.185 This reaction is 
high yielding, requiring stoichiometric quantities of each component and shows 
excellent functional group compatibility under mild reaction conditions.  
With BRD4 azide 276 and alkyne cereblon ligase ligands 277 – 281 in hand, then 
undergoes the typical conditions for a click reaction to generate the library of Von 
Hippel-Lindau (VHL) ligands 282 – 286 (Scheme 5.4).186 
 
 




10 mg of 4’-Azido pyrichalasin 258 was reacted with a series of alkynes (prop-1-yne 
287, phenylacetylene 288, 4-bromo-1-ethynylbenzene 289) and shown to be a good 
substrate for alkyne-azide Huisgen cycloaddition reaction.187 The reaction mixture was 
checked by analytical LCMS. The correct mass pattern of the target compounds was 
found. The starting material in each case was totally consumed (Scheme 5.5). The 
solvent was removed in vacuo. The residue was dissolved in ethyl acetate and washed 
with water, organic phase was dried over MgSO4, filtered and characterized to dryness 
in vacuo. The crude product was dissolved in MeOH and purified by LCMS to give the 
expected triazole products 290 - 292 in good yield, those compounds were fully 
characterized by HRMS and 2D NMR. The typical methyl group resonance from the 
triazole ring can be found from heteronuclear single quantum correlation spectra 




Scheme 5.5 Synthesis of functionalised pyrichalasins. Reagents and conditions: a, DIPEA, 
DMF, CuI, RT, 12 h.187 
               




Synthesis of Hybrid Pyrichalasins 
Biotin is a water soluble vitamin which forms excellent stable complexes with avidin 
and streptavidin.188 It has been investigated in a wide range of applications from 
molecular labelling and bio-interfaces to nanostructure assembly.190 23-hydroxyl-
CODD-Me 293 and related compounds are potential anti-inflammatory, cancer 
chemotherapeutic agents. Biotinylated CDDO weas used as an effective method of 
selectively identifying their protein targets within the proteome of a cell because 
streptavidin has a very high affinity for biotin.189 For example, the C-23 biotin 
conjugate of CDDO-Me 294, was used as a good affinity probe for the identification of 
cellular radicicol-binding proteins.190 
 
 
Figure 5.2 C-23 biotin conjugate of CDDO-Me 294.190 
 
Based on the successful Huisgen cycloaddtion reaction described in the previous section, 
the biotin-propargyl ester 295, biotin-homopropargyl ester 296 and biotin-pent-4-ynyl 
ester 297 (synthetic details were described in chapter 6.2.7) were tested and showed that 
the expected pyrichalasin-biotin products 298 - 300 were formed as expected (Scheme 
5.6 A). Similar chemistry was achieved by coupling the biotin–PEG-azide 301 
(synthetic details was described in chapter 6.2.7) with 4’-O-propargyl pyrichalasin 252 
to create 302 containing a longer and more hydrophilic PEG linker (Scheme 5.6 B).190 
All compounds were synthesised in 10 mg scale using standard procedures, purified and 






Scheme 5.6 Synthesis of hybrid pyrichalasins. Reagents and conditions: a, DIPEA, DMF, CuI, 
RT, 12 h.191 
 
Hybrid molecules, obtained by the combination of structural features of two differently 
active moieties, is one of the most popular chemical entities for developing modified 
backbones often with improved properties in the area of biology and medicinal science. 
Penicillin G 259 features a thiazolidine ring, which is fused to a highly labile β-lactam 
ring carbonyl. It is one of the most widely used antibiotics in a range of agricultural and 
medicinal applications. We also experimented with the production of hybrid metabolites. 
For example, 10 mg of propargyl ester of penicillin G 303 (synthetic details were 
described in chapter 6.2.7) reacted smoothly with 258 to give the conjugate 304 as 





Scheme 5.7 Synthesis of hybrid pyrichalasins. Reagents and conditions: a, DIPEA, DMF, CuI, 
RT, 12h.191 
 
10 mg of 4’-Azido pyrichalasin 258 was reduced (Staudinger reaction) to 4’-amino 
pyrichalasin 305 in good yield, by using triscarboxyethyphosphine (TCEP) as a 
reductive reagent. The highly unusual amino cytochalasin product 305 was purified by 




Scheme 5.8 Preparation of 4’-amino pyrichalasin 305. Reagents and conditions: dioxane, H2O, 
TCEP, RT, 0.5 h.192 
 
5.3.4 Synthesis, Bioevaluation and Application of Fluorescent 
Dye Linked Pyrichalasans in Cell Visualization 
Actin is one of the most abundant proteins in eukaryotic cells and its amino acid 
sequence is very highly conserved from yeast to man. The concentration of actin in 
eukaryotic cells is relatively high and reaches the micromolar range.193 Actin fulfils a 
multitude of cellular functions, such as intracellular transport, adhesion and 
concentration, membrane dynamics and migration, cytokinesis and cell-cell contact 
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regulation, polarity and cell shape control, as well as gene regulation and other less well 
explored functions in the nucleus.194 
Although methods for the visualization of single tissues have been well established for 
decades,195 it has still been a challenge to visualize specific actin structures and their 
related functions, in particular under real-time conditions in living cells and organisms.  
Phalloidin 45 is a bicyclic heptapeptide, which is isolated from the mushroom Amanita 
phalloides. Phalloidin binds to filamentous actin (F-actin) in high affinity and lowers 
the critical concentration of actin polymerization in solution. It has been widely used to 
study actin dynamics in vitro, and dye linked analogues of phalloidin serve as highly 
specific reagents for microscopic visualization of the actin cytoskeleton (Figure 
5.3).196,197 
 
    
Figure 5.3 F-actin stained with Phalloidin - Rhodamine Conjugate 306.198 
 
Cytochalasans bind to the barbed end of actin filaments, which inhibits both the 
association and dissociation of subunits at that end. The binding between actin43 and 
cytochalasan causes inhibition of polymerization.199 Cytochalasan linked with a 
fluorescent dye tail would allow the intracellular locations of actin barbed end to be 






Several well-known commericially available fluorescent tags were easily added to the 
pyrichalasin scaffold using click chemistry. For example, 4’-azidopyrichalasin 258 was 
reacted with the perylene-linked acetylene 307 to give the expected product 308 in high 
yield. Similarly, the acetylene-linked coumarin dye 309 also coupled smoothly to give 
the expected 310. The 7-nitro-4-(prop-2-ynylamino) benzofuran (NBD) dye 311 was 
added to 258 to form the expected 312. Finally, Texas Red- 313 and AF-488- 315 were 
also linked using the same methodology to afford 314 and 315 individually. All 
compounds were synthesised in 5-10 mg scale using standard procedures, purified and 
fully characterised by HRMS and NMR (Scheme 5.9, Appendix, Compound 307, 309 
















Scheme 5.9 Synthesis of dye-linked pyrichalasans. Reagents and conditions: a, 258, DIPEA, 




5.3.6 Generating Dimeric Pyrichalasans with Different Chain 
Length Linkers 
The importance of transition metal catalysed carbon-carbon bond forming reactions is 
well studied in the literature.201 Suzuki-Miyaura cross-coupling reactions, along with 
numerous others in this general field, has sparked great interest in C-C bond formation 
reactions. The palladium-catalysed cross-coupling reaction between organoboron 
compounds and organic halides or triflates provides a powerful and general method for 
the formation of carbon-carbon bonds. There are several advantages to this method: first, 
mild reaction conditions; second, commercial availability of many boronic acids; and 
third, the inorganic by-products are environmentally safer and much less toxic than 
organostannanes etc.202,203 
The mechanism of the Suzuki cross-coupling is analogous to the catalytic cycle for the 
other cross-coupling reactions and has four distinct steps. The cycle is initiated by the 
oxidative addition of the organic halide to the stabilized Pd(0) species to form Pd(II) (Step 
I, Scheme 5.10). Followed by the exchange of the anion attached to the palladium for 
the anion of the base (metathesis, Step II, Scheme 5.10). The transmetalation step 
transfers the R1 group from the metal boron to the metal palladium to generate an 
intermediate containing R1, R2 and ligand in the coordination sphere of palladium (Step 
III, Scheme 5.10). Two reductive eliminations from this intermediate produce the 
coupling R1-R2 product and regeneration of Pd(0) (Step IV, Scheme 5.10). Although 
organoboronic acids do not transmetallate to the Pd(II)-complexes, the corresponding 
ate-complexes readily undergo transmetallation. The quaternization of the boron atom 
with an anion increases the nucleophilicity of the alkyl group and it accelerates its 
transfer to the palladium in the transmetallation step. Very bulky and electron-rich 
ligands (e.g., P(t-Bu)3) increase the reactivity of otherwise unreactive aryl chlorides by 





Scheme 5.10 Catalytic cycle for the Suzuki-Miyaura cross coupling.175 
 
5.3.7 Results 
20 mg of 4’-bromo-pyrichalasin 256 was used to synthesis the 4’-borolated pyrichalasin 
317 by using bis(pinacolato)diboron, in the presence of Pd(dppf)Cl2 under reflux 
conditions. After 8 hours, the mass of target boronic ester intermediate 317 was detected 
by analytic LCMS. The product was then purified by preparative LCMS. The target 
intermediate 317 (mass = 619.4) was obtained as a white solid and confirmed by full 
NMR characterization (Figure 5.4, Appendix). 
 
        




Subsequent reaction of 317 with 10 mg 4’-bromo-pyrichalasin 256 in a separate 
reaction catalysed by Pd(PPh3)4 in the presence of X-phos as a ligand,
205 then produced 
the unprecedented 4’-4’ cytochalasin H symmetrical dimer 318 (Scheme 5.11 A).205,206 
Then the unsymmetrical dimer 319 with a simple hydroxymethyl triazole linker was 
formed by the direct coupling of 252 and 258 through click chemistry (Scheme 5.11 B). 
Moreover, a longer and more polar linker was introduced into the dimer by Huisgen 
coupling between the bis-propargyl-PEG linker 320 and 258 to produce 321 (Scheme 
5.11 C). All these compounds were synthesised in 10 mg scale, and their structures were 
confirmed by HRMS and full NMR characterization (Appendix). 
 
 
Scheme 5.11 Synthesis of dimeric pyrichalasins. Reagents and conditions: a, Pd(dppf)Cl2, CH3CO2K, 




5.3.8 Generating New Pyrichalasins by Sonogashira Reaction 
In 1975, K. Sonogashira and co-workers reported that symmetrically substituted alkynes 
could be prepared under mild conditions by reacting acetylene gas with aryl iododes or 
vinyl bromides in the presence of catalytic amounts of Pd(PPh3)Cl2 and cuprous iodide 
(CuI).170 The copper-palladium catalysed coupling of terminal alkynes with aryl and 
vinyl halides to give enynes is known as the Sonogashira cross-coupling.175 
The mechanism of the Sonogashira cross-coupling follows the expected oxidative 
addition-reductive elimination pathway. However, the structure of the catalytically 
active species and the precise role of the CuI catalyst is unknown. The reaction 
commences with the generation of a coordinatively unsaturated Pd(0) species from a 
Pd(II) complex by reduction with the alkyne substrates or with an added phosphine 
ligand. The Pd(0) then undergoes oxidative addition with the aryl or vinyl halide 
followed by transmetallation by the copper(I)-acetylide (Step I-II, Scheme 5.12). 
Reductive elimination affords the coupled product and the regeneration of the catalyst 
completes the catalytic cycle (Step III, Scheme 5.12).175 
 
 






5 mg 4’-bromo 256 and the alkyne of prop-1-yne 287 were tested as substrates in 
Palladium-catalysed cross-coupling reactions. The brominated derivative 256 did not 
react smoothly in the first attempt of Sonogashira cross-coupling reactions. However, 
the 4’-iodo substrates 257 reacted cleanly, to give the desired product 4’-acetylene 322, 
this compound was also confirmed by HRMS and NMR (Scheme 5.13, 
Appendix).207,208 
 
Scheme 5.13 Sonogashira reaction of 4’- iodopyrichalasin 257. Reagents and conditions: (a) 
Pd(dppf)Cl2, CH3CO2K, dioxane, 110 ˚C, 8 h.207,208 
 
5.4 Discussion & Outlook 
Functional pyrichalasins 251 - 258 were generated by mutasynthesis (Chapter 4). Many 
interesting and unprecedental functionalised cytochalasans were generated based on the 
above substrates. All compounds were synthesised in around 5 - 10 mg scale using 
standard procedures (experimental details are summarized in chapter 6.2.7) and easily 
purified by HPLC. For example, 4’-bromo pyrichalasin 256 can be used as the starting 
material to generate dimeric pyrichalasin 318 by Suzuki cross coupling reaction. 4’-Iodo 
pyrichalasin 257 is the starting reagent for Sonogashira reaction.  
Both 4’-azidophenylalanine 258 and O-propargyl phenylalanine 252 are very popular 
substrates for click chemistry (CC). Dimeric pyrichalasans 319 were synthesized via 
Huisgen chemistry Subsequently, several functional hybrid pyrichalasans were also 
generated by CC. For example, the bioactive molecule biotins were coupled to 
pyrichalasin H to give the corresponding different chain length conjugates 298 - 300, so 
as the penicillin G was linked and produce 304. Cytochalasans can bind to actin protein 
in high affinity, several commonly used fluorescent dyes were linked to pyrichalsan to 
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form the molecular probe 308 - 316, these molecules can be used to track actin protein 
in eukaryotic cell.  
All compounds were sent to our collaborator Prof. Marc Stadler and co-workers and 
tested for their antifungal activities, cytotoxicity and actin-disruption properties. First, 
the compounds were tested in a standard minimal inhibitory concentration (MIC) assay 
towards Schizosaccharomyces pombe, Pichia anomala, Mucor hiemalis, Candida 
albicans, and Rhodotorula glutinis, no candidates showed significant antifungal activity. 
4’-Amino-pyrichalasin 305 had no activity to the microorganisms, weak activity was 
observed from compounds 287, 295, 302, 304, 308, coumarin-linked 310 showed 
moderate activity vs S. pombe only. 
Standard cytotoxicity assays were tested on L929, KB3.1, PC3, A549, MCF-7, A431 
and SKOV-3 tumor cell lines. 4’-amino pyrichalasin 305 was significantly less 
cytotoxic (0.2 - 30 µg/ml), large hybrid compounds such as biotins (295 - 297), 
penicillin 304 and perylene 308 were also much less cytotoxic (0.5 - 37 µg/ml). To our 
surprise, dimeric compounds 318 and 319 showed unexpected cytotoxicity (0.1 - 8.0 
µg/ml), while acetylene 322 showed good potency (0.2 - 3.2 µg/ml). 
Selected compounds were investigated for their actin-disruption activity in vivo. SKOV-
3 cells were immobilised and the nucleus were stained with DAPI, and phalloidin-
atto594 can selectively stains filamentous actin. Cytochalasin B 268 serves as a standard 
compound and clearly collapses actin at 10 µg/ml compared with DMSO control 
(Figure 5.5). Pyrichalasin H 65 and dimeric pyrichalsin 318 shows the same activity at 







Figure 5.5 Actin disruption assay. A, Cytochalasin B; B, DMSO control; C, Pyrichalsin H; D, Dimeric 
pyrichalsin. All sample concentration: 5 µg/ml, red signal from Phalloidin-ATTO 594 bound to actin, Blue 
signal from DAPI stain in the nucleus. 
 
U2OS cells were stained with fluorescent dye linked pyrichalasans and observed under 
fluorescent microscope. Coumarin-linked 310 shows collapse of depolymerization of 
actin at 10 µg/ml (phalloidin red channel). Observation of the blue-green fluorescence 
from coumarin indicating the molecule collocated with actin at lower concentration (2 
µg/ml). In contrast, the perylene-linked compound 308 showed much more diffuse 
location within cells and no significant colocation with actin. A possible explanation 
would be the high hydrophobicity of the perylene molecule (Figure 5.6, this experiment 
was done by M. Sc Christopher Lambert). More hydrophilic dyes Texas Red linked 







Figure 5.6 Actin localisation assay: A, Phalloidin-ATTO 594 stain cells (control); B, 308 co-stain with 
phalloidin (10 µg/ml, red channel); C, 310 co-stain with phalloidin (10 µg/ml, green channel); D, 310 co-
stain with phalloidin (2 µg/ml, red channel); E, 310 co-stain with phalloidin (2 µg/ml, green channel). 
 
In total, 18 novel functionalised cytochalasans were generated by chemical modification. 
Their bioactivities were confirmed by our collaborators. Based on the library we built, 
some more interesting reactions could be done in future. For example, Staudinger 
ligation, Buchwald-Hartwig Cross-Coupling reaction and so on. However, these are all 
the first attempts to determine the biological activities of the newly synthesized 
pyrichalasans. In future, more targeted cytochalasans will be synthesized, more logical 
and specifical biotests will be executed, to explore the possible application of our 









6 Overall Conclusion and Outlook 
Overall, the combination of gene knockout (KO) experiment, combinatorial 
biosynthesis was confirmed to be a powerful strategy to understanding and engineering 
the biosynthesis of fungal polyketide – nonribosomal peptide hybrid pyrichalasin H 65. 
Mutasynthesis and Semisynthesis were effective methods to generate functional 
cytochalasan. Moreover, biotest results showed some of novel cytochalasan have the 
potential to be actin protein imaging tool, some of them exhibit actin disruption ability 
and also showed antimicrobial activity. 
 
First of all, we start to elucidate pyrichalasin H 65 biosynthetic pathway by knockout 
experiment target on pyi BGC. The function of seven genes was investigated 
individually. Thirteen novel cytochalasan were generated. For the first time, we 
confirmed that O-methyltyrosine 175 is the true precursor for compound 65 
biosynthesis. Targeting KO pyiS gene, resulting the abolition of 65, this experiment 
confirmed that the pyi BGC responsible for the biosynthesis of 65. The function of two 
P450 genes were also investigated, pyiD was confirmed encoding C-18 hydrolase due to 
all the isolated metabolites all lack of a C-18 hydroxyl group, while pyiG was confirmed 
to encode C-7 hydrolase because all the C-7 hydroxyl group were missing from the 
purified compounds. All the isolated metabolites were confirmed by both HRMS and 
NMR. The O-methyltransferase encoding gene pyiA was also disrupted, the desired de-
methyl product magnachalasin 173 was obtained. However, the phenylalanine fused 
cytochalasin H 174 was also obtained in lower titre. This result reminds us the true 
precursor might be O-methyltyrosine 175. It was confirmed by the restoration of 
pyrichalasin H 65 by feeding O-methyltyrosine 175 to pyiA mutant strain. Targeting 
pyiB gene KO, which encodes O-acetyltransferase, the de-acetyl product pyrichalasin J 
156 was obtained. By KO the oxidoreductase encoding gene pyiH, three carbonyl 
cytochalasans 161 - 163 were isolated. Put all this results together, the late stage 






Several mutant strains were generated by KO experiment, including two P450 
disruption stains. We developed the two P450 mutant strains as the cell factory for 
generating novel cytochalasan by heterologous expression cryptic P450 genes from 
other biosynthetic pathway. In total, six P450 genes were investigated including hffD 
and hffG from Hypoxylone fragiforme BGC and CYP1-4 from P. oryzae Guy 11 BGC. 
Three novel epoxide cytochalasan were isolated. The function of CYP1, HffD and HffG 
were confirmed as hydroxylase, and the CYP3 was confirmed as epoxidase. The 
function of CYP2 and CYP4 remain unknown, due to the several possible reasons.139 
These results from pathway engineering by combinatorial biosynthesis proved that the 
mutant P450 strain can be a good bioengineer platform to investigate unknown P450s as 
well as other tailoring gene (detailed conclusion in chapter 3.4). 
 
Previous pyiA KO result confirmed the O-methyl tyrosine 175 is the true precursor for 
pyrichalsin H 65 biosynthesis, when 175 is absent, the KO strain can weakly select 
tyrosine and phenylalanine. Therefore, we fed different functional group substituted 
amino acid 243 – 250 to ∆pyiA strain, and seven novel cytochalasan 251 – 258 were 
obtained.  
 
With the novel cytochalasan 251 – 258 generated by mutasynthesis, we further did 
some chemical modification based on these compounds. Eighteen functional 
pyrichalasins were synthesized various kind of chemical reactions. For example, 
compound 256 can be substrate for Suzuki cross coupling reaction to generate dimeric 
pyrichalasin 318. Compound 252 and 258 can be the reagent for the copper catalyzed 
alkyne azide cycloaddition (CuAAC) reaction. Moreover, five dye linked fluorescent 
pyrichalasins 308 – 316 were generated by click chemistry (detailed conclusion in 
chapter 5.3.3).  
 
All the generated compounds were sent to our collaborators in HZI for biotest. The 
fluorescent pyrichalasins shown the ability to localize and visualize the actin cell. Some 
of them showed the inhibition of actin polymerization. Our compounds also showed the 




Base on the result we obtained from above experiments. There are interesting projects 
we can do in the near future. For the newly developed bioengineering platform, 
different tailoring enzymes will be investigated, such as, BVMO, O-MeT. For 
mutasynthesis, different position substituted un-natural amino acids will be feed to the 
∆pyiA strain. The tolerance of adenylation domain will be investigated. Furthermore, 
several more different chemical reactions can be carried out to synthesize more novel 
functional cytochalasan. Therefore, more biotests will be done to explore the potential 




















7. Experimental  
7.1 Biology Parts 
7.1.1 General 
Chemical biology methods were carried out according to guidelines of Cox group, as 
well as kit manufacturers. All chemicals and media ingredients used in this work were 
purchased from the following companies: Bio-Rad, Sigma-Aldrich, Acros, Alfa Aesar, 
abcr, Baseclear and Carbosynth. All solutions and media used throughout the research 
as well as all glassware used for microbial cultures were sterilized by autoclaving. 
Solutions affected by heating were sterilized by filtration through disposable syringe 
filter 0.22 µm and 0.45 µm filters. These heat sensitive solutions used in the study were 
antibiotics solutions, polyethylene glycol (PEG) solutions used in yeast and fungal 
transformations. All microbiological experiments were carried out in a Bio class II 
microbiological safety cabinet. 
 
7.1.2 Enzymes 
Restriction endonucleases, DNA polymerases, reverse transcriptase and LR-clonase 
were purchased from New England Biolabs, Thermo Scientific and Invitrogen. 
Enzymes were used according to manufacturer’s instructions with the appropriate 
supplied buffers. 
Table 7.1 Enzymes used in this study. 
 
Enzyme  Manufacturer 
AscI        NEW ENGLAND BioLabs (Ipswich, MA, USA) 
EcoRI NEW ENGLAND BioLabs (Ipswich, MA, USA) 
HindIII NEW ENGLAND BioLabs (Ipswich, MA, USA) 
NotI NEW ENGLAND BioLabs (Ipswich, MA, USA) 
RNase A NEW ENGLAND BioLabs (Ipswich, MA, USA) 
LR-clonase Invitrogen (Waltham, MA, USA) 
Taq DNA polymerase NEW ENGLAND BioLabs (Ipswich, MA, USA) 
Q5 HiFi DNA 





The antibiotics were purchased from Roth (Karlsruhe, Germany) and amresco (Solon, 
USA). All antibiotics stock solutions were prepared in distilled water. They were then 
filter sterilized through 0.22 µm syringe filters and stored at -20 °C. Stock and working 
concentrations are listed in the Table below. 
 
Table 7.2 Antibiotics used in this study. 
 
Antibiotic 
Stock Solution Final Concentration 
(mg / mL) (µg / mL) 
Carbenicillin       50 in H2O 50 
Kanamycin       50 in H2O 50 
Hygromycin B       50 in H2O 120 - 240 
Glufosinat-ammonium 
(Basta) 
      50 in H2O 50 - 200 
 
7.1.4 plasmids and Vectors 
Plasmids provided to be used in this study with their description and sources. 
 
Table 7.3 Plasmid used in this study.109,139 
 
Plasmid Brief Description Supplier 
pEYA 
Saccharomyces cerevisiae – E. coli 





Magnaporthe grisea expression vector, 
E.coli -fungal Gateway destination 
vectorwith hygromycin B cassette 
Dr. Rozida M. 
Khalid 
pTHGS-eGFP 





Template for heterologous expression 




Targeting pyiS gene knockout vector 
with Hygromycin B cassette 
Dr. Elizabeth J. 
Skellam 
pE-YA-OMET-KO 
Targeting pyiS gene knockout vector 
with Hygromycin B cassette 
Dr. Elizabeth J. 
Skellam 
pE-YA-OACT-KO 
Targeting pyiS gene knockout vector 





Targeting pyiS gene knockout vector 
with Hygromycin B cassette 
Chongqing Wang 
pE-YA-P450-1-KO 
Targeting pyiS gene knockout vector 
with Hygromycin B cassette 
Chongqing Wang 
pE-YA-P450-2-KO 
Targeting pyiS gene knockout vector 
with Hygromycin B cassette 
Chongqing Wang 
pUC57-ccsB-Kan Template for cloing the ccsB gene Baseclear 
pTYGS-bar-ccsB 
Template for ccsB heterologous 
expression with basta cassette 
Chongqing Wang 
pTYGS-bar-CYP1 
pTYGSbar containing the M. oryzae 
Guy11 CYP1 gene under the control of 
the amyB promoter 
Chongqing Wang 
pTYGS-bar-CYP2 
pTYGSbar containing the M. oryzae 
Guy11 CYP2 gene under the control of 
the amyB promoter 
Chongqing Wang 
pTYGS-bar-CYP3 
pTYGSbar containing the M. oryzae 
Guy11 CYP3 gene under the control of 
the amyB promoter 
Chongqing Wang 
pTYGS-bar-CYP4 
pTYGSbar containing the M. oryzae 
Guy11 CYP4 gene under the control of 
the amyB promoter 
Chongqing Wang 
pTYGS-bar-hffD 
pTYGSbar containing the M. oryzae 




pTYGSbar containing the M. oryzae 





7.1.5 Primers and Their Sequences 
Oligonucleotides synthesized and used as PCR or RT-PCR primers were purchased 
from Sigma-Alderich. They are listed in the Table below. 
 
























































































1369 TCTGAACAATAAACCCCACAGCAAGCTCCG ATGTTAGATATGTCCCAACC 
1370 CTCTCCACCCTTCACGAGCTACTACAGATCAGCATTGTTCGAGGTTCCAT 
1371 TCTGAACAATAAACCCCACAGCAAGCTCCG ATGTTGTCTCTTTTGGAAAC 
1372 CTCTCCACCCTTCACGAGCTACTACAGATC CTACTCAACATTCCTGGACT 
1373 TCTGAACAATAAACCCCACAGCAAGCTCCGATGATGACTCCAACCGAACTT 
1374 CTCTCCACCCTTCACGAGCTACTACAGATC CTATTTCTTCCCCTCGTTCACG 
1375 TCTGAACAATAAACCCCACAGCAAGCTCCG ATGACGACAGTCCAGAAAGA 
1376 CTCTCCACCCTTCACGAGCTACTACAGATC CTATAACCTCCTTTCTCGAA 
1466 TCTGAACAATAAACCCCACAGCAAGCTCCGATGTTTTCGAGCATCCAGAC 
1467 CTCTCCACCCTTCACGAGCTACTACAGATC  CTAATACCTCGCCCTCACCC 
163 
 
1468 CTCTCCACCCTTCACGAGCTACTACAGATC  CTAGGCACGAGCCTTTAGAT 
1469 TCTGAACAATAAACCCCACAGCAAGCTCCG  ATGCTGAATTCGTCCGCCAT 
 
7.1.6 Media, Buffers and Solutions 
All media, buffers and solutions were prepared with distilled water. Growth media and 
transformation solutions were sterilised at 121 °C for 15 or by disposable sterile filter 




50x TAE (tris-acetate-EDTA) buffer stock (DNA agarose gel running buffer) 
 
 242 g of Tris acetate in 700 ml distilled water, then 57.2 ml glacial acetic acid and 100 
ml 0.5 M EDTA pH 8.0 were added and mixed. Distilled water was added to bring the 
volume to 1 liter. The agarose was dissolved in 0.5x final concentration of the TAE. 
DEPC-treated water 
Dissolved diethylpyrocarbonate (DEPC, Sigma-Aldrich) was in distilled water to a final 
concentration of 0.1 %. It was then incubated at 37 ⁰C for 24 hours and sterilized by 
autoclaving. 
STC buffer 
200g/l sucrose, 50mM Tris-HCl, 50mM CaCl2 (Sigma-Aldrich) were dissolved in 1 L 
distilled water and sterilised by autoclave. The final PH is around 7.5. 
PTC buffer 
60% PEG 3350, 1 M Sorbito, 50mM Tris-HCl, 50mM CaCl2 (Sigma-Aldrich) were 
dissolved in 1 L distilled water and sterilised by autoclave. The final PH is around 7.5. 
TB4 buffer 
200g/l sucrose (Sigma-Aldrich), 3g/l yeast extract were dissolved in 1 L distilled water 





10 mM Tris-HCl [pH 7.5] and 1 mM EDTA were added together to make the final 
volume to 1 liter, pH 8.0. 
Trace elements  
7.9 mg ZnSO4.7H2O, 0.6 mg CuSO4, 0.1 mg H3BO3, 0.2 mg MnSO4.H2O, 0.14 mg 
NaMoO4 and ddH2O were added together to make the final volumn to 1 liter. 
Vitamin solution 
1.0 mg thiamine and 5 µg biotin were added together with ddH2O to make the final 





0.5 % (w/v) NaCl, 1 % (w/v) Tryptone, 0.5 % (w/v) Yeast extract and 1.5 % (w/v) Agar 
were added together, ddH2O was added to make the final volume to 1 liter. 
SM-URA agar 
0.17 % (w/v) Yeast nitrogen base, 0.5 % (w/v) (NH4)2SO4, 2 % (w/v) D-(+)-Glucose 
Monohydrate, 0.077 % (w/v) Complete supplement mixture minus uracil, 1.5 % (w/v) 
Agar were added together, ddH2O was added to make the final volume to 1 liter. 
CM agar209 
The CM agar was prepared by dissolving 10 g glucose, 2 g peptone, 1 g yeast extract, 1 
g casamino acids, 6 g NaNO3, 0.5 g KCl, 0.5 g MgSO4, 1.5 g KH2PO4 and 15 g agar in 
1 litre of the final volume solution. This is followed by autoclaving at 121 °C for 15 
minutes at 15 psi.  
YPAD agar 
20 g tryptone, 10 g yeast extract, and 0.3 g adenine, 20 g D-(+)-Glucose monohydrate 
and 15 g agar were dissolved in distilled water to make the final solution up to 1 liter. 




20 g dextrin, 10 g polypeptone, 5 g yeast extract, 5 g KH2PO4, 0.5 g MgSO4, and 15 g 
agar were dissolved in 1 liter of distilled water and sterilized by autoclaving at 121 °C 
for 15 minutes at 15 psi. 
TNK-CP agar211 
10 g glucose, 2 g yeast extract, 2 g NaNO3, 0.5 g MgSO4.7H2O, 0.1 g CaCl2.2H2O, 4 mg 
FeSO4.7H2O, 2 g KH2PO4 and 15 g agar were dissolved in distilled water to make the 
final solution up to 1 liter. The medium was autoclaved at 121 °C for 15 minutes at 15 
psi.  
TNK-SU-CP agar211 
10 g glucose, 200 g sucrose, 2 g yeast extract, 2 g NaNO3, 0.5 g MgSO4.7H2O, 0.1 g 
CaCl2.2H2O, 4 mg FeSO4.7H2O, 2 g KH2PO4 and 15 g agar were dissolved in distilled 
water to make the final solution up to 1 liter. The medium was autoclaved at 121 °C for 
15 minutes at 15 psi. 
S.O.C (post-transformation recovery medium)212 
5 g yeast extract, 0.2 g KCl and 20 g tryptone were dissolved in distilled water and the 
pH was adjusted to 7.0 using 2 M NaOH solution. The volume is brought to 1 litre with 
distilled water. Then sterilized by autoclaving at 121 °C for 15 minutes at 15 psi. 
Yeast Extract Peptone Dextrose Medium (YPAD)  
20 g tryptone, 10 g yeast extract, and 0.3 g adenine, 20 g D-(+)-Glucose monohydrate 
were dissolved in distilled water to make the final solution up to 1 liter. The medium 
was autoclaved at 121 °C for 15 minutes at 15 psi. 
Complete medium (CM)209 
The CM medium was prepared by dissolving 20 g cottonseed flour, 10 g lactose 
monohydrate in 1 litre distilled water, followed by autoclaving at 121 °C for 15 minutes 




10 g glucose, 2 g yeast extract, 2 g NaNO3, 0.5 g MgSO4.7H2O, 0.1 g CaCl2.2H2O, 4 mg 
FeSO4.7H2O and 2 g KH2PO4 were dissolved in distilled water to make the final 
solution up to 1 liter. The medium was autoclaved at 121 °C for 15 minutes at 15 psi.  
TNK-CP-Su-Hyg medium211 
TNK-CP-Su-Hyg has the same components and prepared in the same way as TNK-CP 
medium with the addition of 200 g sucrose before autoclaving and addition of 
hygromycin B in a final concentration of 240 mg/l before use.  
TNK-CP-Hyg medium211 
TNK-CP-Hyg has the same components and prepared in the same way as TNK-CP 
medium with the addition of hygromycin B in a final concentration of 120 mg/l before 
use.  
DPY medium210 
20 g dextrin, 10 g polypeptone, 5 g yeast extract, 5 g KH2PO4 and 0.5 g MgSO4 were 
dissolved in 1 liter of distilled water and sterilized by autoclaving at 121 °C for 15 
minutes at 15 psi. 
 
7.1.7 Growth and Storage Conditions for Microorganisms 
 
Escherichia coli  
ccdB strain 
Chemically competent of E. coli ccsB strain (Thermo Fisher Scientific) has a genotype 
F-mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araΔ139 Δ(ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG fhuA::IS2. 
TOP10 strain 
Chemically competent E. coli top 10 strain (Thermo Fisher Scientific) has a genotype F- 
mcrA, Δ(mrr-hsdRMS-mcrBC), φ80lacZΔM15, ΔlacX74, recA1, araD139, 




Saccharomyces cerevisiae  
(Stratagene) YPH499 strain auxotrophic to uracil was kindly provided by Dr. Colin 
Lazarus. Its genotype is MATa, ura3-52, lys2-801amber, ade2-101ochre, trp1-Δ63, 
his3-Δ200, leu2-Δ1.247.  
Magnaporthe grisea NI980 strain  
M. grisea NI980 is a Digitaria smutsii isolate obtained from our collaborators Marc-
Henri Lebrun and co-workers and was used as the wild-type strain in this study. 
Fermentation and extraction protocols 
Strains were cultivated on Oatmeal Agar (OMA) (4% w/v oat meal, 0.5% w/v sucrose, 
2% agar) or Complete Medium (CM) agar at 25 °C. For cytochalasan production strains 
were cultivated in Soy Sauce Sucrose (SSS) medium (5% v/v soy sauce, 5% w/v 
sucrose, in autoclaved tap water) or DPY liquid medium (2% w/v dextrin from potato 
starch, 1% w/v polypeptone, 0.5% w/v yeast extract, 0.5% w/v monopotassium 
phosphate, 0.05% w/v magnesium sulfate, 2.5% w/v agar) for 7 days at 25 °C, 110 rpm. 
For extraction, M. grisea spores were collected from MG agar plates incubated for 7 
days and inoculated into 500mL Erlenmeyer flasks containing 100 mL DPY. The spores 
were allowed to grow in the liquid culture for 7-8 days on shakers at 110 rpm at 25 °C. 
The cells were blended in the fermentation broth, filtered to remove the mycelium, and 
transferred into a separating funnel. An equal volume of EtOAc was added into the 
separating funnel and the aqueous layer was extracted twice. The organic solvent from 
the two extractions was combined and dried with MgSO4, filtered and evaporated to 
dryness. The crude extract was dissolved into 1 mL HPLC grade MeOH. 
 
7.1.8 Feeding Studies 
Compound 246 – 249 were purchased from Sigma-Aldrich, compound 243 – 245 were 
synthesized by three steps chemical reaction (Chapter 4.3.1). 
200 mg of 4‘-O-methyl-tyrosine 175 was dissolved into double distilled water (10 
mg/mL) and filter sterilized. 200 µl of this solution was fed to the ∆pyiA knock-out 
strain inoculated into 500 mL Erlenmeyer flasks containing 100 mL DPY. The feeding 
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was repeated at 24 hour intervals four times. On the 7th day the cultures were extracted 
using the method described above.  
200 mg of 4‘-O-allyl-tyrosine 243 was dissolved into double distilled water (10 mg/mL) 
and filter sterilized. 200 µl of this solution was fed to the ∆pyiA knock-out strain 
inoculated into 500 mL Erlenmeyer flasks containing 100 mL DPY. The feeding was 
repeated at 24 hour intervals four times. On the 7th day the cultures were extracted 
using the method described above.  
200 mg of 4’-O-propargyl-tyrosine 244 was dissolved into double distilled water (10 
mg/mL) and filter sterilized. 200 µl of this solution was fed to the ∆ pyiA knock-out 
strain inoculated into 500 mL Erlenmeyer flasks containing 100 mL DPY. The feeding 
was repeated at 24 hour intervals four times. On the 7th day the cultures were extracted 
using the method described above.  
200 mg of 4’-fluoro- / chloro- /bromo- /iodo-phenylalanine 246 - 249 were dissolved 
into double distilled water (10 mg/mL), stirred at 60 ˚C until dissolved completely and 
filter sterilized. 200 µl of this solution was fed to the ∆ pyiA knock-out strain inoculated 
into 500 mL Erlenmeyer flasks containing 100 mL DPY. The feeding was repeated at 
24 hour intervals four times. On the 7th day the cultures were extracted using the 
method described above.  
200 mg of para-azido-phenylalanine was dissolved into double distilled water (10 
mg/mL) and filter sterilized. 200 µl of this solution was fed to the ∆ pyiA knock-out 
strain inoculated into 500 mL Erlenmeyer flasks containing 100 mL DPY. The feeding 
was repeated at 24 hour intervals four times. On the 7th day the cultures were extracted 
using the method described above. 
 
7.1.9 DNA and RNA Visualization, Isolation and Purification 
 
Agarose Gel Electrophoresis  
DNA electrophoreses were achieved in 1 % agarose (w/v, containing Roti – Safe Gel 
Stain, Roth) gels dissolved in 0.5 x TAE buffer The moulded gels were immersed in the 
same buffer contained in a horizontal electrophoresis apparatus (Sigma-Aldrich). 5 µl of 
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each of the samples mixtures with loading buffer and 1 kb DNA Ladder (Thermo 
Scientific) were loaded onto the gel to run parallel to each other at 130 V, 400 mA, and 
for 0.5 hour. This allowed identification of DNA bands appeared on the samples run as 
DNA ladder provided band sizes range from 500 bp to 10000 bp. DNA bands separated 
on the gel were visualized by the Molecular Imager Gel doc XR + (Bio-Rad) system 
under UV light (312 nm). Digital images recorded using the Software Image Lab (Bio-
Rad). Fresh RNA samples were run in the same manner as DNA samples and visualized 
similarly.  
 
DNA purification from gel or PCR 
Fragments were isolated and DNA was purified using NucleoSpin® Gel and PCR 
Clean-up kit (Macherey-Nagel) according to the manufacturer’s instructions.  
 
Plasmid DNA isolation from E. coli  
E. coli transformants that contained the plasmid were inoculated in 5 ml of LB medium 
containing the selection antibiotic. The cultures were incubated overnight in the shaker 
incubator at 37 °C with shaking at 250 rpm. The cells were collected by centrifugation 
and the plasmid was obtained according to the method of the NucleoSpin® Plasmid kit 
(Machery-Nagel). 
 
Plasmid DNA isolation from Saccharomyces cervisiae (yeast)  
Colonies of yeast recombination appeared on SM–URA plates after incubation at 30 °C 
for 3 or more days were used for plasmids isolation. They were collected and processed 
according to the method described by the Zymoprep II™ Yeast Plasmid Miniprep Kit 
(ZYMO RESEARCH). 
 
Genomic DNA isolation from M. grisea  
Spores of M. grisea transformants were inoculated in DPY medium. They were 
incubated at 25 °C with shaking at 110 rpm around 4-5 days. Grown mycelia were 
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collected by filtration under vacuum and washed with water. Collected mycelia were 
then ground under liquid nitrogen to a very fine powder. 50 mg of the powdered 
mycelia were processed according to instructions of GenElute Plant DNA Isolation Kit 
(Sigma-Aldrich) for genomic DNA preparation.  
 
RNA extraction from M. grisea  
All equipment used in handling mycelia were washed with DEPC-treated water 
overnight at 37 ℃ and autoclaved. Grown mycelia were collected by filtration under 
vacuum and washed with DEPC-treated water. Collected mycelia were then ground 
under liquid nitrogen to a very fine powder. 50 mg of the powdered mycelia were 
processed according to instructions of ZR Fungal/Bacteria RNA Miniprep Kit (ZYMO 
RESEARCH). A digestion step for removal of any DNA contaminations was conducted 
by the DNase according to manufacturer instructions. 
 
7.1.10 DNA Amplification from DNA and RNA Templates 
 
High fidelity DNA polymerase chain reaction (PCR)  
Polymerase chain reactions were conducted by amplification of DNA from plasmid or 
genomic DNA or RNA templates with Q5 high fidelity 2X Master Mix (New England 
Biolabs), follow the manufacturers’ instructions.  
 
Analytical PCR  
PCR analysis performed on E. coli colonies is called colony-PCR. In which a part of 
single or several colonies (tested individually) was transferred via toothpick into 10 µl 
TE buffer placed in eppendorf tubes. The tubes were heated at 55 °C for 5 minutes and 
then 80 °C for 5 minutes then cooled to room temperature. OneTaq® 2X Master Mix 
(New England Biolabs) with standard buffer was used, following the manufacturers’ 
instructions, for screening purposes. The solution was used as DNA source for analysis. 
PCR performed on either DNA sample or DNA extracted from E. coli. The analytical 
PCR run the same programme mentioned under high fidelity PCR with omitting of the 
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final extension step. DNA sequences were checked by DNA sequencing (Mix2Seq kit, 
Eurofins). 
 
7.1.11 Fungal Transformations 
 
Saccharomyces cervisiae transformation for DNA recombination209 
Two criteria are required for yeast recombination: first, all DNA fragments should be in 
similar concentrations. This was achieved by running gel electrophoresis of DNA 
fragments and the densities of their corresponding bands appeared upon UV 
illumination relative to the marker were used as indicators for their concentrations. The 
concentration of DNA fragments can also be measured by DeNovix DS-11+ 
spectrophotometer. The second criterion was that one of DNA fragments was a S. 
cervisiae – E. coli shuttle vector with selection markers suitable for both organisms.  
The process of yeast transformation started by growing yeast cells in 10-20 ml YPAD 
medium overnight at 30 °C with shaking at 200 rpm. Solution of SS-DNA (Single-
Strand Carrier DNA or salmon sperm DNA) (2 mg/ml) was boiled for 5 minutes and 
was then chilled on ice. For each transformation the following components were added 
to the 50 µl yeast suspension aliquot in the following order with mixing by vortex after 
each step: 
 
1- 40 µl DNA in water (with equimolar concentrations of fragments).  
2- 50 µl SS-DNA. (2 mg/ml)  
3- 240 µl PEG solution (50% w/v polyethylene-glycol [PEG] 3350).  
4- 36 µl 1 M Li-acetate (sterilized by filtration).  
5- 50 µl digested vector 
The mixture was incubated at 30 °C for 30 minutes and then incubated at 42 °C for 
another 30 minutes. The cells were precipitated by centrifugation at 6000 rpm for 15 
seconds and resuspended in 1 mL fresh water to give final suspension, 200 µl aliquots 
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were spread on SM-URA plates and incubated at 30 °C for 4-5 days or until the 
appearance of colonies of transformants. 
 
E. coli transformation 
E. coli cells (TOP10) were provided as frozen chemically competent cells in small 1.5 
ml centrifuge tubes. Cells tubes were thawed on ice and 5-10 µl of the plasmid solution 
was immediately added into the cell suspension followed by gentle tapping of the tube 
and incubation on ice for 30 minutes. The cells were then heat-shocked in 42 °C water 
path for exactly 30-45 seconds and returned immediately into ice to be left for 
additional 2 minutes.  
250-300 µl SOC medium was added to the cell suspension and then incubated on 
shaking incubator for 1 hour at 37 °C. 200 µl of the resulted suspension were spread on 
the pre-warmed LB agar plates containing an antibiotic corresponding to the selection 
marker present in the plasmid transformed and plates were eventually incubated 
inverted in a 37 °C incubator overnight. On the next day, transformants colonies 
appeared and used for further experiments.  
 
Magnaporthe grisea transformation 
M. grisea strain used in this research was the NI980 strain known to be sensitive to both 
hygromycin B as well as Basta antibiotics. Constructs used for transformation and 
expression in M. grisea NI980 were containing hygB. Fungus was grown on CM plates 
for 7-10 days. A plug of the medium with fungal mycelia was a transferred to 100 ml 
sterilized CM broth medium in 500 ml Erlenmeyer conical flask. The flask was 
incubated at 25 °C for 3-4 days with shaking at 150 rpm. Mycelia were homogenised 
using glass beads and transferred to a new CM broth medium followed by incubation at 
the same latter conditions for 1-2 days. Mycelia were collected by filtration, and 
protoplasting was performed using Trichoderma harzianum lysing enzymes (20 mg/ml) 
and Driselase enzyme (10 mg/ml) in NaCl (0.9 M) with gentle shaking at room 
temperature for 2-3 h. Protoplasts were filtered through miracloth and centrifuged at 
2000 rpm for 10 min. Protoplasts were then resuspended (washed) in sterilized STC 
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buffer (200 g/l sucrose, 50 mM Tris-HCl, 50 mM CaCl2.2H2O, pH 7.5) and stored at -
80 frizer. 
Protoplasts were diluted to 3x107/ml in STC buffer and approximately 5 μg (20 μl) of 
appropriate plasmid was added to 200 ml protoplast solution. The mixture was 
incubated on ice for 30 min, 1 ml of filter sterilized PTC buffer (60 % PEG 3350, 1 M 
sorbitol, 50 mM Tris-HCl, 50 mM CaCl2.2H2O, pH 7.5) was then added and the mixture 
was incubated at room temperature for a further 30 min. 4 – 5 ml of sterilized TB3 
recovery medium (200 g/l sucrose, 3 g/l yeast extract) was added to the concentrate and 
left to be shaken very gently overnight. The mixture was centrifuged at 3000 rpm for 5 
minutes and supernatant was reduced to 1 ml for concentration. The concentrate was 
then mixed with 19 ml of molten TNK-SU-CP-Hyg containing 240 μg/ml hygromycin 
B at 45-50 °C and mixed well then poured in plates. Plates were incubated at 25 °C for 
5-7 days with daily observation until most or all colonies of transformants appeared. 
Transformants were then further selected on TNK-CP-Hyg plates (2ndry transformation 
plates) containing 120 μg/ml hygromycin B. Finally, clones grown on 2ndry plates were 
purified to single spores and used or stored at -80℃ freezer.  
 
7.2 Chemistry parts 
 
7.2.1 General 
All chemical extractions with organic solvents, evaporations and concentrations of 
various organic extracts were performed within the chemical hoods. Evaporations in 
vacuo were aided by rotary BOSCH or HEIDOLPH evaporator. All chemicals and 
reagents used in microbiology were analytical or molecular biology grade. They were 
purchased from Sigma-Aldrich, Fischer, Alfa Aesar and carbosynth or borrowed from 
OCI labs. Chemicals used in extraction and analysis of the secondary metabolites from 
fungi were analytical or HPLC grade. 
 
7.2.2 Analytical LCMS 
LCMS data were obtained using a Waters LCMS system comprising of a Waters 2767 
autosampler, Waters 2545 pump system and a Phenomenex Kinetex column (2.6 µ, C18, 
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100 Å, 4.6 × 100 mm) equipped with a Phenomenex Security Guard precolumn (Luna 
C5 300 Å) eluted at 1 mL/min. Detection was performed by Waters 2998 diode array 
detector between 200 and 600 nm; Waters 2424 ELSD and Waters SQD-2 mass 
detector operating simultaneously in ES+ and ES- modes between 100 m/z and 1500 m/z. 
Solvents were A, HPLC-grade H2O containg 0.05% formic acid; and B, HPLC-grade 
CH3CN containing 0.045% formic acid. Gradients were as follows: Method 1 
(optimised for non-polar compounds): 0 min, 10% B; 10 min 90% B; 12 min, 90% B; 
13 min, 10% B and 15 min, 10% B. Method 2 (optimised for polar compounds): 0 min, 
10% B; 10 min 40% B; 12 min, 90% B; 13 min, 10% B and 15 min, 10% B.  
 
7.2.3 Preparative LCMS  
Compounds were purified using a Waters massdirected autopurification system 
consisting of a Waters 2545 pump and Waters 2767 autosampler. The chromatography 
column was a Phenomenex Kinetex Axia column (5μ, C18, 100 Å, 21.2 × 250 mm) 
fitted with a Luna C5 300 Å Phenomenex Security Guard precolumn. The column was 
eluted at 20 mL/min at 22 °C. Solvents used were A, H2O + 0.05% formic acid; and B, 
CH3CN + 0.045% formic acid. All solvents were HPLC grade. The column outlet was 
split (100:1) and the minority flow was supplemented with HPLC-grade MeOH + 0.045% 
formic acid to 1000 μL/min and diverted for interrogation by diode array (Waters 2998) 
and evaporative light-scattering (Waters 2424) detectors. The flow was also analysed by 
mass spectrometry (Waters SQD-2 in ES+ and ES− modes). Desired compounds were 
collected into glass test tubes. Combined fractions were evaporated in vacuo, weighed 
and dissolved directly in NMR solvent for analysis. 
 
7.2.4 High Resolution Mass Spectrometry (HRMS) Analysis 
HRMS was obtained using a UPLC system (Waters Acquity Ultraperformance, running 





7.2.5 Infrared Spectrum (IR) Analysis 
Infrared Spectra were recorded using a Shimadzu IR Affinity-1S fourier transform 
infrared spectrophotometer and quest at diamond extended range accessory (black). 
 
7.2.6 Nuclear Magnetic Resonance (NMR) Analysis 
A Bruker Avance 500 instrument equipped with a cryo-cooled probe at 500 MHz 
(1H)/125 MHz (13C) and 600 MHz (1H)/150 MHz (13C) were used for all NMR analysis. 
Standard parameters were used for the collection of 2D spectra (1H, 1H-correlation 
spectroscopy (COSY), heteronuclear single-quantum coherence (HSQC) and HMBC) in 
the indicated solvents. 1H and 13C spectra are referenced relative to residual protonated 




Table 7.5 All softwares used in this study. 
 
Software  Manufacturer 
antiSMASH Open online database  
BLAST® 
basic local alignment search tool of the National 
Center for Biotechnological Information 
Geneious 7.1.9 Biomatters (Auckland 1010, New Zealand) 
Image Lab 
Bio-Rad Laboratories Ltd., Informatics Division 
(Müchen, Germany) 
Leica DM 4000 B LED  Leica microsystems Ltd. (Wetzlar, Germany) 
MassLynx Waters, Milford, MA, USA 
MestReNova 
Mestrelab Research, S.L. (Santiago de Compostela, 
ES) 
Molecular Imager Gel doc 
XR+ 










7.2.7 Synthetic Procedures 
 
Synthesis of 318 
 
To a stirred solution of 256 (20 mg, 0.035 mmol, 1.0 eq) and 2 (17.8 mg, 0.07 mmol, 
2.0 eq) in dioxane (3 mL) was added Pd(dppf)Cl2 (2.6 mg, 0.0035 mmol, 0.1 eq), 
NaHCO3 (10.2 mg, 0.11 mmol, 3.0 eq). The mixture was stirred at 110 °C for 8 hours 
under nitrogen and the solvent was removed in vacuo. The residue was dissolved in 
EtOAc (2 mL) and washed with water (2 mL x 2). The organic phase was dried over 
MgSO4, filtered and evaporated to dryness in vacuo. The residue was dissolved in 
MeOH and purified by LCMS to afford 12.6 mg of desired product (yield: 58.3%) as a 
white solid.205 
 
To a stirred solution of 317 (7.6 mg, 0.012 mmol, 1.5 eq) and 256 (7 mg, 8 µmol, 1.0 eq) 
in dioxane (4 mL) was added Pd(OAc)2 (0.12 mg, 0.8 µmol, 0.1 eq) and XPhos (0.76 
mg, 1.6 µmol, 0.2 eq) and K2CO3 (2.2 mg, 16 µmol, 2.0 eq). The mixture was stirred at 
80 °C for 2 hours under nitrogen and the solvent was removed in vacuo. The residue 
was dissolved in EtOAc (4 mL) and washed with water (3 mL x 2). The organic phase 
was dried over MgSO4, filtered and evaporated to dryness in vacuo. The residue was 
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dissolved in MeOH and purified by LCMS to afford 5.1 mg of desired product (yield: 
42.6%) as a white solid.206 
1H NMR (500 MHz, CDCl3): δ (Hz) = 7.51 (d, J = 8.1 Hz, 2H), 7.22 (d, J = 8.1 Hz, 
2H), 5.89 (dd, J = 2.7 and 16.6 Hz, 1H), 5.75 (ddd, J = 1.3, 9.7 and 15.5 Hz, 1H), 5.58 
(dd, J = 2.5 and 2.7 Hz, 1H), 5.57 (dd, J = 2.4 and 16.6 Hz, 1H), 5.41 (ddd, J = 4.7, 10.0 
and 15.5 Hz, 1H), 5.37 (brs, 1H), 5.13 (brs, 1H), 3.84 (dd, J = 1.3 and 10.8 Hz, 1H), 
3.29 (ddd, J = 0.9, 4.6 and 9.6 Hz, 1H), 2.95 (dd, J = 9.8 and 10.8 Hz, 1H), 2.92 (dd, J = 
4.4 and 13.5 Hz, 1H), 2.81 (m, 1H), 2.68 (dd, J = 9.9 and 13.5 Hz, 1H), 2.26 (s, 3H), 
2.16 (dd, J = 4.6 and 8.9 Hz, 1H), 2.04 (m, 1H), 1.88 (m, 1H), 1.80 (m, 1H), 1.79 (m, 
1H), 1.56 (m, 1H), 1.37 (s, 3H), 1.06 (d, J = 8.6 Hz, 3H), 0.99 (d, J = 6.7 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 174.3, 170.3, 148.1, 139.6, 138.4, 137.8, 129.7, 
129.1, 127.1, 126.7, 125.6, 113.4, 77.1, 74.6, 69.3, 53.5, 53.4, 51.7, 50.3, 46.9, 44.9, 
42.5, 32.5, 30.8, 28.2, 26.2, 20.6, 13.9. 
HRMS (m/z): calculated for [C60H76N2O10 + Na]: 1007.5398, found: 1007.5402. 
 
Synthesis of 308 
 
To a stirred solution of 258 (10 mg, 0.019 mmol, 1.0 eq) and 307 (12.2 mg, 0.038 mmol, 
2.0 eq) in DMF (2 mL) was added CuI (0.2 mg, 0.95 µmol, 0.05 eq) and DIPEA (1.2 
mg, 9.5 µmol, 0.5 eq). The mixture was stirred at room temperature for 12 hours under 
nitrogen and the solvent was removed in vacuo. The residue was dissolved in EtOAc (2 
mL) and washed with water (2 mL x 2). The organic phase was dried over MgSO4, 
filtered and evaporated to dryness in vacuo. The residue was dissolved in MeOH and 




1H NMR (500 MHz, CDCl3): δ (Hz) = 8.23 (dd, J = 1.0 and 7.6 Hz, 2H), 8.18 (s, 1H), 
8.00 (dd, J = 0.9 and 8.3 Hz, 2H), 7.87 (s, 1H), 7.72 (d, J = 8.2 Hz, 1H), 7.65 (d, J = 8.5 
Hz, 1H), 7.56 (m, 1H), 7.52 (dd, J = 1.6 and 7.8 Hz, 2H), 7.27 (d, J = 8.5 Hz, 2H), 5.85 
(dd, J = 2.2 and 17.0 Hz, 1H), 5.76 (ddd, J = 1.4, 9.7 and 15.4 Hz, 1H), 5.58 (brs, 1H), 
5.56 (brs, 1H), 5.42 (ddd, J = 4.8, 10.1 and 15.4 Hz, 1H), 5.39 (brs, 1H), 5.14 (brs, 1H), 
5.09 (s, 2H), 4.90 (s, 2H), 3.88 (dd, J = 1.3 and 10.8 Hz, 1H), 3.29 (m, 1H), 2.98 (m, 
1H), 2.90 (m, 1H), 2.81 (m, 1H), 2.74 (m, 1H), 2.28 (s, 3H), 2.16 (dd, J = 3.7 and 5.0 
Hz, 1H), 2.06 (m, 1H), 1.90 (m, 1H), 1.83 (m, 1H), 1.82 (m, 1H), 1.61 (m, 1H), 1.38 (s, 
3H), 1.07 (d, J = 6.4 Hz, 3H), 0.99 (d, J = 6.6 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 174.3, 170.2, 147.7, 146.1, 138.4, 138.0, 137.9, 
136.0, 135.1, 134.7, 133.0, 132.8, 132.0, 131.1, 130.3, 129.1, 128.5, 128.3, 127.6, 127.3, 
126.7, 126.2, 125.4, 123.2, 120.6, 120.4, 120.0, 119.2, 113.8, 76.8, 74.4, 71.1, 69.4, 
63.4, 53.3, 52.9, 51.6, 49.9, 46.8, 44.7, 42.3, 32.4, 30.8, 28.1, 26.1, 20.6, 13.7. 
HRMS (m/z): calculated for [C54H54N4O6 + Na]: 877.3941, found: 877.3940. 
IR (powder, cm-1): 2922, 1735, 1693, 1519, 1369, 1228, 1043, 1014, 962, 812, 767, 
542. 
 
Synthesis of 305 
 
To a stirred solution of 258 (10 mg, 0.019 mmol, 1.0 eq) in 2.0 mL dioxane-water 
mixture (4.4:1, v/v) was added TCEP (7.0mg, 0.028 mmol, 1.5 eq). The mixture was 
stirred at room temperature for 1 hour and the solvent was removed in vacuo. The 
residue was dissolved in EtOAc (2 mL) and washed with water (2 mL x 2). The organic 
phase was dried over MgSO4, filtered and evaporated to dryness in vacuo. The residue 
was dissolved in MeOH and purified by LCMS to afford 6.7 mg of desired product 
(yield: 70.2%) as a white solid.192 
1H NMR (500 MHz, CDCl3): δ (Hz) = 6.95 (d, J = 8.3 Hz, 2H), 6.65 (d, J = 8.3 Hz, 
2H), 5.89 (dd, J = 2.1 and 17.2 Hz, 1H), 5.76 (ddd, J = 1.3, 9.6 and 15.4 Hz, 1H), 5.58 
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(m, 1H), 5.53 (dd, J = 2.3 and 17.2 Hz, 1H), 5.40 (ddd, J = 4.9, 10.2 and 15.4 Hz, 1H), 
5.37 (brs, 1H), 5.13 (brs, 1H), 3.86 (dd, J = 1.4 and 10.8 Hz, 1H), 3.20 (ddd, J = 1.1, 4.7 
and 9.4 Hz, 1H), 2.96 (dd, J = 9.8 and 10.8 Hz, 1H), 2.80 (m, 1H), 2.75 (dd, J = 4.6 and 
13.7 Hz, 1H), 2.56 (dd, J = 9.8 and 13.7 Hz, 1H), 2.25 (s, 3H), 2.11 (dd, J = 4.4 and 4.7 
Hz, 1H), 2.06 (m, 1H), 1.87 (m, 1H), 1.82 (m, 1H), 1.79 (m, 1H), 1.58 (dd, J = 3.1 and 
14.3 Hz 1H), 1.35 (s, 3H), 1.05 (d, J = 6.4 Hz, 3H), 0.96 (d, J = 6.7 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 174.1, 170.1, 148.1, 145.3, 138.7, 138.0, 133.8, 
130.0, 129.8, 127.1, 126.0, 115.3, 113.9, 77.2, 74.4, 69.6, 53.8, 51.8, 50.2, 47.2, 44.8, 
42.6, 32.9, 31.2, 28.4, 26.5, 20.9, 14.1. 
HRMS (m/z): calculated for [C60H76N2O10 + Na]:  531.2835, found: 531.2830. 
 
Synthesis of 291 
 
To a stirred solution of 258 (10 mg, 0.019 mmol, 1.0 eq) and 288 (4 mg, 0.038 mmol, 
2.0 eq) in DMF (2 mL) was added CuI (0.2 mg, 0.95 µmol, 0.05 eq) and DIPEA (1.2 
mg, 9.5 µmol, 0.5 eq). The mixture was stirred at room temperature for 12 hours under 
nitrogen and the solvent was removed in vacuo. The residue was dissolved in EtOAc (2 
mL) and washed with water (2 mL x 2). The organic phase was dried over MgSO4, 
filtered and evaporated to dryness in vacuo. The residue was dissolved in MeOH and 
purified by LCMS to afford 7.4 mg of desired product (yield: 61.8%) as a white solid.187  
1H NMR (500 MHz, CDCl3): δ (Hz) = 8.18 (s, 1H), 7.92 (dd, J = 1.4 and 8.4 Hz, 2H), 
7.78 (d, J = 8.5 Hz, 2H), 7.47 (dd, J = 7.4 and 8.4 Hz, 2H), 7.40 (dd, J = 8.4 and 18.6 
Hz, 1H), 7.34 (d, J = 8.5 Hz, 2H), 5.87 (dd, J = 3.0 and 16.2 Hz, 1H), 5.74 (ddd, J = 1.4, 
9.7 and 15.4 Hz, 1H), 5.59 (brs, 1H), 5.58 (brs, 1H), 5.44 (ddd, J = 4.8, 10.1 and 15.4 
Hz, 1H), 5.37 (brs, 1H), 5.13 (brs, 1H), 3.85 (dd, J = 1.6 and 10.7 Hz, 1H), 3.32 (m, 1H), 
2.95 (m, 1H), 2.81 (m, 1H), 2.80 (m, 1H), 2.65 (m, 1H), 2.26 (s, 3H), 2.17 (dd, J = 3.8 
and 5.0 Hz, 1H), 2.05 (m, 1H), 1.89 (m, 1H), 1.82 (m, 1H), 1.79 (m, 1H), 1.58 (dd, J = 
2.9 and 14.4 Hz 1H), 1.35 (s, 3H), 1.06 (d, J = 6.5 Hz, 3H), 0.99 (d, J = 6.7 Hz, 3H). 
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13C NMR (125 MHz, CDCl3): δ = 174.2, 170.2, 148.5, 147.7, 138.6, 138.1, 138.1, 
136.3, 130.3, 129.6, 128.7, 128.5, 126.9, 125.6, 117.0, 114.2, 77.0, 74.4, 69.7, 53.9, 
53.3, 51.6, 50.2, 47.1, 44.9, 42.8, 32.7, 31.1, 28.3, 26.5, 20.9, 13.9. 
HRMS (m/z): calculated for [C40H46N1O6 + Na]: 659.3223, found: 659.3218. 
 
Synthesis of 292 
 
To a stirred solution of 258 (10 mg, 0.019 mmol, 1.0 eq) and 289 (6.8 mg, 0.038 mmol, 
2.0 eq) in DMF (2 mL) was added CuI (0.2 mg, 0.95 µmol, 0.05 eq) and DIPEA (1.2 
mg, 9.5 µmol, 0.5 eq). The mixture was stirred at 80 °C for 12 hours under nitrogen and 
the solvent was removed in vacuo. The residue was dissolved in EtOAc (2 mL) and 
washed with water (2 mL x 2). The organic phase was dried over MgSO4, filtered and 
evaporated to dryness in vacuo. The residue was dissolved in MeOH and purified by 
LCMS to afford 8.1 mg of desired product (yield: 60.6%) as a white solid.187 
1H NMR (500 MHz, CDCl3): δ (Hz) = 8.20 (s, 1H), 7.82 (dd, J = 1.4 and 8.4 Hz, 2H), 
7.78 (d, J = 8.5 Hz, 2H), 7.61 (dd, J = 7.4 and 8.4 Hz, 2H), 7.38 (dd, J = 8.5 and 18.6 
Hz, 1H), 5.88 (dd, J = 3.0 and 16.2 Hz, 1H), 5.76 (ddd, J = 1.4, 9.7 and 15.4 Hz, 1H), 
5.58 (brs, 1H), 5.58 (brs, 1H), 5.41 (ddd, J = 4.8, 10.1 and 15.4 Hz, 1H), 5.39 (brs, 1H), 
5.15 (brs, 1H), 3.88 (dd, J = 1.6 and 10.7 Hz, 1H), 3.33 (m, 1H), 2.97 (m, 1H), 2.95 (m, 
1H), 2.81 (m, 1H), 2.80 (m, 1H), 2.28 (s, 3H), 2.18 (dd, J = 3.8 and 5.0 Hz, 1H), 2.06 
(m, 1H), 1.89 (dd, J = 3.0 and 14.4 Hz,, 1H), 1.83 (m, 1H), 1.81 (m, 1H), 1.61 (dd, J = 
2.9 and 14.4 Hz 1H), 1.35 (s, 3H), 1.07 (d, J = 6.5 Hz, 3H), 1.02 (d, J = 6.7 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 174.4, 170.2, 147.6, 147.5, 138.7, 138.3, 136.1, 
132.0, 130.5, 129.1, 127.4, 127.0, 126.9, 125.7, 121.0, 120.9, 117.4, 114.3, 77.1, 74.4, 
69.9, 53.7, 53.4, 51.7, 50.3, 47.2, 44.9, 42.7, 32.7, 31.2, 28.5, 26.5, 20.9, 14.1. 




Synthesis of 290 
 
To a stirred solution of 258 (10 mg, 0.019 mmol, 1.0 eq) and 287 (2.0 mg, 0.038 mmol, 
2.0 eq) in DMF (2 mL) was added CuI (0.2 mg, 0.95 µmol, 0.05 eq) and DIPEA (1.2 
mg, 9.5 µmol, 0.5 eq). The mixture was stirred at room temperature for 12 hours under 
nitrogen and the solvent was removed in vacuo. The residue was dissolved in EtOAc (2 
mL) and washed with water (2 mL x 2). The organic phase was dried over MgSO4, 
filtered and evaporated to dryness in vacuo. The residue was dissolved in MeOH and 
purified by LCMS to afford 8.2 mg of desired product (yield: 76.4%) as a white solid. 
1H NMR (500 MHz, CDCl3): δ (Hz) = 7.73 (s, 1H), 7.70 (d, J = 8.5 Hz, 2H), 7.33 (d, J 
= 8.5 Hz, 1H), 5.85 (dd, J = 3.0 and 16.2 Hz, 1H), 5.78 (ddd, J = 1.4, 9.7 and 15.4 Hz, 
1H), 5.59 (brs, 1H), 5.58 (brs, 1H), 5.43 (ddd, J = 4.8, 10.1 and 15.4 Hz, 1H), 5.38 (brs, 
1H), 5.14 (brs, 1H), 3.87 (dd, J = 1.3 and 10.8 Hz, 1H), 3.31 (m, 1H), 2.97 (m, 1H), 
2.95 (m, 1H), 2.80 (m, 1H), 2.77 (m, 1H), 2.28 (s, 3H), 2.18 (dd, J = 3.8 and 5.0 Hz, 
1H), 2.06 (m, 1H), 1.92 (dd, J = 3.0 and 14.4 Hz,, 1H), 1.83 (m, 1H), 1.81 (m, 1H), 1.61 
(m, 1H), 1.37 (s, 3H), 1.07 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.7 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 174.3, 170.2, 147.7, 144.2, 138.8, 138.2, 137.8, 1, 
130.4, 127.0, 125.9, 120.9, 120.8, 118.9, 114.4, 77.2, 74.3, 70.0, 53.8, 53.5, 51.7, 50.2, 
47.3, 45.1, 42.7, 32.7, 31.2, 28.6, 26.6, 21.0, 14.1. 
HRMS (m/z): calculated for [C60H76N2O10 + Na]: 597.3053, found: 597.3061. 
 




To a stirred solution of 258 (5 mg, 0.01 mmol, 1.0 eq) and 309 (3.0 mg, 0.01 mmol, 1.0 
eq) in DMF (2 mL) was added CuI (0.1 mg, 0.5 µmol, 0.05 eq) and DIPEA (0.6 mg, 4.8 
µmol, 0.5 eq). The mixture was stirred at room temperature for 12 hours under nitrogen 
and the solvent was removed in vacuo. The residue was dissolved in EtOAc (2 mL) and 
washed with water (2 mL x 2). The organic phase was dried over MgSO4, filtered and 
evaporated to dryness in vacuo. The residue was dissolved in MeOH and purified by 
LCMS to afford 6.3 mg of desired product (yield: 78.2%) as a deep yellow solid.187 
1H NMR (500 MHz, CDCl3): δ (Hz) = 8.38 (m, 1H), 8.27 (s, 1H), 7.73 (d, J = 8.5 Hz, 
1H), 7.33 (d, J = 8.5 Hz, 1H), 6.94 (s, 1H), 5.85 (dd, J = 2.2 and 17.0 Hz, 1H), 5.76 
(ddd, J = 1.4, 9.7 and 15.4 Hz, 1H), 5.59 (brs, 1H), 5.56 (brs, 1H), 5.53 (s, 1H), 5.41 
(ddd, J = 4.8, 10.1 and 15.4 Hz, 1H), 5.37 (brs, 1H), 5.13 (brs, 1H), 3.86 (dd, J = 1.3 
and 10.8 Hz, 1H), 3.35 (m, 4H), 3.31 (m, 1H), 2.96 (m, 1H), 2.90 (m, 1H), 2.79 (m, 1H), 
2.77 (m, 1H), 2.27 (s, 3H), 2.17 (dd, J = 3.7 and 5.0 Hz, 1H), 2.05 (m, 1H), 1.98 (m, 
2H),1.88 (m, 1H), 1.82 (m, 1H), 1.81 (m, 1H), 1.58 (m, 1H), 1.37 (s, 3H), 1.07 (d, J = 
6.4 Hz, 3H), 0.94 (d, J = 6.6 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 174.3, 170.2, 164.0, 158.7, 153.6, 149.6, 149.0, 
148.9, 144.2, 138.6, 138.2, 138.0, 136.0, 130.3, 127.1, 127.0, 125.8, 122.1, 121.0, 119.4, 
114.2, 107.3, 105.8, 77.2, 74.4, 69.8, 58.0, 53.8, 53.3, 51.6, 50.1, 49.8, 47.2, 45.0, 42.7, 
32.7, 31.2, 28.4, 27.4, 26.5, 20.9, 20.0, 20.4, 14.0. 
HRMS (m/z): calculated for [C49H55N5O9 + Na]: 880.3897, found: 880.3904. 
IR (powder, cm-1): 3419, 2924, 1735, 1685, 1618, 1585, 1560, 1517, 1442, 1369, 1309, 
1238, 1197, 1172, 1111, 1045, 962, 792, 439. 
 
Synthesis of 298 
 
 
To a stirred solution of 1 (100.0 mg, 0.41 mmol, 1.0 eq) and 2 (0.1mL, 0.82 mmol, 2.0 
eq) in dry THF (4 mL) was added K2CO3 (50.0 mg, 0.49 mmol, 1.2 eq). The mixture 
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was stirred at 55 °C for 12 hours under nitrogen and the solvent was removed in vacuo. 
The residue was dissolved in EtOAc (4 mL) and washed with water (3 mL x 2). The 
organic phase was dried over MgSO4, filtered and evaporated to dryness in vacuo. The 
residue was dissolved in MeOH and purified by LCMS to afford 69.0 mg of desired 
product (yield: 59.7%) as a white solid.191 
1H NMR (500 MHz, CDCl3): δ (Hz) = 4.70 (d, J = 2.5 Hz, 2H), 4.56 (m, 1H), 4.37 (m, 
2H), 3.20 (m, 1H), 2.95 (dd, J = 5.0 and 12.9 Hz, 1H), 2.77 (d, J = 12.9 Hz, 1H), 2.51 (t, 
J = 2.5 Hz, 2H), 2.41 (t, J = 7.1 Hz, 2H), 1.73 (m, 2H), 1.50 (m, 2H), 1.27 (m, 2H). 
13C NMR (125 MHz, CDCl3): δ = 172.6, 163.1, 79.5, 75.5, 62.0, 60.3, 55.2, 51.9, 40.6, 
33.6, 29.8, 28.3, 24.6. 
HRMS (m/z): calculated for [C13H18N2O3S + Na]: 305.0936, found: 305.0936. 
 
 
To a stirred solution of 258 (10 mg, 0.019 mmol, 1.0 eq) and 295 (10.7 mg, 0.038 mmol, 
2.0 eq) in DMF (2 mL) was added CuI (0.2 mg, 0.95 µmol, 0.05 eq) and DIPEA (1.2 
mg, 9.5 µmol, 0.5 eq). The mixture was stirred at room temperature for 12 hours under 
nitrogen and the solvent was removed in vacuo. The residue was dissolved in EtOAc (2 
mL) and washed with water (2 mL x 2). The organic phase was dried over MgSO4, 
filtered and evaporated to dryness in vacuo. The residue was dissolved in MeOH and 
purified by LCMS to afford 8.6 mg of desired product (yield: 56.4%) as a light yellow 
solid.191 
1H NMR (500 MHz, CDCl3): δ (Hz) = 8.16 (s, 1H), 7.75 (d, J = 8.2 Hz, 2H), 7.33 (d, J 
= 8.2 Hz, 2H), 5.88 (dd, J = 2.7 and 16.5 Hz, 1H), 5.74 (ddd, J = 1.4, 9.6 and 15.5 Hz, 
1H), 5.58 (brs, 1H), 5.52 (brs, 1H), 5.42 (ddd, J = 4.8, 10.3 and 15.5 Hz, 1H), 5.39 (brs, 
1H), 5.34 (s, 1H), 5.15 (brs, 1H), 4.48 (m, 1H), 4.25 (dd, J = 4.4 and 7.8 Hz, 1H), 3.86 
(d, J = 10.8 Hz, 1H), 3.33 (m, 1H), 3.15 (m, 1H), 2.97 (m, 1H), 2.94 (dd, J = 4.8 and 
13.5 Hz, 1H), 2.82 (m, 1H), 2.74 (m, 1H), 2.69 (m, 2H), 2.43 (t, J = 6.9 Hz, 2H), 2.27 (s, 
3H), 2.15 (t, J = 4.3 Hz, 1H), 2.06 (m, 1H), 1.91 (m, 1H), 1.82 (m, 1H), 1.73 (m, 2H), 
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1.67 (m, 2H), 1.48 (m, 2H), 1.35 (s, 3H), 1.07 (d, J = 6.7 Hz, 3H), 1.06 (d, J = 6.5 Hz, 
3H). 
13C NMR (125 MHz, CDCl3): δ = 174.8, 173.5, 170.2, 163.3, 147.9, 145.1, 138.8, 
138.2, 130.6, 130.3, 127.0, 125.9, 120.9, 119.6, 114.2, 77.4, 74.3, 69.6, 61.6, 60.1, 55.3, 
53.8, 53.7, 51.9, 50.5, 47.2, 45.1, 42.8, 40.6, 33.6, 32.9, 31.2, 28.5, 28.3, 28.1, 26.5, 
25.5, 24.6, 21.0, 14.4. 
HRMS (m/z): calculated for [C43H56N6O8S + Na]:  839.3778, found: 839.3773. 
 
Synthesis of 299 
 
To a stirred solution of 1 (100.0 mg, 0.41 mmol, 1.0 eq) and 2 (80.0 mg, 0.61 mmol, 1.5 
eq) in dry THF (4 mL) was added K2CO3 (50.0 mg, 0.49 mmol, 1.2 eq). The mixture 
was stirred at 55 °C for 12 hours under nitrogen and the solvent was removed in vacuo. 
The residue was dissolved in EtOAc (4 mL) and washed with water (3 mL x 2). The 
organic phase was dried over MgSO4, filtered and evaporated to dryness in vacuo. The 
residue was dissolved in MeOH and purified by LCMS to afford 100.2 mg of desired 
product (yield: 82.6%) as a white solid (compound 296 was synthesized by Maurice).191 
1H NMR (500 MHz, CDCl3): δ (Hz) = 4.54 (m, 1H), 4.35 (m, 1H), 4.21 (t, J = 6.8 Hz 
2H), 3.19 (m, 1H), 2.96 (dd, J = 5.1 and 12.8 Hz, 1H), 2.75 (dd, J = 1.0 and 12.8 Hz, 
1H), 2.55 (ddd, J = 2.7, 6.8 and 13.5 Hz 2H), 2.39 (t, J = 7.4 Hz, 2H), 1.73 (m, 2H), 
1.71 (m, 1H), 1.46 (m, 1H), 1.28 (m, 2H). 
13C NMR (125 MHz, CDCl3): δ = 173.3, 163.1, 80.1, 69.9, 62.0, 61.9, 60.1, 55.2, 40.6, 
33.7, 29.7, 28.1, 24.7. 






To a stirred solution of 258 (10 mg, 0.019 mmol, 1.0 eq) and 296 (11.2 mg, 0.038 mmol, 
2.0 eq) in DMF (2 mL) was added CuI (0.2 mg, 0.95 µmol, 0.05 eq) and DIPEA (1.2 
mg, 9.5 µmol, 0.5 eq). The mixture was stirred at room temperature for 12 hours under 
nitrogen and the solvent was removed in vacuo. The residue was dissolved in EtOAc (2 
mL) and washed with water (2 mL x 2). The organic phase was dried over MgSO4, 
filtered and evaporated to dryness in vacuo. The residue was dissolved in MeOH and 
purified by LCMS to afford 9.6 mg of desired product (yield: 61.9%) as a white solid.191 
1H NMR (500 MHz, CDCl3): δ (Hz) = 7.93 (s, 1H), 7.74 (d, J = 8.2 Hz, 2H), 7.34 (d, J 
= 8.2 Hz, 2H), 5.87 (dd, J = 2.9 and 16.4 Hz, 1H), 5.74 (m, 1H), 5.55 (brs, 1H), 5.49 
(brs, 1H), 5.44 (m, 1H), 5.40 (brs, 1H), 5.15 (brs, 1H), 4.53 (m, 1H), 4.34 (m, 1H), 4.21 
(m, 1H), 3.87 (dd, J = 1.7 and 11.0 Hz, 1H), 3.33 (m, 1H), 3.18 (m, 1H), 3.16 (m, 1H), 
2.97 (dd, J = 5.0 and 11.0 Hz 1H), 2.95 (m, 1H ), 2.93 (dd, J = 5.0 and 12.9 Hz, 1H), 
2.83 (m, 1H), 2.73 (dd, J = 1.1 and 12.9 Hz 1H), 2.72 (m, 1H), 2.39 (m, 2H), 2.26 (s, 
3H), 2.13 (m, 1H), 2.06 (m, 1H), 1.88 (m, 1H), 1.80 (m, 1H), 1.71 (m, 2H), 1.69 (m, 
2H), 1.61 (m, 2H), 1.46 (m, 2H), 1.35 (s, 3H), 1.10 (d, J = 6.7 Hz, 3H), 1.07 (d, J = 6.5 
Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 175.2, 173.4, 170.1, 163.2, 147.7, 145.1, 138.8, 
138.2, 137.9, 130.7, 130.6, 126.8, 125.7, 120.6, 119.6, 114.1, 77.3, 74.2, 69.5, 61.8, 
61.7, 60.0, 55.2, 53.9, 53.6, 52.4, 50.4, 47.1, 45.1, 42.7, 40.5, 33.7, 32.9, 31.2, 28.6, 
28.2, 28.1, 26.5, 25.6, 24.6, 20.9, 14.3. 
HRMS (m/z): calculated for [C44H58N6O8S + Na]: 853.3935, found: 853.3936. 
 




To a stirred solution of 1 (100.0 mg, 0.41 mmol, 1.0 eq) and 2 (90.0 mg, 0.61 mmol, 1.5 
eq) in dry THF (4 mL) was added K2CO3 (50.0 mg, 0.49 mmol, 1.2 eq). The mixture 
was stirred at 55 °C for 12 hours under nitrogen and the solvent was removed in vacuo. 
The residue was dissolved in EtOAc (4 mL) and washed with water (3 mL x 2). The 
organic phase was dried over MgSO4, filtered and evaporated to dryness in vacuo. The 
residue was dissolved in MeOH and purified by LCMS to afford 96.0 mg of desired 
product (yield: 75.6%) as a white solid (compound 297 was synthesized by Maurice).191 
1H NMR (500 MHz, CDCl3): δ (Hz) = 4.53 (m, 1H), 4.33 (m, 1H), 4.19 (t, J = 6.3 Hz 
2H), 2.92 (dd, J = 5.0 and 12.8 Hz, 1H), 2.78 (d, J = 12.8 Hz, 1H), 2.29 (m, 2H), 1.99 (t, 
J = 2.6 Hz, 1H), 1.87 (m, 2H), 1.73 (m, 2H), 1.71 (m, 1H), 1.48 (m, 1H), 1.28 (m, 2H). 
13C NMR (125 MHz, CDCl3): δ = 173.6, 163.6, 83.1, 69.5, 62.9, 62.0, 60.1, 40.3, 29.7, 
28.6, 27.6, 24.8, 24.7, 15.4. 
HRMS (m/z): calculated for [C15H22N2O3S + Na]: 333.1249, found: 333.1246. 
 
To a stirred solution of 258 (10 mg, 0.019 mmol, 1.0 eq) and 297 (11.7 mg, 0.038 mmol, 
2.0 eq) in DMF (2 mL) was added CuI (0.2 mg, 0.95 µmol, 0.05 eq) and DIPEA (1.2 
mg, 9.5 µmol, 0.5 eq). The mixture was stirred at room temperature for 12 hours under 
nitrogen and the solvent was removed in vacuo. The residue was dissolved in EtOAc (2 
mL) and washed with water (2 mL x 2). The organic phase was dried over MgSO4, 
filtered and evaporated to dryness in vacuo. The residue was dissolved in MeOH and 
purified by LCMS to afford 10.1 mg of desired product (yield: 63.8%) as a white yellow 
solid.191 
1H NMR (500 MHz, CDCl3): δ (Hz) = 7.83 (s, 1H), 7.72 (d, J = 8.2 Hz, 2H), 7.33 (d, J 
= 8.2 Hz, 2H), 5.84 (dd, J = 2.7 and 16.5 Hz, 1H), 5.74 (ddd, J = 1.4, 9.6 and 15.5 Hz, 
1H), 5.54 (brs, 1H), 5.52 (brs, 1H), 5.45 (ddd, J = 4.8, 10.3 and 15.5 Hz, 1H), 5.39 (brs, 
1H), 5.14 (brs, 1H), 4.52 (m, 1H), 4.33 (m, 1H), 4.18 (m, 1H), 3.88 (dd, J = 1.5 and 
10.8 Hz, 1H), 3.33 (ddd, J = 0.9, 4.8 and 9.6 Hz 1H), 3.19 (m, 1H), 2.94 (m, 1H), 2.93 
(m, 1H ), 2.81 (m, 1H), 2.75 (m, 1H), 2.74 (m, 1H), 2.37 (m, 2H), 2.27 (s, 3H), 2.13 (m, 
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2H), 2.06 (m, 1H), 1.91 (m, 1H), 1.89 (m, 2H),1.82 (m, 2H), 1.80 (m, 1H), 1.70 (m, 2H), 
1.69 (m, 1H), 1.61 (m, 1H), 1.48 (m, 2H), 1.36 (s, 3H), 1.06 (d, J = 6.5 Hz, 3H), 1.04 (d, 
J = 6.6 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 175.2, 173.6, 170.1, 163.3, 147.7, 147.6, 138.7, 
138.2, 137.9, 130.7, 130.4, 127.1, 125.8, 120.8, 119.1, 114.2, 77.2, 74.2, 69.7, 63.1, 
61.7, 60.0, 55.2, 53.7, 53.6, 52.4, 50.2, 47.2, 45.0, 42.6, 40.6, 33.8, 32.8, 31.3, 28.4, 
28.2, 28.1, 27.6, 26.2, 24.7, 21.0, 14.2. 
HRMS (m/z): calculated for [C45H60N6O8S + Na]: 867.4091, found: 867.4095. 
 
Synthesis of 304 
 
To a stirred solution of 259 (100.0 mg, 0.30 mmol, 1.0 eq) and 2 (0.1mL, 0.60 mmol, 
2.0 eq) in dry DMF (4 mL) was added K2CO3 (50.0 mg, 0.49 mmol, 1.2 eq). The 
mixture was stirred at 70 °C for 12 hours under nitrogen and the solvent was removed in 
vacuo. The residue was dissolved in EtOAc (4 mL) and washed with water (3 mL x 2). 
The organic phase was dried over MgSO4, filtered and evaporated to dryness in vacuo. 
The residue was dissolved in MeOH and purified by LCMS to afford 77.3 mg of desired 
product (yield: 69.4%) as a white solid.191 
1H NMR (500 MHz, CDCl3): δ (Hz) = 7.38-7.29 (m, 5H), 5.67 (dd, J = 4.2 and 9.0 Hz, 
1H), 5.53 (d, J = 4.2 Hz, 1H), 4.82 (d, J = 2.5 Hz, 1H), 4.71 (d, J = 2.5 Hz, 1H), 4.42 (s, 
1H), 3.65 (s, 2H), 2.53 (t, J = 2.5 Hz, 1H), 1.50 (s, 3H), 1.48 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 173.5, 170.5, 166.8, 133.8, 129.4, 129.0, 127.6, 76.4, 
76.2, 70.0, 67.9, 64.7, 58.7, 52.7, 43.6, 26.8. 






To a stirred solution of 258 (10 mg, 0.019 mmol, 1.0 eq) and 303 (14.1 mg, 0.038 mmol, 
2.0 eq) in DMF (4 mL) was added CuI (0.2 mg, 0.95 µmol, 0.05 eq) and DIPEA (1.2 
mg, 9.5 µmol, 0.5 eq). The mixture was stirred at room temperature for 12 hours under 
nitrogen and the solvent was removed in vacuo. The residue was dissolved in EtOAc (4 
mL) and washed with water (3 mL x 2). The organic phase was dried over MgSO4, 
filtered and evaporated to dryness in vacuo. The residue was dissolved in MeOH and 
purified by LCMS to afford 15.0 mg of desired product (yield: 88.6%) as a white yellow 
solid.191 
1H NMR (500 MHz, CDCl3): δ (Hz) = 8.07 (s, 1H), 7.72 (d, J = 8.5 Hz, 2H), 7.34 (d, J 
= 8.5 Hz, 2H), 7.39 (m, 2H), 7.30 (m, 2H), 7.28 (m, 2H), 5.86 (dd, J = 2.6 and 16.5 Hz, 
1H), 5.75 (m, 1H), 5.69 (dd, J = 4.2 and 9.1 Hz, 1H), 5.55 (brs, 1H), 5.54 (d, J = 4.2 Hz, 
1H), 5.52 (brs, 1H), 5.43 (m, 1H), 5.39 (s, 2H), 5.14 (brs, 1H), 4.42 (s, 1H), 3.88 (d, J = 
10.6 Hz, 1H), 3.66 (m, 2H) ,3.33 (m, 1H), 2.96 (m, 1H), 2.90 (m, 1H ), 2.85 (m, 1H), 
2.74 (m, 1H), 2.26 (s, 3H), 2.17 (m, 1H), 2.08 (m, 1H), 1.91 (m, 1H), 1.82 (m, 1H), 1.61 
(m, 2H), 1.50 (m, 6H), 1.69 (m, 1H), 1.38 (s, 3H), 1.07 (d, J = 6.4 Hz, 3H), 0.98 (d, J = 
6.6 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 174.6, 173.5, 173.4, 170.3, 170.2, 147.5, 142.4, 
138.9, 138.4, 135.7, 133.8, 129.6, 129.5, 129.2, 127.8, 127.6, 127.1, 125.8, 122.2, 121.1, 
114.3, 77.1, 74.1, 70.1, 69.7, 67.9, 64.7, 58.5, 58.1, 53.5, 53.2, 51.9, 49.9, 47.0, 44.7, 
43.4, 42.6, 40.6, 32.6, 31.4, 28.4, 28.2, 26.9, 26.3, 21.1, 13.8. 
HRMS (m/z):  calculated for [C49H58N6O9S + Na]:  1007.5398, found: 1007.5402. 
IR (powder, cm-1): 1784, 1749, 1653, 1521, 1456, 1379, 1300, 1203, 449, 418. 
 





To a stirred solution of 1 (100.0 mg, 0.41 mmol, 1.0 eq) and 2 (98.0 mg, 0.45 mmol, 1.1 
eq) in dry THF (4 mL) was added EDCI (94.0 mg, 0.49 mmol, 1.2 eq) and DMAP (10.0 
mg, 0.082 mmol, 0.2 eq). The mixture was stirred at room temperature for 12 hours 
under nitrogen and the solvent was removed in vacuo. The residue was dissolved in 
EtOAc (4mL) and washed with water 3 mL x 2). The organic phase was dried over 
MgSO4, filtered and evaporated to dryness in vacuo. The residue was dissolved in 
MeOH and purified by LCMS to afford 111.5 mg of desired product (yield: 61.3%) as a 
white solid (compound 301 was synthesized by Maurice).213 
1H NMR (500 MHz, CDCl3): δ (Hz) = 4.46 (m, 1H), 4.27 (m, 2H), 3.65 (m, 2H), 3.62 
(m, 2H), 3.59 (m, 2H), 3.50 (m, 2H), 3.40 (t, J = 5.6 Hz, 2H), 3.32 (dd, J = 5.6 and 11.2 
Hz 2H), 3.18 (m, 1H), 2.96 (m, 1H), 2.90 (dd, J = 5.0 and 12.7 Hz, 1H), 2.68 (d, J = 
12.7 Hz 1H), 2.15 (dd, J = 1.0 and 7.9 Hz, 2H), 1.62 (m, 2H), 1.57 (m, 2H), 1.39 (m, 
2H). 
13C NMR (125 MHz, CDCl3): δ = 172.8, 163.2, 70.2, 69.8, 69.6, 69.3, 61.4, 59.9, 55.4, 
50.5, 40.1, 38.3, 35.4, 28.1, 25.3. 





To a stirred solution of 252 (13.0 mg, 0.024 mmol, 1.1 eq) and 301 (10.0 mg, 0.022 
mmol, 1.0 eq) in DMF (2 mL) was added CuI (0.23 mg, 1.2 µmol, 0.05 eq) and DIPEA 
(1.5 mg, 12 µmol, 0.5 eq). The mixture was stirred at room temperature for 12 hours 
under nitrogen and the solvent was removed in vacuo. The residue was dissolved in 
EtOAc (4mL) and washed with water 3 mL x 2). The organic phase was dried over 
MgSO4, filtered and evaporated to dryness in vacuo. The residue was dissolved in 
MeOH and purified by LCMS to afford 14.3 mg of desired product (yield: 64.3%) as a 
white solid. 
1H NMR (500 MHz, CDCl3): δ (Hz) = 7.86 (s, 1H), 7.10 (d, J = 8.5 Hz, 2H), 6.97 (d, J 
= 8.5 Hz, 2H), 5.88 (dd, J = 2.6 and 16.6 Hz, 1H), 5.74 (ddd, J = 1.3, 9.7 and 15.3 Hz, 
1H), 5.56 (brs, 1H), 5.49 (brs, 1H), 5.41 (ddd, J = 5.1, 10.4 and 15.3 Hz, 1H), 5.37 (brs, 
1H), 5.21 (s, 2H), 5.12 (brs, 1H), 4.58 (dd, J = 4.5 and 5.6 Hz 2H), 4.50 (m, 1H), 4.32 
(m, 1H), 3.91 (dd, J = 4.5 and 5.5 Hz, 2H), 3.84 (dd, J = 1.3 and 10.8 Hz, 1H), 3.62 (m, 
1H), 3.54 (m, 1H), 3.42 (dd, J = 5.3 and 10.5 Hz, 1H), 3.24 (m, 1H), 3.16 (m, 1H), 2.96 
(m, 1H), 2.91 (m, 1H), 2.80 (m, 1H), 2.79 (m, 1H), 2.74 (m, 1H), 2.61 (m, 2H), 2.26 (s, 
3H), 2.19 (m, 2H), 2.10 (m, 1H), 2.07 (m, 1H), 1.90 (m, 1H), 1.82 (m, 1H), 1.81 (m, 
1H), 1.69 (m, 2H), 1.68 (m, 2H), 1.61 (m, 2H), 1.47 (s, 2H), 1.38 (s, 3H), 1.06 (d, J = 
6.4 Hz, 3H), 1.00 (d, J = 6.7 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 174.6, 173.1, 170.1, 163.6, 157.3, 150.0, 143.9, 
138.5, 138.2, 130.3, 130.1, 127.2, 126.0, 124.0, 115.2, 114.0, 77.6, 74.3, 70.4, 70.2, 
69.9, 69.8, 69.4, 62.1, 61.8, 60.1, 55.4, 54.0, 53.9, 51.9, 50.3, 50.2, 47.2, 44.5, 43.0, 
40.5, 39.2, 35.8, 33.0, 31.2, 28.6, 28.4, 28.2, 26.7, 25.7, 20.9, 14.3. 
HRMS (m/z): calculated for [C51H73N7O11S + Na]: 1014.4986, found: 1014.4977. 
 






To a stirred solution of 252 (11.0 mg, 0.021 mmol, 1.1 eq) and 258 (10.0 mg, 0.019 
mmol, 1.0 eq) in DMF (2 mL) was added CuI (0.2 mg, 0.95 µmol, 0.05 eq) and DIPEA 
(1.2 mg, 9.5 µmol, 0.5 eq). The mixture was stirred at room temperature for 12 hours 
under nitrogen and the solvent was removed in vacuo. The residue was dissolved in 
EtOAc (2mL) and washed with water 2 mL x 2). The organic phase was dried over 
MgSO4, filtered and evaporated to dryness in vacuo. The residue was dissolved in 
MeOH and purified by LCMS to afford 16.5 mg of desired product (yield: 81.5%) as a 
white solid.191 
1H NMR (500 MHz, CDCl3): δ (Hz) = 8.08 (s, 1H), 7.71 (d, J = 8.5 Hz, 2H), 7.34 (d, J 
= 8.5 Hz, 2H), 7.10 (d, J = 8.6 Hz, 2H), 7.00 (d, J = 8.6 Hz, 2H), 5.86 (m, 1H), 5.75 (m, 
1H), 5.56 (brs, 1H), 5.52 (brs, 1H), 5.42 (m, 1H), 5.38 (brs, 1H), 5.30 (s, 2H), 5.14 (brs, 
1H), 3.86 (dd, J = 2.2 and 11.8 Hz, 1H), 3.25 (m, 1H), 2.96 (m, 1H), 2.80 (m, 1H), 2.26 
(s, 3H), 2.16 (dd, J = 3.9 and 5.1 Hz, 1H), 2.05 (m, 1H), 1.91 (m, 1H), 1.82 (m, 1H), 
1.81 (m, 1H), 1.58 (m, 1H), 1.36 (s, 3H), 1.07 (d, J = 6.4 Hz, 3H), 1.01 (d, J = 6.6 Hz, 
3H). 
13C NMR (125 MHz, CDCl3): δ = 174.3, 170.2, 157.3, 147.9, 145.0, 138.8, 138.3, 
138.2, 136.0, 130.4, 130.2, 127.9, 125.8, 121.0, 120.5, 115.2, 114.2, 77.5, 74.7, 69.6, 
62.0, 53.8, 53.7, 51.8, 50.4, 47.3, 44.9, 42.7, 32.8, 31.3, 28.6, 26.5, 21.0, 14.2. 
HRMS (m/z): calculated for [C60H76N2O10 + Na]: 1104.5674, found: 1104.5688. 
 





To a stirred solution of 257 (10 mg, 0.019 mmol, 1.0 eq) and 287 (2.0 mg, 0.038 mmol, 
2.0 eq) in touluen (2 mL) was added CuI (0.2 mg, 0.95 µmol, 0.05 eq), Et3N (3.0 mg, 
0.03 mmol, 1.5 eq) and Pd(PPh3)4 (0.2 mg, 0.1 µmol, 0.009 eq). The mixture was stirred 
at 80 °C for 12 hours under nitrogen and the solvent was removed in vacuo. The residue 
was dissolved in EtOAc (2 mL) and washed with water (2 mL x 2). The organic phase 
was dried over MgSO4, filtered and evaporated to dryness in vacuo. The residue was 
dissolved in MeOH and purified by LCMS to afford 6.7 mg of desired product (yield: 
78.2%) as a yellow solid.207,208  
1H NMR (500 MHz, CDCl3): δ (Hz) = 7.36 (d, J = 8.2 Hz, 2H), 7.09 (d, J = 8.2 Hz, 
2H), 5.90 (dd, J = 2.9 and 16.4 Hz, 1H), 5.76 (ddd, J = 1.4, 9.6 and 15.5 Hz, 1H), 5.60 
(brs, 1H), 5.54 (brs, 1H), 5.42 (ddd, J = 4.8, 10.3 and 15.5 Hz, 1H), 5.37 (brs, 1H), 5.12 
(brs, 1H), 3.85 (d, J = 10.2 Hz, 1H), 3.24 (ddd, J = 1.1, 4.4 and 9.1 Hz, 1H), 2.95 (t, J = 
10.2 Hz, 1H), 2.82 (dd, J = 4.8 and 13.5 Hz, 1H), 2.78 (m, 1H), 2.67 (dd, J = 9.5 and 
13.5 Hz, 1H), 2.27 (s, 3H), 2.13 (t, J = 4.4 Hz, 1H), 2.05 (m, 1H), 2.04 (s, 3H), 1.82 (m, 
1H), 1.80 (m, 1H), 1.57 (m, 1H), 1.37 (s, 3H), 1.06 (d, J = 6.5 Hz, 3H), 0.98 (d, J = 6.7 
Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 174.2, 170.2, 147.9, 138.4, 138.0, 132.0, 131.9, 
128.8, 126.9, 126.0, 122.9, 114.2, 86.2, 79.2, 77.5, 74.4, 69.6, 53.7, 53.3, 51.7, 50.6, 
47.2, 45.6, 42.7, 32.7, 31.2, 28.7, 26.1, 20.9, 14.1, 4.2. 
HRMS (m/z): calculated for [C33H41NO5 + Na]: 554.2882, found: 554.2889. 
 




To a stirred solution of 258 (10 mg, 0.019 mmol, 1.0 eq) and 311 (4.5 mg, 0.021 mmol, 
1.1 eq) in DMF (2 mL) was added CuI (0.2 mg, 0.95 µmol, 0.05 eq) and DIPEA (1.2 
mg, 9.5 µmol, 0.5 eq). The mixture was stirred at room temperature for 12 hours under 
nitrogen and the solvent was removed in vacuo. The residue was dissolved in EtOAc (2 
mL) and washed with water (2 mL x 2). The organic phase was dried over MgSO4, 
filtered and evaporated to dryness in vacuo. The residue was dissolved in MeOH and 
purified by LCMS to afford 8.6 mg of desired product (yield: 61.1%) as a brown 
solid.191 
1H NMR (500 MHz, CDCl3): δ (Hz) = 8.54 (d, J = 8.5 Hz, 1H), 8.04 (s, 1H), 7.69 (d, J 
= 8.5 Hz, 2H), 7.35 (d, J = 8.5 Hz, 1H), 6.44 (d, J = 8.6 Hz, 1H),5.85 (dd, J = 3.0 and 
16.2 Hz, 1H), 5.74 (m, 1H), 5.57 (brs, 1H), 5.46 (brs, 1H), 5.43 (m, 1H), 5.39 (brs, 1H), 
5.14 (brs, 1H), 4.93 (s, 2H), 3.86 (dd, J = 1.6 and 10.7 Hz, 1H), 3.35 (m, 1H), 2.98 (m, 
1H), 2.96 (m, 1H), 2.81 (m, 1H), 2.78 (m, 1H), 2.26 (s, 3H), 2.17 (dd, J = 3.8 and 5.0 
Hz, 1H), 2.06 (m, 1H), 1.88 (m, 1H), 1.82 (m, 1H), 1.81 (m, 1H), 1.60 (m, 1H), 1.37 (s, 
3H), 1.07 (d, J = 6.5 Hz, 3H), 1.03 (d, J = 6.7 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 174.5, 170.1, 147.8, 144.3, 144.2, 143.1, 138.8, 
138.2, 135.9, 135.6, 130.7, 130.6, 126.9, 125.7, 125.2, 121.2, 119.9 114.3, 99.7, 77.2, 
74.4, 69.7, 53.9, 53.3, 51.8, 50.3, 47.3, 44.9, 42.8, 39.4, 32.9, 31.2, 28.4, 26.5, 21.0, 
14.3. 
HRMS (m/z):  calculated for [C39H44N8O8 + Na]: 775.3180, found: 775.3179. 
 





To a stirred solution of 258 (5.6 mg, 0.02 mmol, 2.0 eq) and 313 (3.0 mg, 0.01 mmol, 
1.0 eq) in 4.25 mL DMF-water mixture (4:1, v/v) was added sodium ascorbate (0.2 mg, 
1 µmol, 0.1 eq) and copper sulfate (0.12 mg, 1 µmol, 0.1 eq). The mixture was stirred at 
room temperature for 12 hours under nitrogen and the solvent was removed in vacuo. 
The residue was dissolved in EtOAc (2 mL) and washed with water (2 mL x 2). The 
organic phase was dried over MgSO4, filtered and evaporated to dryness in vacuo. The 
residue was dissolved in MeOH and purified by LCMS to afford 1.7 mg of desired 
product (yield: 28.5%) as a red solid.200 
1H NMR (500 MHz, CDCl3): δ (Hz) = 8.65 (s, 1H), 8.19 (d, J = 7.7 Hz 1H), 8.05 (d, J 
= 7.7 Hz 1H), 7.84 (d, J = 8.5 Hz, 2H), 7.71 (s, 1H), 7.35 (d, J = 8.5 Hz, 1H), 6.47 (d, J 
= 8.8 Hz, 1H), 6.36 (d, J = 8.8 Hz, 1H), 5.68 (dd, J = 2.2 and 17.0 Hz, 1H), 5.68 (dd, J 
= 8.8 and 15.5 Hz, 1H), 5.54 (ddd, J = 1.4, 9.7 and 15.4 Hz, 1H), 5.39 (brs, 1H), 5.29 
(brs, 1H), 5.09 (ddd, J = 4.8, 10.1 and 15.4 Hz, 1H), 5.06 (m, 2H), 4.84 (brs, 2H), 4.54 
(s, 2H), 3.63 (dd, J = 1.3 and 10.8 Hz, 1H), 3.15 (m, 1H), 2.85 (m, 1H), 2.74 (m, 1H), 
2.66 (m, 2H), 2.51 (m, 1H), 2.24 (s, 3H), 1.97 (dd, J = 3.7 and 5.0 Hz 1H), 1.90 (m, 1H), 
1.69 (m, 1H),1.62 (m, 2H), 1.60 (m, 1H), 1.39 (s, 2H), 1.14 (s, 3H), 0.48 (d, J = 6.6 Hz, 
3H). 
13C NMR (125 MHz, CDCl3): δ = 174.6, 170.6, 168.7, 165.5, 151.2, 149.4, 146.1, 
146.0, 144.2, 140.4, 138.3, 138.2, 135.6, 134.9, 131.3, 130.3, 130.0, 129.6, 129.5, 129.3, 
129.2, 125.8, 125.3, 121.0, 114.7, 114.6, 114.1, 111.8, 105.5, 105.2, 77.0, 72.7, 71.0, 
54.3, 53.0, 52.4, 48.3, 46.6, 43.8, 43.5, 35.6, 32.2, 31.4, 28.2, 26.7, 21.1, 13.7. 




Synthesis of 316 
 
 
To a stirred solution of 258 (5.6 mg, 0.02 mmol, 2.0 eq) and 315 (4.0 mg, 0.005 mmol, 
1.0 eq) in 1.25 mL DMF-water mixture (4:1, v/v) was added sodium ascorbate (0.1 mg, 
0.5 µmol, 0.1 eq) and copper sulfate (0.06 mg, 0.5 µmol, 0.1 eq). The mixture was 
stirred at room temperature for 12 hours under nitrogen and the solvent was removed in 
vacuo. The residue was dissolved in EtOAc (2 mL) and washed with water (2 mL x 2). 
The organic phase was dried over MgSO4, filtered and evaporated to dryness in vacuo. 
The residue was dissolved in MeOH and purified by LCMS to afford 2.6 mg of desired 
product (yield: 38.6%) as a purple solid.200 
1H NMR (500 MHz, CDCl3): δ (Hz) = 8.36 (m, 1H), 8.01 (d, J = 7.9 Hz, 2H), 7.79 (d, 
J = 8.1 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 7.27 (s, 1H), 6.83 (s, 1H), 5.91 (dd, J = 2.8 
and 16.5 Hz, 1H), 5.76 (ddd, J = 1.4, 9.7 and 15.4 Hz, 1H), 5.59 (brs, 1H), 5.45 (m, 1H), 
5.38 (brs, 1H), 5.14 (brs, 1H), 4.81 (s, 2H), 3.85 (dd, J = 1.4 and 10.8 Hz, 1H), 3.79 (m, 
2H), 3.68 (m, 12H), 3.47 (m, 8H), 3.34 (m, 2H), 3.27 (m, 1H), 2.97 (m, 1H), 2.90 (m, 
1H), 2.80 (m, 1H), 2.77 (m, 2H), 2.73 (m, 2H), 2.66 (m, 2H), 2.26 (s, 3H), 2.15 (dd, J = 
3.7 and 4.7 Hz, 1H), 2.05 (m, 1H), 1.97 (m, 1H), 1.89 (m, 1H), 1.83 (m, 1H), 1.81 (m, 
1H), 1.58 (m, 1H), 1.37 (s, 3H), 1.28 (m, 4H), 1.08 (d, J = 6.5 Hz, 3H), 1.04 (d, J = 6.7 
Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 174.2, 170.1, 152.7, 151.3, 150.0, 148.0, 145.9, 
145.7, 138.7, 138.1, 137.7, 137.5, 134.4, 131.5, 129.1, 129.0, 128.8, 128.1, 127.4, 127.1, 
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126.8, 126.5, 125.8, 121.2, 120.8, 114.2, 104.6, 77.4, 74.3, 73.6, 70.2, 69.7, 64.3, 53.8, 
53.6, 51.7, 50.5, 50.4, 47.2, 45.0, 43.3, 42.7, 32.9, 31.2, 29.6, 28.5, 27.4, 26.5, 20.9, 
20.6, 14.2. 
HRMS (m/z): calculated for [C70H89N7O15S2 + H]: 1354.5756, found: 1354.5781. 
 
Synthesis of 321 
 
To a stirred solution of 1 (100 mg, 0.67 mmol, 1.0 eq) in dry DMF (3 mL) was added 
sodium hydride (32.2 mg, 1.34 mmol, 2.0 eq). The mixture was stirred at room 
temperature for 1 hour under nitrogen after which propargyl bromide (0.6 mL, 6.7 
mmol, 10.0 eq) was added. The reaction solution was stirred at 80 °C for 12 hours under 
nitrogen and the solvent was removed in vacuo. The residue was diluted with water (10 
mL) and then neutralized with 0.1 M HCl (15 mL). The resulting mixture was extracted 
with EtOAc (15 mL × 2) and the exract was washed with brine (20 mL)). The organic 
phase was dried over MgSO4, filtered and evaporated to dryness in vacuo. The crude 




To a stirred solution of 258 (20 mg, 0.038 mmol, 1.0 eq) and 320 (25.8 mg, 0.114 mmol, 
3. 0 eq) in DMF (4 mL) was added CuI (0.4 mg, 1.90 µmol, 0.05 eq) and DIPEA (2.4 
mg, 19.0 µmol, 0.5 eq). The mixture was stirred at room temperature for 12 hours under 
nitrogen and the solvent was removed in vacuo. The residue was dissolved in EtOAc (2 
mL) and washed with water (3 mL x 2). The organic phase was dried over MgSO4, 
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filtered and evaporated to dryness in vacuo. The residue was dissolved in MeOH and 
purified by LCMS to afford 15.4 mg of desired product (yield: 31.7%) as a brown 
solid.191 
1H NMR (500 MHz, CDCl3): δ (Hz) = 8.04 (s, 1H), 7.68 (d, J = 8.5 Hz, 2H), 7.31 (d, J 
= 8.5 Hz, 1H), 5.88 (dd, J =2.2 and 17.0 Hz, 1H), 5.75 (ddd, J =1.4, 9.7 and 15.4 Hz, 
1H), 5.56 (brs, 1H), 5.55 (brs, 1H), 5.42 (ddd, J =4.8, 10.1 and 15.4 Hz, 1H), 5.39 (brs, 
1H), 5.14 (brs, 1H), 4.77 (s, 2H), 3.88 (dd, J = 1.3 and 10.8 Hz, 1H), 3.76 (m, 1H), 3.70 
(m, 1H), 3.33 (m, 1H), 2.96 (m, 1H), 2.93 (m, 1H), 2.81 (m, 1H), 2.76 (m, 1H), 2.26 (s, 
3H), 2.16 (dd, J = 3.8 and 5.1 Hz, 1H), 2.06 (m, 1H), 1.88 (m, 1H), 1.82 (m, 1H), 1.81 
(m, 1H), 1.60 (m, 1H), 1.36 (s, 3H), 1.07 (d, J = 6.3 Hz, 3H), 1.02 (d, J = 6.7 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 174.3, 170.2, 147.9, 145.0, 138.8, 138.3, 138.2, 
136.0, 126.9, 125.7, 120.8, 120.4, 114.2, 77.3, 74.7, 70.6, 69.9, 53.6, 53.5, 51.8, 50.3, 
47.3, 45.1, 42.7, 32.8, 31.3, 28.6, 26.5, 21.0, 14.2. 
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8. Appendix  
 
8.1 NMR Data for Chapter 2 
 
 
Table 8.1 NMR data of compound 157 recorded at 500 MHz in CDCl3. 
 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H cosy 
1 - - - 204.4 - - - 
2a 2.66 d 8.5 43.6 CH2 1,3 3 
2b 3.00 d 8.5 - - - - 
3 3.99 m - 70.2 CH 1,5 2,4 
4 4.50 d 6.1 71.4 CH 3,8,7,5 2,3 
5 - - - 145.9 - - - 
6 6.87 d 6.3 116.4 CH 8,9 7 
7 7.56 t 4.2,9.6 137.3 CH 8,5,9 6,8 
8 7.07 d 6.8 119.8 CH 1,4,6,9 7 
9 - - - 161.4 - - - 

















Position δH M JH-H/Hz δC HSQC HMBC H to C H-H cosy 
1 4.54 Brs - 54.7 CH2 2, 3, 7 - 
2 - - - 125.23 - - - 
3 - - - 156.12 - - - 
4 6.71 d 7.8 114.38 CH 3, 5 - 
5 7.26 t 3.0, 7.8 128.3 CH 7 - 
6 6.88 d 7.8 116.8 CH 5, 7 - 
7 - - - 138.82 - - - 
8 6.9 d 7.3 127.9 CH 7 9 
9 6.13 dd 7.3, 15.9 133.1 CH 7, 10 8, 10 
10 3.97 t 6.4 75.5 CH 9, 11 9, 11 
11 3.86 t 6.4 75.4 CH 10, 12 10, 12 
12 5.57 m - 125.6 CH 11 11 
13 5.55 m - 132.8 CH 12 14 











Table 8.3 NMR data of compound 65a recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H cosy 
1 - - - 174.4 - - - 
2 5.58 s - - - - - 
3 3.23 ddd 4.5, 9.6, 4.6 54.0 CH 1,4,5 4,5,10 
4 2.13 dd 4.5, 4.9 50.3 CH 5,6,9,10,21 3,5 
5 2.81 m - 32.9 CH 1’,3 3,4,12 
6 - - - 147.9 - - - 
7 3.85 dd 10.7, 1.4 69.7 CH 4’,5,6,8,11,13 8,12 
8 2.94 dd 10.7, 9.8 47.3 CH 1,7,19,21 7,13 
9 - - - 51.9 - - - 
10a 2.60 dd 13.6, 9.6 44.7 CH2 1’,3,4 3,11 
10b 2.80 dd 13.6, 4.5 - - - - 
11 1.00 d 6.5 14.1 CH3 4,5,6 10 
12a 5.13 br.s - 114.1 CH2 5,6,7 5,7 
12b 5.37 br.s - - - - - 
13 5.76 ddd 9.6, 15.6, 
1.4 
127.1 CH 7,9,15,16,20 8,14 
14 5.43 ddd 5.2, 15.6, 
10.4 
138.6 CH 8,16,21 5,13 
15a 1.81 m - 42.8 CH2 13,16,19 14,22 
15b 2.08 m - - - - - 
16 1.81 m - 28.4 CH 15 - 
17a 1.58 dd 14.4, 2.9 53.8 CH2 18,19,22 - 
17b 1.89 m - - - - - 
18 - - - 74.3 - - - 
19 5.55 dd 17.2, 2.4 138.0 CH 9,20,21,23,24 21 
20 5.89 dd 17.2, 2.1 125.8 CH 8,18,19,21 19,21 
21 5.57 dd 2.1, 2.3 77.5 CH 19 - 
22 1.07 d 6.3 26.4 CH3 15,16,17 15 
23 1.37 s - 31.3 CH3 17,18,19 - 
1‘ - - - 130.3 - - - 
2’ 6’ 7.08 d 8.5 129.9 2×CH 3’,4’,10 3’,5’ 
3’ 5’ 6.87 d 8.5 114.2 2×CH 6’,4’ 2’,6’ 
4’ - - - 158.7 - - - 
24 - - - 170.0 - - - 
25 2.27 s - 20.9 CH3 21,24 21 




Table 8.4 NMR data of compound 65b recorded at 500 MHz in CDCl3. 
 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H cosy 
1 - - - 174.2 - - - 
2 5.58 s  - - - - 
3 3.23 ddd 4.5, 9.6, 
4.6 
54.2 CH 1,4 4,10 
4 2.13 dd 4.5, 4.8 50.3 CH 5,6,10,11 3,5 
5 2.81 m - 32.9 CH 6,11 4,10,11 
6 - - - 147.9 - - - 
7 3.84 dd 10.7, 1.4 69.7 CH 5,6,13 8,12 
8 2.96 dd 10.7, 9.8 47.3 CH 1,6,7,19,21 7,13 
9 - - - 51.8 - - - 
10a 2.61 dd 13.6, 9.6 44.6 CH2 1’,3,4 3,12 
10b 2.80 dd 13.6, 4.5 - - - - 
11 1.01 d 6.7 14.4 CH3 4,5,6 5 
12a 5.13 br.s - 114.1 CH2 5,6,7 7,10 
12b 5.37 br.s - - - - - 
13 5.76 ddd 9.5, 15.6, 
1.7 
127.1 CH 7,8,15,16 8,14 
14 5.42 ddd 5.2, 15.6, 
10.4 
138.7 CH 8,15,16 13,16 
15a 1.82 m - 42.7 CH2 13,14,16,17 22 
15b 2.08 m - - - - - 
16 1.81 m - 28.4 CH 15 14 
17a 1.57 dd 13.4, 2.8 53.7 CH2 15,18,19,23 19 
17b 1.89 m - - - - - 
18 - - - 74.3 - - - 
19 5.55 dd 17.3, 2.4 138.0 CH 8,9,20,21,23 17,23 
20 5.87 dd 17.3, 2.1 125.9 CH 18,21 21 
21 5.57 dd 2.1, 2.4 77.4 CH 8,9,19,20 20 
22 1.07 d 6.5 26.5 CH3 15,16,17 15 
23 1.37 s - 31.5 CH3 16,17,18,19 19 
1‘ - - - 131.5 - - - 
2’ 6’ 7.06 d 8.4 129.9 2×CH 3’,4’,10 3’,5’ 
3’ 5’ 6.85 d 8.4 114.2 2×CH 6’,4’ 2’,6’,26 
4’ - - - 160.1 - - - 
24 - - - 170.1 - - - 
25 2.27 s - 21.1 CH3 21,24 - 
26 3.81 s  - 55.3      CH3 4’ 3’,5’ 
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8.2 NMR Data for Chapter 4 
 
Table 8.5 NMR data of compound 258 recorded at 500 MHz in CDCl3. 
 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.2 - - - 
2 5.47 brs - - - - - 
3 3.22 ddd 1.1, 5.0, 9.6 53.7 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.11 dd 3.8, 5.0 50.3 CH 1, 3, 5, 6, 10,  
21 
3, 5, 10 
5 2.77 m - 32.8 CH 1’, 3 4, 11, 12 
6 - - - 147.7 - - - 
7 3.84 dd 1.4, 10.2 69.8 CH 5, 6, 8, 12, 13 8, 12 
8 2.93 t 10.2 47.3 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.6 - - - 
10a 2.65 dd 9.3, 13.6 44.9 CH2 1’, 3 3, 4, 12 
10b 2.84 dd 4.9, 13.6 - - - - 
11 0.96 d 6.7 14.1 CH3 4, 5, 6 5 
12a 5.10 brs - 114.2 CH2 5, 6, 7 5, 7, 11 
12b 5.35 brs - - - - - 
13 5.74 ddd 1.4, 9.7, 
15.5 
127.1 CH 7, 8, 15 8, 14, 15 
14 5.42 ddd 4.8, 10.2, 
15.5 
138.7 CH 9, 15 13, 15 
15a 1.82 m - 42.8 CH2 13, 14, 16, 17 13, 14,  
15b 2.04 m - - - - - 
16 1.79 m - 28.6 CH 13, 14, 17 22 
17a 1.58 dd 3.1, 14.3 53.9 CH2 18, 19 - 
17b 1.87 dd 3.2, 14.3 - - - - 
18 - - - 74.3 - - - 
19 5.56 dd 3.8, 15.2 138.1 CH - 20 
20 5.83 m - 125.8 CH 9, 18, 19 19 
21 5.55 brs - 77.3 CH 19, 20, 24 - 
22 1.05 d 6.4 26.6 CH3 15, 16, 17  16 
23 1.35 s - 31.3 CH3 17, 18, 19 - 
1‘ - - - 133.8 - - - 
2’ 6’ 7.14 d 8.4 130.4 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 6.99 d 8.4 119.1 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 138.9 - - - 
24 - - - 170.2 - - - 





Table 8.6 NMR data of compound 257 recorded at 500 MHz in CDCl3. 
 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.3 - - - 
2 5.46 brs - - - - - 
3 3.23 ddd 1.1, 4.8, 9.6 53.5 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.13 dd 3.6, 5.1 50.5 CH 1,  3, 5 3, 5, 10 
5 2.80 m - 32.7 CH 1’, 3 4, 11, 12 
6 - - - 147.9 - - - 
7 3.84 dd  1.3, 10.8 69.7 CH 5, 6, 8, 12, 13 8, 12 
8 2.95 dd 9.8, 10.8 47.2 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.7 - - - 
10a 2.63 dd 9.5, 13.5 45.2 CH2 1’, 3 3, 4, 12 
10b 2.82 dd 4.8, 13.5 - - - - 
11 0.99 d 6.7 14.0 CH3 4, 5, 6 5 
12a 5.12 brs - 114.3 CH2 5, 6, 7 5, 7, 11 
12b 5.37 brs - - - - - 
13 5.78 ddd 1.4, 9.6, 
15.5 
127.1 CH 7, 8, 15 8, 14, 15 
14 5.43 ddd 4.8, 10.3, 
15.5 
138.8 CH 9, 15 13, 15 
15a 1.82 m - 42.7 CH2 13, 14, 16, 17 13, 14,  
15b 2.05 m - - - - - 
16 1.81 m - 28.5 CH 13, 14, 17 22 
17a 1.60 m - 53.9 CH2 18, 19 - 
17b 1.89 m - - - - - 
18 - - - 74.4 - - - 
19 5.55 brs - 138.3 CH - 20 
20 5.88 dd 2.9, 16.4 126.0 CH 18, 19 19 
21 5.58 brs - 77.2 CH 8, 9, 19, 20, 23  - 
22 1.07 d 6.5 26.4 CH3 15, 16, 17  16 
23 1.37 s - 31.1 CH3 17, 18, 19 - 
1‘ - - - 131.0 - - - 
2’ 6’ 6.93 d 8.2 131.1 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.67 d 8.2 138.0 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 137.3 - - - 
24 - - - 170.2 - - - 





Table 8.7 NMR data of compound 252 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.2 - - - 
2 5.50 brs - - - - - 
3 3.24 ddd 1.1, 5.0, 9.6 53.8 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.13 dd 3.8, 5.0 50.5 CH 1, 3, 5, 6, 10,  
21 
3, 5, 10 
5 2.80 m - 32.9 CH 1’, 3 4, 11, 12 
6 - - - 147.8 - - - 
7 3.85 dd 1.6, 10.7 69.6 CH 6, 12 8, 12 
8 2.96 t 10.7 47.2 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.8 - - - 
10a 2.61 dd 9.4, 13.6 44.8 CH2 1’, 3 3, 4, 12 
10b 2.82 dd 4.9, 13.6 - - - - 
11 1.03 d 6.7 14.1 CH3 4, 5, 6 5 
12a 5.13 brs - 114.2 CH2 5, 6, 7 5, 7, 11 
12b 5.37 brs - - - - - 
13 5.76 ddd 1.4, 9.7, 
15.4 
127.1 CH 7, 8, 15 8, 14, 15 
14 5.41 ddd 4.8, 10.1, 
15.4 
138.8 CH 9, 15 13, 15 
15a 1.83 m - 42.8 CH2 13, 14, 16, 17 13, 14,  
15b 2.05 m - - - - - 
16 1.81 m - 28.5 CH 13, 14, 17 22 
17a 1.60 dd 3.0, 14.4 53.6 CH2 18, 19 - 
17b 1.82 dd 3.0, 14.4 - - - - 
18 - - - 74.4 - - - 
19 5.54 dd 2.3, 16.2 138.2 CH - 20 
20 5.89 dd 3.0, 16.2 126.0 CH 18, 19 19 
21 5.58 dd 2.6, 3.0 77.5 CH 8, 9, 19, 20, 21 
23  
- 
22 1.07 d 6.3 26.4 CH3 15, 16, 17  16 
23 1.37 s - 31.2 CH3 17, 18, 19 - 
1‘ - - - 130.4 - - - 
2’ 6’ 7.09 d 8.3 130.2 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 6.96 d 8.3 115.4 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 156.7 - - - 
24 - - - 170.2 - - - 
25 2.26 s - 20.9 CH3 21, 24 - 
7’ 4.70 d 2.4 55.9 CH2 4‘, 8‘, 9‘ 9‘ 
8’ - - - 78.5 - - - 




Table 8.8 NMR data of compound 251 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.4 - - - 
2 5.50 brs - - - - - 
3 3.23 ddd 1.1, 5.0, 9.6 54.0 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.12 dd 3.8, 5.0 50.2 CH 1, 3, 5, 6, 10,  
21 
3, 5, 10 
5 2.79 m - 33.0 CH 1’, 3 4, 11, 12 
6 - - - 147.9 - - - 
7 3.87 dd 1.6, 10.7 69.8 CH 6, 12 8, 12 
8 2.96 t 10.7 47.3 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.9 - - - 
10a 2.62 dd 9.4, 13.6 44.8 CH2 1’, 3 3, 4, 12 
10b 2.81 dd 4.9, 13.6 - - - - 
11 0.99 d 6.7 14.1 CH3 4, 5, 6 5 
12a 5.13 brs - 114.0 CH2 5, 6, 7 5, 7, 11 
12b 5.37 brs - - - - - 
13 5.75 ddd 1.4, 9.7, 
15.4 
127.1 CH 7, 8, 15 8, 14, 15 
14 5.42 ddd 4.8, 10.1, 
15.4 
138.7 CH 9, 15 13, 15 
15a 1.84 m - 42.8 CH2 13, 14, 16, 17 13, 14,  
15b 2.05 m - - - - - 
16 1.81 m - 28.6 CH 13, 14, 17 22 
17a 1.60 dd 3.0, 14.4 53.7 CH2 18, 19 - 
17b 1.89 m 3.0, 14.4 - - - - 
18 - - - 74.4 - - - 
19 5.57 dd 2.3, 16.2 138.1 CH - 20 
20 5.89 dd 3.0, 16.2 126.0 CH 18, 19 19 
21 5.57 dd 2.6, 3.0 77.4 CH 8, 9, 19, 20, 21 
23  
- 
22 1.07 d 6.3 26.6 CH3 15, 16, 17  16 
23 1.37 s - 31.2 CH3 17, 18, 19 - 
1‘ - - - 129.5 - - - 
2’ 6’ 7.07 d 8.3 130.0 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 6.88 d 8.3 115.1 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 157.7 - - - 
24 - - - 170.1 - - - 
25 2.27 s - 20.9 CH3 21, 24 - 
7’ 4.54 t 1.6 68.8 CH2 4‘, 8‘, 9‘ 8‘, 9‘ 
8’ 6.06 dddd 5.3, 10.5, 
15.8, 22.6 
133.2 CH 7‘ 7‘, 9‘ 
9a’ 5.30 dd 1.6, 3.2 117.6 CH2 7‘, 8‘ 7‘, 8‘ 
9b‘ 5.41 m - - - - - 
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8.3 NMR Data for Chapter 5 
Table 8.9 NMR data of compound 318 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.3 - - - 
2 5.48 brs - - - - 3 
3 3.29 ddd 0.9, 9.6, 
4.6 
53.4 CH - 2 
4 2.16 dd 4.6, 8.9 50.3 CH 9, 21 5 
5 2.81 m - 32.5 CH - 4, 11, 12 
6 - - - 148.1 - - - 
7 3.83 d 10.8 69.3 CH 6, 12, 13 8, 12 
8 2.95 dd 10.2, 
10.8 
46.9 CH 1, 3,  7, 13, 14 7, 13 
9 - - - 51.7 - - - 
10a 2.68 dd 13.5, 9.9 44.9 CH2 1’, 2’, 6’, 3  
10b 2.92 dd 13.5, 4.4 - - - - 
11 1.05 d 6.5 13.9 CH3 4, 5, 6 5 
12a 5.13 brs - 113.8 CH2 5, 6, 7 5, 7 
12b 5.37 brs - - - -  
13 5.75 ddd 9.7, 
15.5, 1.3 
126.7 CH  8, 9 8, 14 
14 5.41 ddd 15.5, 
4.7, 10.0 
138.4 CH - 13, 15 
15a 1.80 m - 42.5 CH2 13, 14, 16 14, 17 
15b 2.04 m - - - - - 
16 1.79 m - 28.2 CH - 17 
17a 1.56 m - 53.5 CH2 18, 19 15, 16 
17b 1.88 dd 3.0, 14.4 - - - - 
18 - - - 74.6 - - - 
19 5.57 dd 16.6, 2.4 137.8 CH 8, 9, 20 20 
20 5.89 dd 16.6, 2.7 125.6 CH 18, 21  21 
21 5.58 dd 2.5, 2.7 77.1 CH 19, 20 20 
22 1.05 d 6.5 26.2 CH3 15, 16, 17 15 
23 1.37 s - 30.8 CH3 16, 17, 18, 19 - 
1‘ - - - 129.7 - - - 
2’ 6’ 7.22 d 8.1 129.1 2 x CH 3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.51 d 8.1 127.1 2 x CH 2’, 6’, 4’ 2’, 6’ 
4’ - - - 139.6 - - - 
24 - - - 170.3 - - - 





Table 8.10 NMR data of compound 308 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.3 - - - 
3 3.29 m - 52.9 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.16 dd 3.7, 5.0 49.9 CH 1, 3, 5, 6, 10 3, 5, 10 
5 2.81 m - 32.4 CH 1’, 3 4, 11, 12 
6 - - - 147.7 - - - 
7 3.88 dd 1.3, 10.8 69.4 CH 6, 12 8, 12 
8 2.98 m - 46.8 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.6 - - - 
10a 2.74 m - 44.7 CH2 1’, 3 3, 4, 12 
10b 2.90 m - - - - - 
11 0.99 d 6.6 13.7 CH3 4, 5, 6 5 
12a 5.14 brs - 113.8 CH2 5, 6, 7 5, 7, 11 
12b 5.39 brs - - - - - 
13 5.76 ddd 1.4, 9.7, 15.4 126.7 CH 7, 8, 15 8, 14, 15 
14 5.42 ddd 4.8, 10.1, 15.4 138.4 CH 9, 15 13, 15 
15a 1.83 m - 42.3 CH2 13, 14, 16, 17 13, 14,  
15b 2.06 m - - - - - 
16 1.82 m - 28.1 CH 13, 14, 17 22 
17a 1.61 m - 53.3 CH2 18, 19 - 
17b 1.90 m - - - - - 
18 - - - 74.4 - - - 
19 5.56 brs - 137.9 CH - 20 
20 5.85 dd 2.2, 17.0 125.4 CH 18, 19 19 
21 5.58 brs - 76.8 CH 8, 9, 19, 20, 23  - 
22 1.07 d 6.4 26.1 CH3 15, 16, 17  16 
23 1.38 s - 30.8 CH3 17, 18, 19 - 
1‘ - - - 138.0 - - - 
2’ 6’ 7.27 d 8.5 130.3 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.65 d 8.5 120.6 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 136.0 - - - 
24 - - - 170.2 - - - 
25 2.28 s - 20.6 CH3 24 - 
4‘‘ - - - 146.1 - - - 
5‘‘ 7.87 s - 120.4 CH 4‘‘ - 
6‘‘ 4.90 s - 63.4 CH2 4’’, 5’’,7’’ - 
7‘‘  5.09 s - 71.1  CH2 6‘‘, 8‘‘, 17‘‘ - 
8‘‘ - - - 133.0 - - - 
9‘‘  8.18 s - 119.2 CH 8‘‘, 10‘‘ - 
10‘‘ - - - 129.1 - - - 
11‘‘ 8.00 dd 0.9, 8.3 123.2 CH 10‘‘, 13‘‘, 15‘‘ 12‘‘, 13‘‘ 
12‘‘20‘‘26‘‘ 7.56 m - 127.3 3 x CH 13‘‘, 19‘‘, 25‘‘, 16‘‘, 
22‘‘ 
11‘‘, 13‘‘ 
13‘‘19‘‘25‘‘ 8.23 dd 1.0, 7.6 120.0 3 x CH 14‘‘, 15‘‘, 23‘‘ 11‘‘, 12‘‘ 
14‘‘ - - - 128.3 - - - 
15‘‘ - - - 132.8 - - - 
16‘‘ - - - 131.1 - - - 
17‘‘ 7.72 d 8.2 127.6 CH 8‘‘, 9‘‘, 16‘‘, 18‘‘ 21‘‘ 
18‘‘ - - - 128.5 - - - 
21‘‘27‘‘ 7.52 dd 1.6, 7.8 126.2 2 x CH 19‘‘, 22‘‘ 17‘‘ 
22‘‘ - - - 134.7 - - - 
23‘‘ - - - 135.1 - - - 









Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.1 - - - 
2 5.56 brs - - - - - 
3 3.20 ddd 1.1, 4.7, 9.4 53.9 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.11 dd 4.4, 4.7 50.2 CH 1, 3, 5, 6, 10,  
21 
3, 5, 10 
5 2.80 m - 32.9 CH 1’, 3 4, 11, 12 
6 - - - 148.1 - - - 
7 3.86 dd 1.4, 10.8 69.6 CH 6, 12 8, 12 
8 2.96 dd 9.8, 10.8 47.2 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.8 - - - 
10a 2.56 dd 9.8, 13.7 44.8 CH2 1’, 3 3, 4, 12 
10b 2.75 dd 4.6, 13.7 - - - - 
11 1.02 d 6.7 14.1 CH3 4, 5, 6 5 
12a 5.13 brs - 113.9 CH2 5, 6, 7 5, 7, 11 
12b 5.37 brs - - - - - 
13 5.76 ddd 1.3, 9.6, 
15.4 
127.1 CH 7, 8, 15 8, 14, 15 
14 5.40 ddd 4.9, 10.2, 
15.4 
138.7 CH 9, 15 13, 15 
15a 1.82 m - 42.6 CH2 13, 14, 16, 17 13, 14,  
15b 2.06 m - - - - - 
16 1.81 m - 28.4 CH 13, 14, 17 22 
17a 1.58 dd 2.9, 14.3 53.8 CH2 18, 19 - 
17b 1.89 m 3.1, 14.3 - - - - 
18 - - - 74.4 - - - 
19 5.53 dd 2.3, 17.2 138.0 CH - 20 
20 5.89 dd 2.1, 17.2 126.0 CH 18, 19 19 
21 5.58 m - 77.2 CH 8, 9, 19, 20, 21 
23  
- 
22 1.06 d 6.3 26.5 CH3 15, 16, 17  16 
23 1.37 s - 31.2 CH3 17, 18, 19 - 
1‘ - - - 130.0 - - - 
2’ 6’ 6.95 d 8.3 129.8 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 6.65 d 8.3 115.3 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 145.3 - - - 
24 - - - 170.1 - - - 





Table 8.12 NMR data of compound 291 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.2 - - - 
2 5.56 brs - - - - - 
3 3.32 m - 53.3 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.17 dd 3.8, 5.0 50.2 CH 1, 3, 5, 6, 10 3, 5, 10 
5 2.80 m - 32.7 CH 1’, 3 4, 11, 12 
6 - - - 147.7 - - - 
7 3.85 dd 1.6, 10.7 69.7 CH 6, 12 8, 12 
8 2.95 m - 47.1 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.6 - - - 
10a 2.65 m - 44.9 CH2 1’, 3 3, 4, 12 
10b 2.81 m - - - - - 
11 0.99 d 6.7 13.9 CH3 4, 5, 6 5 
12a 5.13 brs - 114.2 CH2 5, 6, 7 5, 7, 11 
12b 5.37 brs - - - - - 
13 5.74 ddd 1.4, 9.7, 
15.4 
126.9 CH 7, 8, 15 8, 14, 15 
14 5.44 ddd 4.8, 10.1, 
15.4 
138.6 CH 9, 15 13, 15 
15a 1.82 m - 42.8 CH2 13, 14, 16, 17 13, 14,  
15b 2.05 m - - - - - 
16 1.79 m - 28.3 CH 13, 14, 17 22 
17a 1.58 dd 2.9, 14.4 53.9 CH2 18, 19 - 
17b 1.89 m - - - - - 
18 - - - 74.4 - - - 
19 5.58 brs 2.3, 16.2 138.1 CH - 20 
20 5.87 dd 3.0, 16.2 125.6 CH 18, 19 19 
21 5.59 brs - 77.0 CH 8, 9, 19, 20, 23  - 
22 1.06 d 6.5 26.5 CH3 15, 16, 17  16 
23 1.35 s - 31.1 CH3 17, 18, 19 - 
1‘ - - - 136.3 - - - 
2’ 6’ 7.34 d 8.5 130.3 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.78 d 8.5 120.8 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 138.1 - - - 
24 - - - 170.2 - - - 
25 2.26 s - 20.9 CH3 24 - 
4‘‘ - - - 148.5 - - - 
5‘‘ 8.18 s - 117.0 CH 4‘‘ - 
6‘‘ - - - 129.6 - - - 
7‘‘ 11‘' 7.92 dd 1.4, 8.4 125.7 2 x CH 4‘‘, 9‘‘ 8‘‘, 10‘‘ 
9‘‘ 7.40 dd 8.4, 18.6 128.5 CH 7‘‘, 11‘‘ 8‘‘, 10‘‘ 




Table 8.13 NMR data of compound 292 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.4 - - - 
2 5.56 brs - - - - - 
3 3.33 m - 53.4 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.18 dd 3.8, 5.0 50.3 CH 1, 3, 5, 6, 10 3, 5, 10 
5 2.81 m - 32.7 CH 1’, 3 4, 11, 12 
6 - - - 147.6 - - - 
7 3.88 dd 1.6, 10.7 69.9 CH 6, 12 8, 12 
8 2.95 m - 47.2 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.7 - - - 
10a 2.80 m - 44.9 CH2 1’, 3 3, 4, 12 
10b 2.97 m - - - - - 
11 1.02 d 6.7 14.1 CH3 4, 5, 6 5 
12a 5.15 brs - 114.3 CH2 5, 6, 7 5, 7, 11 
12b 5.39 brs - - - - - 
13 5.76 ddd 1.4, 9.7, 
15.4 
127.0 CH 7, 8, 15 8, 14, 15 
14 5.41 ddd 4.8, 10.1, 
15.4 
138.7 CH 9, 15 13, 15 
15a 1.83 m - 42.7 CH2 13, 14, 16, 17 13, 14,  
15b 2.06 m - - - - - 
16 1.81 m - 28.5 CH 13, 14, 17 22 
17a 1.61 dd 2.9, 14.4 53.7 CH2 18, 19 - 
17b 1.89 dd 3.0, 14.4 - - - - 
18 - - - 74.4 - - - 
19 5.58 brs - 138.3 CH - 20 
20 5.88 dd 3.0, 16.2 125.7 CH 18, 19 19 
21 5.58 brs - 77.1 CH 8, 9, 19, 20, 23  - 
22 1.07 d 6.5 26.5 CH3 15, 16, 17  16 
23 1.35 s - 31.2 CH3 17, 18, 19 - 
1‘ - - - 136.1 - - - 
2’ 6’ 7.38 d 8.5 130.5 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.78 d 8.5 121.0 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 120.9 - - - 
24 - - - 170.2 - - - 
25 2.28 s - 20.9 CH3 24 - 
4‘‘ - - - 147.5 - - - 
5‘‘ 8.20 s - 117.4 CH 4‘‘ - 
6‘‘ - - - 129.1 - - - 
7‘‘ 11‘' 7.82 dd 1.4, 8.4 127.4 2 x CH 4‘‘, 9‘‘ 8‘‘, 10‘‘ 





Table 8.14 NMR data of compound 290 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.3 - - - 
2 5.56 brs - - - - - 
3 3.31 m - 53.5 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.18 dd 3.8, 5.0 50.2 CH 1, 3, 5, 6, 10 3, 5, 10 
5 2.80 m - 32.7 CH 1’, 3 4, 11, 12 
6 - - - 147.7 - - - 
7 3.87 dd 1.3, 10.8 70.0 CH 6, 12 8, 12 
8 2.96 m - 47.3 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.7 - - - 
10a 2.77 m - 45.1 CH2 1’, 3 3, 4, 12 
10b 2.95 m - - - - - 
11 1.00 d 6.7 14.1 CH3 4, 5, 6 5 
12a 5.14 brs - 114.4 CH2 5, 6, 7 5, 7, 11 
12b 5.38 brs - - - - - 
13 5.78 ddd 1.4, 9.7, 
15.4 
127.0 CH 7, 8, 15 8, 14, 15 
14 5.43 ddd 4.8, 10.1, 
15.4 
138.8 CH 9, 15 13, 15 
15a 1.83 m - 42.7 CH2 13, 14, 16, 17 13, 14,  
15b 2.06 m - - - - - 
16 1.81 m - 28.6 CH 13, 14, 17 22 
17a 1.61 m - 53.8 CH2 18, 19 - 
17b 1.92 dd 3.0, 14.4 - - - - 
18 - - - 74.3 - - - 
19 5.59 brs - 138.2 CH - 20 
20 5.85 dd 3.0, 16.2 125.9 CH 18, 19 19 
21 5.58 brs - 77.2 CH 8, 9, 19, 20, 23  - 
22 1.07 d 6.5 26.6 CH3 15, 16, 17  16 
23 1.37 s - 31.2 CH3 17, 18, 19 - 
1‘ - - - 137.8 - - - 
2’ 6’ 7.33 d 8.5 130.4 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.70 d 8.5 120.8 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 120.9 - - - 
24 - - - 170.2 - - - 
25 2.28 s - 21.0 CH3 24 - 
4‘‘ - - - 144.2 - - - 
5‘‘ 7.73 s - 118.9 CH 4‘‘ - 






Table 8.15 NMR data of compound 310 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.3 - - - 
3 3.31 m - 53.3 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.17 dd 3.7, 5.0 50.1 CH 1, 3, 5, 6, 10 3, 5, 10 
5 2.79 m - 32.7 CH 1’, 3 4, 11, 12 
6 - - - 148.9 - - - 
7 3.86 dd 1.3, 10.8 69.8 CH 6, 12 8, 12 
8 2.96 m - 47.2 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.6 - - - 
10a 2.77 m - 45.0 CH2 1’, 3 3, 4, 12 
10b 2.90 m - - - - - 
11 0.94 d 6.6 14.0 CH3 4, 5, 6 5 
12a 5.13 brs - 114.2 CH2 5, 6, 7 5, 7, 11 
12b 5.37 brs - - - - - 
13 5.76 ddd 1.4, 9.7, 15.4 127.1 CH 7, 8, 15 8, 14, 15 
14 5.41 ddd 4.8, 10.1, 15.4 138.6 CH 9, 15 13, 15 
15a 1.82 m - 42.7 CH2 13, 14, 16, 17 13, 14,  
15b 2.05 m - - - - - 
16 1.81 m - 28.4 CH 13, 14, 17 22 
17a 1.58 m - 53.8 CH2 18, 19 - 
17b 1.88 m - - - - - 
18 - - - 74.4 - - - 
19 5.59 brs - 138.2 CH - 20 
20 5.85 dd 2.2, 17.0 125.8 CH 18, 19 19 
21 5.56 brs - 77.2 CH 8, 9, 19, 20, 23  - 
22 1.07 d 6.4 26.5 CH3 15, 16, 17  16 
23 1.37 s - 31.2 CH3 17, 18, 19 - 
1‘ - - - 138.0 - - - 
2’ 6’ 7.33 d 8.5 130.3 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.73 d 8.5 121.0 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 136.0 - - - 
24 - - - 170.2 - - - 
25 2.27 s - 20.9 CH3 24 - 
4‘‘ - - - 144.2 - - - 
5‘‘ 8.27 s - 122.1 CH 4‘‘ - 
6‘‘ 5.53 s - 58.0 CH2 4’’, 5’’,7’’ - 
7‘‘  - - - 164.0  - - - 
8‘‘ - - - 106.1 - - - 
9‘‘  - - - 158.7 - - - 
10‘‘ - - - 153.6 - - - 
11‘‘ - - - 107.3 - -  
12‘‘ 8.38 m - 149.6 CH 7‘‘, 8‘‘, 9‘‘, 10‘‘, 13‘‘,  - 
13‘‘ 6.94 s - 127.0 CH 10‘‘, 11‘‘, 12‘‘, 22‘‘ - 
14‘‘ - - - 119.4 - - - 
15‘‘ - - - 149.0 - - - 
16‘‘ - - - 105.8 - - - 
17‘‘ 2.89 d 8.2 20.0 CH2 10‘‘, 15‘‘, 16‘‘, 18‘‘, 
19‘‘   
18‘‘ 
18‘‘21‘‘ 1.98 m - 20.4 2 x CH2 17’’, 19’’, 16’’, 22’’ 17’’, 20’’, 22’’ 
19‘‘20‘‘ 3.35 m - 49.8 2 x CH2 15‘‘, 18‘‘, 22‘‘ 21‘‘ 






Table 8.16 NMR data of compound 298 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.8 - - - 
3 3.33 m - 53.7 CH 1‘, 4, 5 4, 5, 10 
4 2.15 t 4.3 50.5 CH   3, 5 3, 5, 10 
5 2.82 m - 32.9 CH 1’, 3 4, 11, 12 
6 - - - 147.9 - - - 
7 3.86 d  10.8 69.6 CH 5, 6, 8, 12, 13 8, 12 
8 2.97 m - 47.2 CH 1, 7, 9, 13, 21 7, 13 
9 - - - 51.9 - - - 
10a 2.74 m - 45.1 CH2 1’, 3 3, 4, 12 
10b 2.94 dd 4.8, 13.5 - - - - 
11 1.07 d 6.7 14.4 CH3 4, 5, 6 5 
12a 5.15 brs - 114.2 CH2 5, 6, 7 5, 7, 11 
12b 5.39 brs - - - - - 
13 5.74 ddd 1.4, 9.6, 15.5 127.0 CH 7, 8, 15 8, 14, 15 
14 5.42 ddd 4.8, 10.3, 15.5 138.8 CH 9, 15 13, 15 
15a 1.82 m - 42.8 CH2 13, 14, 16, 17 13, 14,  
15b 2.06 m - - - - - 
16 1.82 m - 28.5 CH 13, 14, 17 22 
17a 1.61 m - 53.8 CH2 18, 19 - 
17b 1.91 m - - - - - 
18 - - - 74.3 - - - 
19 5.58 brs - 138.2 CH - 20 
20 5.88 dd 2.7, 16.5 125.9 CH 18, 19 19 
21 5.52 brs - 77.4 CH 8, 9, 19, 20, 23  - 
22 1.06 d 6.5 26.5 CH3 15, 16, 17  16 
23 1.35 s - 31.2 CH3 17, 18, 19 - 
1‘ - - - 130.6 - - - 
2’ 6’ 7.33 d 8.2 130.6 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.75 d 8.2 120.9 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 138.2 - - - 
24 - - - 170.2 - - - 
25 2.27 s - 21.0 CH3 21, 24 - 
4’’ - - - 145.1 - - - 
5’’ 8.16 s - 119.6 CH 4‘‘ - 
6‘‘ 5.34 s - 25.5 CH2 4‘‘, 5‘‘, 7‘‘ 7‘‘ 
8‘‘ - - - 173.5 - - - 
9‘‘ 2.43 t 6.9 33.6 CH2 8‘‘, 10‘‘ 10‘‘, 12‘‘ 
10‘‘ 1.67 m - 28.3 CH2 8‘‘, 9‘‘, 11‘‘, 12‘‘, 
13‘‘ 
9‘‘, 11‘‘ 
11‘‘ 1.48 m - 28.1 CH2 9‘‘, 10‘‘,12‘‘, 13‘‘ 10‘‘ 
12‘‘ 1.73 m - 24.6 CH2 11‘‘, 13‘‘, 14‘‘,  9‘‘ 
13‘‘ 3.15 m - 55.3 CH 11‘‘, 14‘‘ 14‘‘ 
14‘‘ 4.25 dd 4.4, 7.8 61.6 CH 16‘‘ 13‘‘, 18‘‘ 
16‘‘ - - - 163.3 - - - 
18‘‘ 4.48 m - 60.1 CH 13‘‘, 16‘‘ 14‘‘, 19‘‘ 
19a‘‘ 2.69 m - 40.6 CH2 13‘‘, 18‘‘ 18‘‘ 






Table 8.17 NMR data of compound 299 recorded at 500 MHz in CDCl3. 
 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 175.2 - - - 
3 3.33 m - 53.9 CH 1‘, 4, 5 4, 5, 10 
4 2.13 m - 50.4 CH   3, 5 3, 5, 10 
5 2.83 m - 32.9 CH 1’, 3 4, 11, 12 
6 - - - 147.7 - - - 
7 3.87 dd  1.7, 11.0 69.5 CH 5, 6, 8, 12, 13 8, 12 
8 2.97 dd 5.0, 11.0 47.1 CH 1, 7, 9, 13, 21 7, 13 
9 - - - 52.4 - - - 
10a 2.73 dd 1.1, 12.9 45.1 CH2 1’, 3 3, 4, 12 
10b 2.93 dd 5.0, 12.9 - - - - 
11 1.10 d 6.7 14.3 CH3 4, 5, 6 5 
12a 5.15 brs - 114.1 CH2 5, 6, 7 5, 7, 11 
12b 5.40 brs - - - - - 
13 5.74 m - 126.8 CH 7, 8, 15 8, 14, 15 
14 5.44 m - 138.8 CH 9, 15 13, 15 
15a 1.80 m - 42.7 CH2 13, 14, 16, 17 13, 14,  
15b 2.06 m - - - - - 
16 1.80 m - 28.6 CH 13, 14, 17 22 
17a 1.61 m - 53.6 CH2 18, 19 - 
17b 1.88 m - - - - - 
18 - - - 74.2 - - - 
19 5.55 brs - 138.2 CH - 20 
20 5.87 dd 2.9, 16.4 125.7 CH 18, 19 19 
21 5.49 brs - 77.3 CH 8, 9, 19, 20, 23  - 
22 1.07 d 6.5 26.5 CH3 15, 16, 17  16 
23 1.35 s - 31.2 CH3 17, 18, 19 - 
1‘ - - - 130.7 - - - 
2’ 6’ 7.34 d 8.2 130.6 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.74 d 8.2 120.6 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 137.9 - - - 
24 - - - 170.1 - - - 
25 2.26 s - 20.9 CH3 21, 24 - 
4’’ - - - 145.1 - - - 
5’’ 7.93 s - 119.6 CH 4‘‘ - 
6‘‘ 3.18 m - 25.6 CH2 4‘‘, 5‘‘, 7‘‘ 7‘‘ 
7‘‘ 4.21 m - 61.7 CH2 6‘‘, 8‘‘ 6‘‘ 
8‘‘ - - - 173.4 - - - 
9‘‘ 2.39 m - 33.7 CH2 8‘‘, 10‘‘ 10‘‘, 12‘‘ 
10‘‘ 1.71 m - 28.2 CH2 8‘‘, 9‘‘, 11‘‘, 12‘‘, 
13‘‘ 
9‘‘, 11‘‘ 
11‘‘ 1.46 m - 28.1 CH2 9‘‘, 10‘‘,12‘‘, 13‘‘ 10‘‘ 
12‘‘ 1.69 m - 24.6 CH2 11‘‘, 13‘‘, 14‘‘,  9‘‘ 
13‘‘ 3.16 m - 55.2 CH 11‘‘, 14‘‘ 14‘‘ 
14‘‘ 4.34 m - 61.8 CH 16‘‘ 13‘‘, 18‘‘ 
16‘‘ - - - 163.2 - - - 
18‘‘ 4.53 m - 60.0 CH 13‘‘, 16‘‘ 14‘‘, 19‘‘ 
19a‘‘ 2.72 m - 40.5 CH2 13‘‘, 18‘‘ 18‘‘ 





Table 8.18 NMR data of compound 300 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 175.2 - - - 
3 3.33 ddd 0.9, 4.8, 9.6 53.7 CH 1‘, 4, 5 4, 5, 10 
4 2.15 m - 50.2 CH   3, 5 3, 5, 10 
5 2.81 m - 32.8 CH 1’, 3 4, 11, 12 
6 - - - 147.7 - - - 
7 3.88 dd  1.5, 10.8 69.7 CH 5, 6, 8, 12, 13 8, 12 
8 2.94 m - 47.2 CH 1, 7, 9, 13, 21 7, 13 
9 - - - 52.4 - - - 
10a 2.75 m - 45.0 CH2 1’, 3 3, 4, 12 
10b 2.93 m - - - - - 
11 1.04 d 6.6 14.2 CH3 4, 5, 6 5 
12a 5.14 brs - 114.2 CH2 5, 6, 7 5, 7, 11 
12b 5.39 brs - - - - - 
13 5.74 ddd 1.4, 9.6, 15.5 127.1 CH 7, 8, 15 8, 14, 15 
14 5.45 ddd 4.8, 10.3, 15.5 138.7 CH 9, 15 13, 15 
15a 1.82 m - 42.6 CH2 13, 14, 16, 17 13, 14,  
15b 2.06 m - - - - - 
16 1.80 m - 28.4 CH 13, 14, 17 22 
17a 1.61 m - 53.7 CH2 18, 19 - 
17b 1.91 m - - - - - 
18 - - - 74.2 - - - 
19 5.54 brs - 138.2 CH - 20 
20 5.84 dd 2.7, 16.5 125.8 CH 18, 19 19 
21 5.52 brs - 77.2 CH 8, 9, 19, 20, 23  - 
22 1.06 d 6.5 26.2 CH3 15, 16, 17  16 
23 1.36 s - 31.3 CH3 17, 18, 19 - 
1‘ - - - 130.7 - - - 
2’ 6’ 7.33 d 8.2 130.4 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.72 d 8.2 120.8 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 137.9 - - - 
24 - - - 170.1 - - - 
25 2.27 s - 21.0 CH3 21, 24 - 
4’’ - - - 147.6 - - - 
5’’ 7.83 s - 119.1 CH 4‘‘ - 
6‘‘ 2.13 m - 28.1 CH2 4‘‘, 5‘‘, 7‘‘ 7‘‘ 
7‘‘ 1.89 m - 27.6 CH2 6‘‘, 8‘‘ 6‘‘ 
8‘‘ 4.18 m - 63.1 CH2 - - 
9‘‘ - - - 173.6 - - - 
10‘‘ 2.37 m - 33.8 CH2 8‘‘, 10‘‘ 9‘‘, 11‘‘ 
11‘‘ 1.70 m - 28.2 CH2 8‘‘, 9‘‘, 11‘‘,12‘‘, 
13‘‘ 
10‘‘ 
12‘‘ 1.48 m - 28.2 CH2 9‘‘, 10‘‘, 12‘‘, 13‘‘ 9‘‘ 
13‘‘ 1.69 m - 24.7 CH 11‘‘, 13‘‘, 14‘‘ 14‘‘ 
14‘‘ 3.19 m - 55.2 CH 11‘‘ 13‘‘, 15‘‘, 18‘‘ 
15‘‘ 4.33 m - 61.7 CH 14‘‘, 17‘‘, 20‘‘ 14‘‘, 19‘‘ 
17‘‘ - - - 163.3 - - - 
19‘‘ 4.52 m - 60.0 CH 13‘‘, 16‘‘ 15‘‘, 20‘‘ 
20a‘‘ 2.74 m - 40.6 CH2 13‘‘, 18‘‘ 18‘‘ 





Table 8.19 NMR data of compound 304 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.6 - - - 
3 3.33 m - 53.2 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.17 m - 49.9 CH 1, 3, 5, 6, 10 3, 5, 10 
5 2.85 m - 32.6 CH 1’, 3 4, 11, 12 
6 - - - 147.5 - - - 
7 3.88 d 10.6 69.7 CH 6, 12 8, 12 
8 2.96 m - 47.0 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.9 - - - 
10a 2.74 m - 44.7 CH2 1’, 3 3, 4, 12 
10b 2.90 m - - - - - 
11 0.98 d 6.6 13.8 CH3 4, 5, 6 5 
12a 5.14 brs - 114.3 CH2 5, 6, 7 5, 7, 11 
12b 5.39 brs - - - - - 
13 5.75 m - 127.1 CH 7, 8, 15 8, 14, 15 
14 5.43 m - 138.9 CH 9, 15 13, 15 
15a 1.82 m - 42.6 CH2 13, 14, 16, 17 13, 14,  
15b 2.08 m - - - - - 
16 1.82 m - 28.2 CH 13, 14, 17 22 
17a 1.61 m - 53.5 CH2 18, 19 - 
17b 1.91 m - - - - - 
18 - - - 74.1 - - - 
19 5.55 brs - 138.4 CH - 20 
20 5.86 dd 2.6, 16.5 125.8 CH 18, 19 19 
21 5.52 brs - 77.1 CH 8, 9, 19, 20, 23  - 
22 1.07 d 6.4 26.3 CH3 15, 16, 17  16 
23 1.38 s - 31.4 CH3 17, 18, 19 - 
1‘ - - - 129.5 - - - 
2’ 6’ 7.34 d 8.5 127.8 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.72 d 8.5 121.1 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 135.7 - - - 
24 - - - 170.2 - - - 
25 2.26 s - 21.1 CH3 24 - 
4‘‘ - - - 142.4 - - - 
5‘‘ 8.07 s - 122.2 CH 4‘‘ - 
6‘‘ 5.39 s - 58.1 CH2 4’’, 5’’,7’’ - 
7‘‘  - - - 173.4 - - - 
8‘‘ 4.42 s - 70.1 CH 7‘‘, 9‘‘, 10‘‘, 11‘‘, 13‘‘,  - 
9‘‘  - - - 64.7 - - - 
10‘‘11‘‘ 1.50 s - 26.9 2 x CH3 8‘‘, 9‘‘ - 
13‘‘ 5.54 d 4.2 67.9 CH 15‘‘, 16‘‘ 16‘‘ 
15‘‘ - - - 173.5 - - - 
16‘‘ 5.69 dd 4.2, 9.1 58.5 CH 13‘‘, 15‘‘, 18‘‘ 13‘‘ 
18‘‘ - - - 170.3 - - - 
19‘‘ 3.66 s - 43.4 CH2 18‘‘, 20‘‘, 21‘‘, 25‘‘ - 
20‘‘ - - - 133.8 - - - 
21‘‘25‘‘ 7.30 m - 129.6 2 x CH 22‘‘ 24‘‘ 22‘‘ 24‘‘ 
22‘‘ 24‘‘ 7.39 m - 129.2 2 x CH 21‘‘25‘‘ 21‘‘25‘‘ 







Table 8.20 NMR data of compound 302 recorded at 500 MHz in CDCl3. 
 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.6 - - - 
3 3.24 m - 54.0 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.10 m - 50.2 CH 1, 3, 5, 6, 10 3, 5, 10 
5 2.79 m - 33.0 CH 1’, 3 4, 11, 12 
6 - - - 150.0 - - - 
7 3.84 dd 1.3, 10.8 69.8 CH 6, 12 8, 12 
8 2.96 m - 47.2 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.9 - - - 
10a 2.61 m - 44.5 CH2 1’, 3 3, 4, 12 
10b 2.80 m - - - - - 
11 1.00 d 6.7 14.3 CH3 4, 5, 6 5 
12a 5.12 brs - 114.0 CH2 5, 6, 7 5, 7, 11 
12b 5.37 brs - - - - - 
13 5.74 ddd 1.3, 9.7, 15.3 127.2 CH 7, 8, 15 8, 14, 15 
14 5.41 ddd 5.1, 10.4, 15.3 138.5 CH 9, 15 13, 15 
15a 1.81 m - 43.0 CH2 13, 14, 16, 17 13, 14,  
15b 2.07 m - - - - - 
16 1.82 m - 28.6 CH 13, 14, 17 22 
17a 1.61 m - 53.9 CH2 18, 19 - 
17b 1.90 m - - - - - 
18 - - - 74.3 - - - 
19 5.56 brs - 138.2 CH - 20 
20 5.88 dd 2.6, 16.6 126.0 CH 18, 19 19 
21 5.49 brs - 77.6 CH 8, 9, 19, 20, 23  - 
22 1.06 d 6.4 26.7 CH3 15, 16, 17  16 
23 1.38 s - 31.2 CH3 17, 18, 19 - 
1‘ - - - 130.1 - - - 
2’ 6’ 7.10 d 8.5 130.3 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 6.97 d 8.5 115.2 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 157.3 - - - 
24 - - - 170.1 - - - 
25 2.26 s - 20.9 CH3 24 - 
1‘‘ 5.21 s - 62.1 - 2’’, 3’’, 4’ 3’’ 
2‘‘ - - - 143.9 - - - 
3‘‘ 7.86 s - 124.0 CH 2‘‘ 1‘‘, 4‘‘ 
4‘‘ 4.58 dd 4.5, 5.6 50.3 CH2 5‘‘ 3‘‘, 5‘‘ 
5‘‘ 3.91 dd 4.5, 5.5 69.4 CH2 4‘‘, 6‘‘ 4‘‘ 
6‘‘9‘‘ 3.58 m - 70.2 CH2 7’’, 8’’ - 
7‘‘ 8‘‘ 3.62 m - 70.4 CH2 6’’, 9’’ - 
10‘‘ 3.54 m - 69.9 CH2 9’’, 11’’ 11’’ 
11‘‘ 3.42 dd 5.3, 10.5 39.2 CH2 10‘‘, 13‘‘ 10‘‘ 
12‘‘ 6.56 t 5.6 - - - - 
13‘‘ - - - 173.1 - - - 
14‘‘ 2.19 m - 35.8 CH2 13’’, 15’’, 16’’ 15’’ 
15‘‘ 1.68 m  25.7 CH2 13‘‘, 14‘‘, 16‘‘ 14‘‘, 16‘‘ 
16‘‘ 1.47 m - 28.4 CH2 14’’, 15’’, 17’’, 18’’ 15’’ 
17‘‘ 1.69 m - 28.2 CH2 18‘‘, 19‘‘ - 
18‘‘ 3.16 m - 55.4 CH 17’’ - 
19‘‘ 4.32 m - 61.8 CH 18‘‘, 21‘‘, 23‘‘, 24‘‘ 23‘‘ 
21‘‘ - - - 163.6 - - - 
22‘‘ - - - - - - - 
23‘‘ 4.50 m - 60.1 CH 18‘‘, 19‘‘, 21‘‘, 23‘‘ 19‘‘, 24‘‘ 
24a‘‘ 2.74 m - 40.5 CH2 18‘‘, 19‘‘ 23‘‘ 




Table 8.21 NMR data of compound 319 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.3 - - - 
3 3.25 m - 53.8 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.16 dd 3.9, 5.1 50.4 CH 1, 3, 5, 6, 10 3, 5, 10 
5 2.80 m - 32.8 CH 1’, 3 4, 11, 12 
6 - - - 147.9 - - - 
7 3.86 dd 2.2, 11.8 69.6 CH 6, 12 8, 12 
8 2.96 m - 47.3 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.8 - - - 
10a 2.79 m - 44.9 CH2 1’, 3 3, 4, 12 
10b 2.96 m - - - - - 
11 1.01 d 6.6 14.2 CH3 4, 5, 6 5 
12a 5.14 brs - 114.2 CH2 5, 6, 7 5, 7, 11 
12b 5.38 brs - - - - - 
13 5.75 m - 127.9 CH 7, 8, 15 8, 14, 15 
14 5.42 m - 138.8 CH 9, 15 13, 15 
15a 1.82 m - 42.7 CH2 13, 14, 16, 17 13, 14,  
15b 2.05 m - - - - - 
16 1.81 m - 28.6 CH 13, 14, 17 22 
17a 1.58 m - 53.7 CH2 18, 19 - 
17b 1.91 m - - - - - 
18 - - - 74.7 - - - 
19 5.56 brs - 138.2 CH - 20 
20 5.86 m - 125.8 CH 18, 19 19 
21 5.52 brs - 77.5 CH 8, 9, 19, 20, 23  - 
22 1.07 d 6.4 26.5 CH3 15, 16, 17  16 
23 1.36 s - 31.3 CH3 17, 18, 19 - 
1‘ - - - 138.3 - - - 
2’ 6’ 7.34 d 8.5 130.4 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.71 d 8.5 121.0 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 136.0 - - - 
24 - - - 170.2 - - - 
25 2.26 s - 21.0 CH3 24 - 
4‘‘ - - - 145.0 - - - 
5‘‘ 8.08 s - 120.5 CH 4‘‘ - 
6‘‘ 5.30 s - 62.0 CH2 4’’, 5’’,7’’ - 
7‘‘  - - - 157.3  CH2 6‘‘, 8‘‘, 17‘‘ - 
8‘‘12‘‘ 7.00 d 8.6 115.2 2 x CH 7’’, 9’’, 11’’ 9’’, 11’’ 
9‘‘ 11‘‘ 7.10 d 8.6 130.2 2 x CH 8‘‘, 10‘‘ 8’’, 12’’ 






Table 8.22 NMR data of compound 322 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.2 - - - 
3 3.24 ddd 1.1, 4.4, 9.1 53.3 CH 1‘, 4, 5 4, 5, 10 
4 2.13 t 4.4 50.6 CH   3, 5 3, 5, 10 
5 2.78 m - 32.7 CH 1’, 3 4, 11, 12 
6 - - - 147.9 - - - 
7 3.85 d   10.2 69.6 CH 5, 6, 8, 12, 13 8, 12 
8 2.95 t   10.2 47.2 CH 1, 7, 9, 13, 21 7, 13 
9 - - - 51.7 - - - 
10a 2.67 dd 9.5, 13.5 45.6 CH2 1’, 3 3, 4, 12 
10b 2.82 dd 4.8, 13.5 - - - - 
11 0.98 d 6.7 14.1 CH3 4, 5, 6 5 
12a 5.12 brs - 114.2 CH2 5, 6, 7 5, 7, 11 
12b 5.37 brs - - - - - 
13 5.76 ddd 1.4, 9.6, 
15.5 
126.9 CH 7, 8, 15 8, 14, 15 
14 5.42 ddd 4.8, 10.3, 
15.5 
138.4 CH 9, 15 13, 15 
15a 1.82 m - 42.7 CH2 13, 14, 16, 17 13, 14,  
15b 2.05 m - - - - - 
16 1.80 m - 28.7 CH 13, 14, 17 22 
17a 1.57 m - 53.7 CH2 18, 19 - 
17b 1.91 m - - - - - 
18 - - - 74.4 - - - 
19 5.54 brs - 138.0 CH - 20 
20 5.90 dd 2.9, 16.4 126.0 CH 18, 19 19 
21 5.60 brs - 77.5 CH 8, 9, 19, 20, 23  - 
22 1.06 d 6.5 26.1 CH3 15, 16, 17  16 
23 1.37 s - 31.2 CH3 17, 18, 19 - 
1‘ - - - 132.0 - - - 
2’ 6’ 7.09 d 8.2 128.8 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.36 d 8.2 131.9 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 122.9 - - - 
24 - - - 170.2 - - - 
25 2.27 s - 20.9 CH3 21, 24 - 
7’ - - - 86.2 - - - 
8’ - - - 79.2 - - - 




Table 8.23 NMR data of compound 312 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.5 - - - 
2 5.56 brs - - - - - 
3 3.35 m - 53.3 CH - 4, 5, 10 
4 2.17 dd 3.8, 5.0 50.3 CH 1, 3, 5, 6, 10 3, 5, 10 
5 2.81 m - 32.9 CH 1’, 3 4, 11, 12 
6 - - - 147.8 - - - 
7 3.86 dd 1.6, 10.7 69.7 CH 6, 12 8, 12 
8 2.96 m - 47.3 CH 1, 7, 9, 13, 20, 21 7, 13 
9 - - - 51.8 - - - 
10a 2.78 m - 44.9 CH2 1’, 3 3, 4, 12 
10b 2.98 m - - - - - 
11 1.03 d 6.7 14.3 CH3 4, 5, 6 5 
12a 5.14 brs - 114.3 CH2 5, 6, 7 5, 7, 11 
12b 5.39 brs - - - - - 
13 5.74 m - 126.9 CH 7, 8, 15 8, 14, 15 
14 5.43 m - 138.8 CH 9, 15 13, 15 
15a 1.82 m - 42.8 CH2 13, 14, 16, 17 13, 14,  
15b 2.06 m - - - - - 
16 1.81 m - 28.4 CH 13, 14, 17 22 
17a 1.60 m - 53.9 CH2 18, 19 - 
17b 1.88 m - - - - - 
18 - - - 74.4 - - - 
19 5.57 brs - 138.2 CH - 20 
20 5.85 dd 3.0, 16.2 125.7 CH 18, 19 19 
21 5.46 brs - 77.2 CH 8, 9, 19, 20, 23  - 
22 1.07 d 6.5 26.5 CH3 15, 16, 17  16 
23 1.37 s - 31.2 CH3 17, 18, 19 - 
1‘ - - - 130.7 - - - 
2’ 6’ 7.35 d 8.5 130.6 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.69 d 8.5 121.2 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 135.6 - - - 
24 - - - 170.1 - - - 
25 2.26 s - 21.0 CH3 24 - 
4‘‘ - - - 144.2 - - - 
5‘‘ 8.04 s - 119.9 CH 4‘‘ - 
6‘‘ 4.93 s - 39.4 CH2 - - 
8‘‘ - - - 143.1 - - - 
9‘‘ 6.44 d 8.6 99.7 CH 11‘‘, 12‘‘ 10‘‘ 
10‘‘ 8.54 d 8.5 135.9 CH 11‘‘, 13‘‘  9‘‘ 
11‘‘ - - - 125.2 - - - 
12‘‘ - - - 144.3 - - - 








Table 8.24 NMR data of compound 314 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.6 - - - 
3 3.15 m - 53.0 CH  1 10 
4 1.97 dd 3.7, 5.0 48.3 CH  3, 5 5 
5 2.51 m - 32.2 CH 1’, 3 4 
6 - - - 146.1 - - - 
7 3.63 dd 1.3, 10.8 71.0 CH - 8 
8 2.74 m - 46.6 CH - 7 
9 - - - 52.4 - - - 
10a 2.66 m - 43.8 CH2 1’, 3 3 
10b 2.85 m - - - - - 
11 0.48 d 6.6 13.7 CH3 4, 5, 6 5 
12a 4.84 brs - 111.8 CH2 5, 6, 7  7 
12b 5.06 brs - - - - - 
13 5.54 ddd 1.4, 9.7, 15.4 129.2 CH 7, 8, 15 8 
14 5.09 ddd 4.8, 10.1, 15.4 134.9 CH 9, 15 13, 15 
15a 1.62 m - 43.5 CH2 114, 16, 13, 14,  
15b 1.90 m - - - - - 
16 1.69 m - 28.2 CH 13, 14, 17 22 
17a 1.39 m - 54.3 CH2 18, 19 - 
17b 1.60 m - - - - - 
18 - - - 72.7 - - - 
19 5.39 brs - 138.4 CH - 20 
20 5.68 dd 2.2, 17.0 125.8 CH 18, 19 19 
21 5.29 brs - 77.0 CH 19, 20  - 
22 0.95 d 6.4 26.7 CH3 15, 16, 17  16 
23 1.14 s - 31.4 CH3 17, 18, 19 - 
1‘ - - - 138.3 - - - 
2’ 6’ 7.35 d 8.5 131.3 2 x CH  3’, 4’, 5’ 3’, 5’ 
3’ 5’ 7.84 d 8.5 120.0 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 135.6 - - - 
24 - - - 170.6 - - - 
25 2.24 s - 21.1 CH3 24 - 
4‘‘ - - - 146.0 - - - 
5‘‘ 8.65 s - 121.0 CH 4‘‘ - 
6‘‘ 4.54 s - 35.6 CH2 4’’, 5’’,7’’ - 
7‘‘  - - - 168.7  - - - 
8‘‘ - - - 140.4 - - - 
9‘‘  8.05 d 7.7 125.3 CH 8’’ 10’’ 
10‘‘ 8.19 d 7.7 129.6 CH 9’’, 11’’, 12’’ 9’’ 
11‘‘ - - - 130.3 - - - 
12‘‘ - - - 165.5 - -  - 
13‘‘ - - - 138.3 - - - 
14‘‘ 7.71 s - 123.1 CH 12’’, 15’’ - 
15‘‘ - - - 129.3 - - - 
16‘‘ - - - 130.0 - - - 
17‘‘ 5.68 dd 8.8, 15.5 138.3 CH - - 
18‘‘ 6.47 d 8.8 114.1 CH 19‘‘, 20‘‘ - 
19‘‘, 24‘‘ - - - 114.7 2 x CH - - 
20‘‘ - - - 105.2 - - - 
21‘‘ - - - 151.2 - - - 
22‘‘ - - - 149.4 - - - 
23‘‘ - - - 114.6 - - - 
25‘‘ 6.36 d 8.8 129.5 CH 22‘‘ - 
26‘‘ 5.06 m - 134.9 2 x CH - - 




Table 8.25 NMR data of compound 316 recorded at 500 MHz in CDCl3. 
 
Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.2 - - - 
3 3.27 m - 53.6 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.15 dd 3.7, 4.7 50.4 CH 1, 3, 5, 6, 10 3, 5, 10 
5 2.80 m - 32.9 CH 1’, 3 4, 11, 12 
6 - - - 148.0 - - - 
7 3.85 dd 1.4, 10.8 69.7 CH 6, 12 8, 12 
8 2.97 m - 47.2 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.7 - - - 
10a 2.77 m - 45.0 CH2 1’, 3 3, 4, 12 
10b 2.90 m - - - - - 
11 1.04 d 6.7 14.2 CH3 4, 5, 6 5 
12a 5.14 brs - 114.2 CH2 5, 6, 7 5, 7, 11 
12b 5.38 brs - - - - - 
13 5.76 ddd 1.4, 9.7, 
15.4 
127.1 CH 7, 8, 15 8, 14, 15 
14 5.45 m - 138.7 CH 9, 15 13, 15 
15a 1.83 m - 42.7 CH2 13, 14, 16, 17 13, 14,  
15b 2.05 m - - - - - 
16 1.81 m - 28.5 CH 13, 14, 17 22 
17a 1.58 m - 53.8 CH2 18, 19 - 
17b 1.89 m - - - - - 
18 - - - 74.3 - - - 
19 5.59 brs - 138.1 CH - 20 
20 5.91 dd 2.8, 16.5 125.8 CH 18, 19 19 
21 5.59 brs - 77.4 CH 8, 9, 19, 20, 23  - 
22 1.08 d 6.5 26.5 CH3 15, 16, 17  16 
23 1.37 s - 31.2 CH3 17, 18, 19 - 
1‘ - - - 137.7 - - - 
2’ 6’ 7.36 d 8.1 128.8 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.79 d 8.1 120.8 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 137.5 - - - 
24 - - - 170.1 - - - 
25 2.26 s - 20.9 CH3 24 - 
4‘‘ - - - 145.9 - - - 
5‘‘ 8.36 s - 121.2 CH 4‘‘ - 
6‘‘ 4.81 s - 64.3 CH2 4‘‘, 5‘‘, 7‘‘ - 
7‘‘, 8‘‘, 9‘‘, 
10‘‘, 11‘‘, 12‘‘ 
3.68 m - 70.2 6 x CH2 7’’, 8’’, 9’’, 
10’’, 11’’, 12’’ 
- 
13‘‘ 3.79 m - 69.7 CH2 - 14‘‘ 
14‘‘ 3.34 m - 43.3 CH2 - 13’’ 
15‘‘ - - - 145.7 - - - 
16‘‘, 17‘‘ 8.01 d 7.9 126.8 2 x CH 18’’, 19’’ - 
18‘‘ - - - 127.4 - - - 
19‘‘ - - - 131.5 - - - 
20‘‘ 8.36 s - 121.2 CH 21‘‘, 22‘‘ - 
21‘‘ - - - 134.4 - - - 
22‘‘ - - - 126.5 - - - 
23‘‘ 7.27 s - 127.1 CH 24‘‘, 31‘‘ - 
24‘‘ - - - 129.1 - - - 
234 
 
25‘‘, 30‘‘ 2.73 m - 27.4 2 x CH2 23‘‘, 24‘‘ - 
26‘‘, 29‘‘ 1.28 m - 29.6 2 x CH2 25‘‘, 27‘‘ - 
27‘‘, 28‘‘ 3.85 m - 47.2 2 x CH2 26‘‘ - 
31‘‘ - - - 137.5 - - - 
32‘‘ - - - 73.6 - - - 
33‘‘ - - - 150.0 - - - 
34‘‘ - - - 129.0 - - - 
35‘‘ - - - 151.3 - - - 
36‘‘, 41‘‘ 2.66 m - 27.4 2 x CH2 34‘‘, 38‘‘ 38‘‘ 
37‘‘, 40‘‘ 1.97 m - 20.6 2 x CH2 36‘‘ 38‘‘ 
38‘‘, 25‘‘, 27‘‘, 39‘‘ 3.47 m - 50.5 2 x CH2 37‘‘, 43‘‘ 36‘‘, 37‘‘ 
42‘‘ - - - 113.7 - - - 
43‘‘ - - - 152.7 - - - 
44‘‘ 6.83 s - 128.1 CH 41‘‘, 42‘‘, 43‘‘, 45‘‘ - 




























Position δH M JH-H/Hz δC HSQC HMBC H to C H-H COSY 
1 - - - 174.3 - - - 
3 3.33 m - 53.5 CH 1‘, 1, 4, 5 4, 5, 10 
4 2.16 dd 3.8, 5.1 50.3 CH 1, 3, 5, 6, 10 3, 5, 10 
5 2.81 m - 32.8 CH 1’, 3 4, 11, 12 
6 - - - 147.9 - - - 
7 3.88 dd 1.3, 10.8 69.9 CH 6, 12 8, 12 
8 2.96 m - 47.3 CH 7, 9, 13, 20, 21 7, 13 
9 - - - 51.8 - - - 
10a 2.76 m - 45.1 CH2 1’, 3 3, 4, 12 
10b 2.93 m - - - - - 
11 1.02 d 6.7 14.2 CH3 4, 5, 6 5 
12a 5.14 brs - 114.2 CH2 5, 6, 7 5, 7, 11 
12b 5.39 brs - - - - - 
13 5.75 ddd 1.4, 9.7, 
15.4 
126.9 CH 7, 8, 15 8, 14, 15 
14 5.42 ddd 4.8, 10.1, 
15.4 
138.8 CH 9, 15 13, 15 
15a 1.82 m - 42.7 CH2 13, 14, 16, 17 13, 14,  
15b 2.06 m - - - - - 
16 1.81 m - 28.6 CH 13, 14, 17 22 
17a 1.60 m - 53.6 CH2 18, 19 - 
17b 1.88 m - - - - - 
18 - - - 74.7 - - - 
19 5.56 brs - 138.2 CH - 20 
20 5.88 dd 2.2, 17.0 125.7 CH 18, 19 19 
21 5.55 brs - 77.3 CH 8, 9, 19, 20, 23  - 
22 1.07 d 6.3 26.5 CH3 15, 16, 17  16 
23 1.36 s - 31.3 CH3 17, 18, 19 - 
1‘ - - - 138.3 - - - 
2’ 6’ 7.31 d 8.5 130.4 2 x CH  3’, 4’, 5’, 10 3’, 5’ 
3’ 5’ 7.68 d 8.5 120.8 2 x CH 1’, 4’ 2’, 6’ 
4’ - - - 136.0 - - - 
24 - - - 170.2 - - - 
25 2.27 s - 21.0 CH3 24 - 
4‘‘ - - - 145.0 - - - 
5‘‘ 8.04 s - 120.4 CH 4‘‘ - 
6‘‘ 4.77 s - 64.7 CH2 4’’, 5’’,7’’ - 
7‘‘  3.76 m - 69.9  CH2 6‘‘, 8‘‘, 17‘‘ - 
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